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CHAPTER 1 
INTRODUCTION AND AIM OF THE STUDY 
Introduction of a new intravenous anaesthetic agent into modern clinical 
practice is only possible after an extensive programme of investigations has 
been carried out. This programme of investigations involves experiments on 
toxicity and animal pharmacology, which have to be completed before clinical 
trials can start. 
Each new compound has to be compared with the profile of previous 
drugs. The disadvantages of the older drugs have to be avoided in the newer 
drugs and some of their properties need to be improved. New developments or 
demands in the fields of surgery and anaesthesia, for instance out patient 
surgery, microlaryngeal surgery with laser beams, and total intravenous 
anaesthesia, have created new criteria to be fulfilled by a new anaesthetic 
agent. 
In animal investigations as well as in clinical trials a full profile of a new 
agent is determined. In spite of this careful evaluation it is still possible that 
after longterm clinical experience some disadvantages become evident. This 
can lead to withdrawal of an agent from clinical use and it therefore introduces 
new aspects to be studied with further compounds. 
It is obvious that this work cannot be performed by one research group 
alone. World-wide cooperation of research groups, each with their special 
interests and expertise, is necessary to evaluate all the aspects of a new agent 
within an acceptable time schedule. It is not surprising that it takes around 
10 years before a new agent becomes commercially available. 
Propofol, 2,6-diisopropylphenol, is the latest intravenous anaesthetic 
agent to become available for clinical practice. Its development is an example 
of well coordinated investigation by several research groups all over Europe. 
Our own studies with propofol, described in this thesis, are therefore to be 
considered in relation to other studies to obtain a full overview of the 
properties of propofol. 
Propofol is one result of the search for an intravenous agent with 
improved properties over previously available compounds. Rapid and smooth 
induction of anaesthesia are needed, combined with a short duration of action 
as a result of rapid metabolism to allow administration by continuous infusion 
for maintenance of anaesthesia. These are the properties looked for in new 
agents. Rapid recovery without side effects was another prerequisite. 
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Our studies dealt with the clinical application of this new anaesthetic 
agent. The general aim of our studies was to investigate some of the properties 
of propofol itself and its interactions with other anaesthetic adjuvents. Five 
main topics were selected: 
1. The influence of premedication on the propofol induction regimen, in 
particular speed of induction and changes in cardiovascular parameters 
(chapter 5). 
2. Investigation of the dose of propofol required to maintain anaesthesia by 
continuous infusion: 
- in combination with regional anaesthesia (chapter 6), 
- in combination with short acting narcotic analgesics for a total 
intravenous anaesthesia technique (chapter 7). 
3. Evaluation of the interaction of propofol with non-depolarizing muscle 
relaxants such as vecuronium (chapter 8). 
4. Comparison of the recovery profile and postoperative side effects of 
propofol anaesthesia with that of other anaesthesia techniques (chapter 9 
and chapter 10). 
5. Pharmacokinetics after a bolus injection (chapter 11 and 12). 
These investigations have contributed answers to the general question: "What 
are the advantages and shortcomings of propofol in routine anaesthesia 
compared to a theoretical ideal intravenous anaesthetic and currently used 
techniques". 
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CHAPTER 2 
THE IDEAL INTRAVENOUS ANAESTHETIC. 
" The introduction of each new intravenous anaesthetic seems 
to have sparked off a spate of publications on the properties of the 
ideal agent...." 
John Dundee 
2.1 HISTORICAL NOTES 
Before the introduction of the intravenous agents hexobarbital in 1932 (Weese 
and Scharpff 1932) and thiopentone in 1934 (Pratt et al. 1936) hypnosis, 
analgesia, suppression of vegetative reflexes and muscle relaxation - the pillars 
of general anaesthesia - were provided by single inhalation agents, such as 
ether or chloroform. Unfortunately the barbiturates were also used at that 
time as sole agents to fulfill all the objectives of anaesthesia. The large 
induction dose which was commonly used in those early days, caused severe 
cardiovascular and ventilatory depression. The lack of knowledge of 
pharmacokinetics and the inability to ventilate the patients adequately resulted 
during World War II in a high mortality among severely wounded patients 
after thiopentone induction. In 1943 a single agent anaesthesia technique, such 
as (total) intravenous anaesthesia with thiopentone, was described as an "ideal 
form of euthanasia" (Halford 1943). 
After the clinical introduction of muscle relaxants in 1942 (Griffith and 
Johnson 1942) the concept of single agent anaesthesia was abandoned and the 
concept of balanced anaesthesia was introduced (Gray and Recs 1952). With 
the use of specific agents for hypnosis, analgesia and muscle relaxation it was 
no longer necessary to fulfill all the pillars of anaesthesia with one single 
agent. Administered in lower doses, thiopentone regained popularity as an 
induction agent. After induction, anaesthesia was maintained by inhalation 
anaesthetics and in this way thiopentone is still widely used today. 
Despite the increasing popularity of intravenous agents, inhalation 
anaesthetics played an important role in general anaesthesia. The question of 
whether chronic exposure of operating room personnel to waste anaesthetic 
gases in trace amounts is harmful is still under debate (Dundee 1978, Mazze 
1983, Morgan 1983). Modern scavenging devices should solve for the most part 
the pollution problem. However, leaks in the administration systems are 
difficult to avoid (Reiz et al. 1986). In the recovery room, where patients 
exhale anaesthetic vapours and gases, pollution is also almost unavoidable. It 
is still not known if there is a safe threshold of contamination (National 
Institute for Occupational Safety and Health 1977). The pollution problem 
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strengthens the argument that an ideal intravenous anaesthetic should be able 
to replace both nitrous oxide and the volatile anaesthetics as an induction 
agent and as an agent for maintenance of anaesthesia (Dundee 1978, Morgan 
1983, Booij 1984) 
TABLE 2.1 
THE FIRST YEAR OF CLINICAL ADMINISTRATION 
OF INTRAVENOUS ANAESTHETICS 
Thiopentone 
Methohexital 
Ketamine 
Gamma OH Butyric acid 
Propanidid* 
1934 
1957 
1957 
1960 
1961 
Diazepam 
Althesin* 
Etomidate 
Propofol 
Midazolam 
1964 
1971 
1973 
1977 
1978 
* these drugs are no longer available 
New developments in pharmacology and physiology have further 
contributed to the definition of the properties of an ideal intravenous 
anaesthetic. Awareness of unwanted side effects is another stimulus to look 
for better and safer drugs. General anaesthesia has become a controllable and 
reversible interference with physiological functions which maintain 
consiousness. Unconsiousness, loss of sensations and suppression of excessive 
autonomic reflexes are the result. Recent advances in analgesics and muscle 
relaxants mean that the sole function of a modern intravenous anaesthetic 
agent is to induce and maintain sleep. 
2.2 PROPERTIES OF AN IDEAL INTRAVENOUS ANAESTHETIC AGENT 
In table 2.2 the properties of an ideal intravenous anaesthetic agent are 
summarized. Several of these properties need more discussion and can be 
clarified by reference to known compounds. 
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TABLE 2.2 
IDEAL PROPERTIES OF AN INTRAVENOUS ANAESTHETIC AGENT 
Physico-chemical and pharmaceutical properties 
1. SOLUBILITY 
Water soluble or at least in a neutral vehicle. 
Injectable in a running drip. 
2. STABILITY 
Stable in solution at room temperature for a long period of time ( ± 1 year). 
Stable on exposure to light for a long period of time (±24 hours). 
3. CONCENTRATION 
Small volume (± 10 ml) required for induction. 
4. INTERACTION WITH ADMINISTRATION SYSTEMS 
No absorption to materials used for syringes and infusion catheters. 
Pharmacodynamics 
1. POTENCY 
Large potentcy with a small variations in interindividual sensitivity. 
Safe therapeutic ratio. 
2. ONSET 
Onset in one arm-brain circulation time. 
3. DURATION 
Short duration of action (5 to 10 min). 
Maintenance of anaesthesia by a continuous infusion possible. 
4. RECOVERY 
Fast recovery rate, independent of mode of administration (bolus or infusion). 
Metabolism and excretion 
1. IN ACTIVATION 
Inactivation by metabolism. 
Metabolism independent of liver and renal function. 
No cumulative effects. 
2. METABOLITES 
Non toxic metabolites. 
Metabolites themselves inactive. 
No cumulative properties of metabolites. 
3. EXCRETION 
Excretion of the drug itself as well as metabolites by the lungs, kidneys and 
digestive tract. 
Clearance of the drug and its metabolites from the blood by haemodialysis 
possible. 
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Hypersensitivity 
1 ANAPHYLACTIC AND ANAPHYLACTOID REACTIONS 
No sensitization of the patient to subsequent administration 
2 HISTAMINE RELEASE 
No direct histamine release 
Side effects 
1 HAEMODYNAMIC EFFECTS 
No direct myocardial depression 
Reduced peripheral resistance which is dose related 
No influence on the heart rate nor induction of arrythmias 
2 VENTILATORY EFFECTS 
No depression of the normal response to carbon dioxide 
3 EXCITATORY EFFECTS 
Free of excitatory effects during induction 
Free of excitatory effects during maintenance 
Uneventful clear headed recovery 
4 VASCULAR EFFECTS 
Free of pain during injection 
No venous sequelae 
Inadvertant intra arterial injection possible without serious damage 
Interactions 
1 INTERACTION WITH OTHER ANAESTHETICS 
No antalgesic properties 
Slight interaction with muscle relaxants is acceptable 
2 INTERACTION WITH ENDOCRINE SYSTEMS 
No other changes than the normal physiological changes during sedation 
No suppresion of Cortisol production 
3 TERATOGENIC EFFECT 
Free of teratogenic effects 
Limited placental transfer 
No supression of immune response 
Miscilleneous 
1 PORPHYRIA 
No induction of acute porphyria 
2 MALIGNANT HYPERTHERMIA 
Safe to be used in patients suceptible to malignant hyperthermia 
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2.2.1 Physico-chemical and Pharmaceutical Properties 
2.2.1.1 Solubility 
An anaesthetic stable when dissolved in water avoids all the possible side 
effects of solubilizing agents preservatives and stabilizers. In general 
solubilizing agents are feared for their adverse reactions like anaphylactoid 
reactions, toxicity and interaction with other drugs used during anaesthesia. 
Anaesthetics need to be lipophilic to pass the blood-brain barrier. The 
combination of these two physical properties is the ideal. When a drug cannot 
be dissolved in water another harmless suitable solvent must be found despite 
the possible disadvantages (table 2.3). 
TABLE 2.3 
ANAESTHETIC DRUGS AND THEIR SOLVENTS 
Drug 
Thiopentone 
Methohexital 
Ketamine 
γΟΗ Butyric acid 
Propanidid 
Diazepam 
Althesin 
Etomidate 
Propofol 
Midazolam 
Vehicle 
water 
water 
water 
water 
Cremophor EL 
propylene glycol 
ethyl alcohol 
soya bean oil emulsion 
Cremophor EL 
propylene glycol 
ethyl alcohol 
soya bean oil emulsion 
water 
Remarks 
Stable in water for 48-72 hr 
Stable in water for 6 weeks 
Soluble, but unstable in water 
For infusion solutions only 
Cremophor EL, a polyoxylated castor oil, was used as a vehicle for 
propanidid, diazepam, Althesin and an early formulation of propofol. Several 
case reports describe anaphylactoid reactions with these drugs and it became 
clear that Cremophor EL was responsible for these adverse reactions. (Dye 
and Watkins 1980, Briggs et al. 1982, Moneret-Vautrin et al. 1983). During 
continuous infusion of Althesin for sedation in intensive care, the total dose of 
Cremophor EL can reach 100 grams per 24 hours. With these amounts of 
Cremophor EL blood viscosity is decreased to such an extent that it becomes 
impossible to make blood smears for haematological examinations. This effect 
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persists for two weeks after stopping the infusion (Knell et al. 1983). Because 
of the side effects of Cremophor EL, propanidid and Althesin were withdrawn 
from the market. 
Another frequently used solubilizing agent is propylene glycol (etomidate, 
diazepam). High doses of propylene glycol lead to haemolysis. Ethyl alcohol is 
used for a highly concentrated etomidate preparation. An emulsion of soya 
bean oil has recently been used for diazepam and propofol and in clinical trials 
for etomidate and thiopentone. Soya bean oil is routinely administered to 
patients for intravenous nutrition. The low toxicity of this fat emulsion has 
been documented in several studies which are briefly reviewed in chapter 3. 
The size of the emulsion micelles is of importance. If the micelles have a 
diameter of 0.2 μπι the total fat surface in 1 ml emulsion will be about 6 m2. 
Thus the finely distributed oleaginous phase has a large area of contact with 
the plasma, which promotes rapid diffusion of .the drug from fat to blood 
(Von Dardel et al. 1983). Larger particle sizes (> 2 μπι) used for the emulsion 
formulation of barbiturates resulted in prolonged sleeping times compared with 
aqueous formulations like sodium salts (Jeppsson et al. 1972). 
Solvents can interfere with muscle relaxants. Fragen et al. (1983) have 
demonstrated that Cremophor EL potentiates the effect of suxamethonium and 
inhibits the effect of a continuous infusion of non-depolarizing relaxants such 
as vecuronium and pancuronium. They suggested that Cremophor inhibits 
acetylcholinesterase activity. Driessen et al. (1985) demonstrated the 
antagonistic effects of propylene glycol and ethyl alcohol on a constant neuro­
muscular block with vecuronium. 
The water or lipid solubility of an agent can be influenced by its pH. 
Midazolam for example is water soluble below pH 4. Above this pH, in the 
blood stream, the ring structure is fully closed resulting in better lipid solubility 
(Greenblatt and Abernethy 1985). 
2.2.1.2 Stability 
Storage at room temperature and stability on exposure to light are desirable 
properties, especially when an anaesthetic is used as a continuous infusion for 
maintenance of anaesthesia. Thiopentone and etomidate, despite being water 
soluble, are unstable in this medium. 
2.2.1.3. Concentration 
The ideal concentration of a drug for adminstration is determined by several 
factors such as potency and tonicity, and the risk of overdose from too rapid 
injection. It is desirable that the same formulation used for induction of 
anaesthesia can be used for maintenance by continuous infusion. 
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2.2.1.4 Interaction with administration systems 
Morgan (1983) paid attention to the possible absorption of anaesthetics into 
the material used for syringes and infusion systems. Absorption into 
administration system has been reported for diazepam by Winsnes et al. 
(1981). 
2.2.2 Pharmacodynamics and Pharmacokinetics 
2.2.2.1 Rapid onset of action 
"For easy control of dosage and to minimize the risk of overdosage, a drug 
which produces its action in one arm-brain circulation time is clearly desirable" 
(Dundee 1979). This statement is still valid (Dundee 1985) and has been 
repeated by others (Morgan 1983). A short delay between the start of 
administration and the first signs of effect makes titration possible according to 
individual sensitivity. 
Only lipid soluble agents can penetrate biological membranes e.g. the 
blood-brain barrier. Therefore onset of action is highly dependent on the 
lipid/blood partition coefficient. Gamma-hydroxy butyric acid (GHBA) is an 
exception to this rule. It can pass the blood-brain barrier but a delay occurs 
before an effect is noted: it takes about 10 min. before sleep ensues 
(Blumenfeld et al. 1962). 
Fast passage of membranes implies enlarged risk of organ-toxicity better 
known as 'bolus' action. This leads, particularly in high risk patients, to 
depression of the cardiovascular and respiratory systems. The bolus effect can 
be minimized by a slow injection but this prolonges induction. 
Onset of action is influenced by premedication. For example midazolam 
has an induction time of upto 3 min. (Gamble et al. 1981, Malthy et al. 1981). 
However, Driessen et al. (1983) found that premedication reduced the 
induction time to 50 sec , which in their study was significantly longer 
compared to thiopentone. 
Most of the induction agents are protein bound, particularly to albumin 
(table 2.4). Therefore, low plasma albumin levels can lead to unexpectedly 
high concentrations of free drug in richly perfused organs such as the brain. 
The bolus effect will be more pronounced and can lead to severe 
complications. An increased free fraction of the drug can also influence its 
pharmacokinetic behaviour. 
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TABLE 2.4 
MEAN PHARMACOKINETIC PARAMETERS OF SOME ANAESTHETIC AGENTS 
Drug 
Thiopentone 
(Burch et al. 1983) 
Methohexitone 
(Hudson et al. 1983) 
Diazepam 
(Mandelli et al. 1978) 
Etomidate 
(Van Hamme et al. 1978) 
Flunitrazepam 
(Kangas et al. 1982) 
Midazolam 
(Greenblatt et al. 1984) 
Dose 
mg kg'1 
6.0 
3.0 
0.1 
0.3 
0.03 
0.07 
T
 Vza 
min 
59.0 
58.0 
60 
28.7 
114 
30 
Τι/φ 
min 
719 
234 
1800 
275 
1500 
126 
Vd 
Ikg-1 
2.3 
2.2 
1.2 
4.5 
3.6 
1.3 
CI 
mi kg'1 
3.4 
10.9 
0.3 
11.6 
1.4 
7.8 
Protein 
binding 
8 0 % 
8 0 % 
9 7 % 
75 % 
80 % 
97 % 
2.2.2.2 Short duration 
Differentiation must be made between duration of action after a single dose 
and a continuous infusion. Duration after a single induction dose is determined 
by two different processes: biotransformation and distribution. Drugs with 
slow inactivation by biotransformation can still have short duration of action 
after an induction dose. As a result of distribution to other tissues the initially 
high cerebral concentration of the anaesthetic agent can decrease below the 
threshold level of anaesthetic action. The perfusion of the tissues, the drug 
permeability through tissue membranes and the various partition coefficients of 
the drug are the most important factors determining the speed of this process. 
A classical example is thiopentone. It has a fast onset of action and a short 
duration after a single bolus dose despite slow metabolism. 
After repeated administration or after a continuous infusion the duration 
of action is determined by excretion or inactivation by biotransformation. 
Althesin and etomidate are examples of agents which are rapidly inactivated 
resulting in easy control of anaesthesia by continuous infusion. The 
barbiturates and some benzodiazepines, for example diazepam and 
flunitrazepam, penetrate the blood-brain barrier rapidly but their half lives are 
very long (table 2.4). This results in slow recovery after repeated 
adminstration. 
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Drugs with too short a duration of action have the possible danger that 
the patient awakes before the procedure gets properly established or before 
other agents like inhalation anaesthetics reach effective blood levels. 
Propanidid is an example. It has a rapid elimination time as a result of 
hydrolysis by plasma and liver esterases (Doenicke et al. 1968). Here the 
overall rate of elimination is so fast that it becomes an important factor in 
single bolus kinetics. On the other hand fast elimination processes can be an 
advantage in short procedures for out patients. Kortilla et al. (1975) 
demonstrated that the duration of action of propanidid is so short that within 
two hours after administration (simulated) motor car driving is possible. 
2.2.2.3 Interindividual variations 
Benzodiazepines exhibit a large interindividual variability in potency and are 
therefore not very useful for routine induction of anaesthesia (Dundee 1979, 
Booij 1984). They are often used, however, for this purpose because of their 
cardiovascular stability. 
2.2.2.4 Metabolism and excretion 
There are two good reasons for rapid metabolism and excretion of an 
intravenous anaesthetic. First, such properties make the drug suitable for the 
maintenance of anaesthesia by continuous infusion techniques. Secondly, 
these properties make out patient surgery possible. 
In order to know the limits for the application of a drug the mechanism of 
metabolism must be well understood. For instance capacity-limited metabolism 
(for example gamma-hydroxy butyric acid and ethyl alcohol, Van den Bogert 
et al. 1978, Vree et al. 1978) has the disadvantage that metabolism of one 
agent can interfere with that of other agents using the same enzymes. High 
intrinsic hepatic clearance of a drug leads to changes in metabolism with 
alteration in hepatic blood flow. This can occur easily during anaesthesia (for 
example Althesin). 
Barbiturates and benzodiazepines have metabolites which do have 
hypnotic activity. Therefore, they should not be used for continuous infusion. 
Midazolam with its shorter half life may be an exception (Lauven et al. 1982). 
Anaesthestic agents can be excreted as unchanged compounds by the 
kidney and/or digestive tract. However, this plays a minor role in total body 
clearance. Biotransformation followed by renal excretion of the metabolites is 
the major pathway. Primary excretion of the parent agent itself or its active 
metabolites by the kidneys limits its applicability in patients with renal failure. 
An almost ideal mechanism of elimination is that of gamma-hydroxy butyric 
acid (GHBA); about 94% of the drug leaves the body as CO2 and water and 
about 5% is excreted by the kidney (Nirenberg and Jacoby 1960). 
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2.2.3 Hypersensitivity 
The immunological mechanisms of hypersensitivity to anaesthetic drugs have 
been well described recently by Simpson (1984) and by Watkins (1985) The 
original classification of hypersensitivity reactions defines the speed of 
response and the predominant immune effector (Gell et al 1975) 
Type I, immediate hypenensitivity 
Antigens react with specific reagirne antibody, usually IgE bound to the 
surface of mast cells, causing degranulation and the release of histamine 
and other vasoactive amines 
Type 11, cytotoxic-type of hypersensivity 
Antibodies bind to an antigen on the cell surface, producing phagocytosis, 
wich may be enhanced either by opsonic or immune adherence, or by K-
cell mediated non-phagocytic extracellular cytotoxicity Activation of the 
classical complement pathway then produces cell lysis 
Type III, immune complex mediated hypersensitivity 
Formation of immune comlexes between antigen and humoral antibody, 
leading to classical complement pathway activation 
Type IV, cell-mediated (delayed) hypersensitivity 
T-lymphocytes, with specific surface receptors are stimulated by antigen 
contact to release factors which mediate delayed hypersensitivity 
In the case of intravenous anaesthetic agents this classification of 
hypersensitivity needs modification because many of the normal protective 
mechanisms are inevitably bypassed by direct intravenous injection 
(Simpson 1984). 
Direct pharmacological effect 
A non-specific effect producing immediate release of vasoactive amines, 
problably histamine 
Classical complement pathway activation 
Hypersensitivity following intravenous injection of an agent which has 
previously been administered uneventfully Although specific antibodies 
have not been demonstrated, such a reaction implies that this has occurred 
and therefore that this is either a Type II or Type III reaction 
Alternative complement pathway activation 
Hypersensitivity occurring on first exposure to the agent, but which 
involves direct activation of C3, histamine release and symptoms of 
anaphylaxis 
Type I, immediate hypersensitivity 
12 
This classification includes immune (anaphylactic) reactions and non-immune 
(anaphylactoid) reactions. Their clinical manifestations are totally 
indistinguishable (Watkins 1985). There are a number of symptoms and signs 
of acute hypersensitivity which may occur during anaesthesia and which may 
not necessarily be associated with the development of hypersensitivity. 
However, they should always alert the anaesthetist to the possibility of a drug 
induced reaction (Simpson 1984): 
1. Cutaneous flushing or the development of an overt rash. 
2. Pruritus or arthralgia (only in an awake patient). 
3. Cough - many anaesthetists regard a single cough on induction as a 
common sign preceding the development of a hypersensitivity reaction. 
4. Tachycardia. 
5. Bronchospasm. 
6. Hypotension. 
7. Cardiac arrest. 
TABLE 2.5 
INCIDENCE OF ADVERSE REACTIONS TO INTRAVENOUS ANAESTHETICS 
thiopentone 
Althesin 
methohexitone 
propanidid 
Clarke 1981 
1:29000 -
1:1000 
1:7000 
1:170 
- 1:36000 
- 1:30000 
- 1:1600 
Simpson 
1:14000 -
1:400 
1:7000 
1:500 
1984 
1:20000 
1:2000 
1:17000 
Anaphylactoid reactions can occur unexpectedly in an otherwise healthy 
patient (table 2.5). After the introduction of propanidid and Althesin the 
number of case reports of such reactions increased markedly (Clarke 1980, 
1985). As discussed in paragraph 2.2.1 they were not related to the drug itself, 
but to the solubilizing agent Cremophor EL. These case reports represent only 
a fraction of the incidents occurring (Clarke 1985). Simpson (1984) also 
noticed this problem. He came to the conclusion that hypersensitivity is so 
commonly observed that it is seldom reported as a side effect. For example 
many anaesthetists would hardly remark at cutaneous flushing or local wheals 
following intravenous injection of thiopentone or d-tubocurarine, so frequent is 
their occurrence. His explanation of the low incidence of fatalities due to 
adverse reactions was that they may be due to the understandable reluctance 
of clinicians involved, to report fatalities. Or more likely, because death may 
have been due to a number of causes of which drug hypersensitivity is only 
one possibility. 
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Barbiturates and Althesin frequently produce local or generalized signs of 
histamine release (Doenicke et al. 1985). Most of the time these reactions tend 
to be mild. Sometimes they are associated with severe tachycardia, 
hypotension or bronchospasm. Etomidate is devoid of histamine releasing 
effects (Doenicke et al. 1973). However, cutaneous reactions have been 
observed in association with succinylcholine (Clarke 1985). 
2.2.4 Side Effects 
A drug without side effects is an ideal, but never reality. During clinical 
research with a new intravenous agent, the occurence of all side effects known 
to exist with other intravenous anaesthetic agents, have to be evaluated. 
Unexpected side effects and their influence on the final outcome are even 
more important. Clarke (1981) has reviewed several side effects of anaesthetic 
agents. One of the problems in this respect is that in comparing several reports 
of side effects one notices the lack of standardization in the methods of 
assessment. An example is pain on injection. Most of the patients fail to 
complain because they think that it is a normal accompaniment of the 
induction of anaesthesia. A standard interview is required for the evaluation of 
this side effect. 
2.2.4.1 Excitatory effects 
During the induction of anaesthesia a lot of excitatory effects can be observed. 
Hiccups, cough, restlessness, vomiting, laryngospasm, brochospasm and 
myoclonus are the most important. In the past they were feared, as during the 
induction of ether anaesthesia, but they present less of a problem when 
modern anaesthetic agents are used. 
Etomidate, for instance, is notorious for the occurence of myoclonia on 
induction. The incidence is so large that prior administration of an opiate is 
recommended. With the use of methohexitone particulary cough and hiccups 
are common (Clarke 1981). 
2.2.4.2 Changes in cardiovascular parameters 
Depression of the vasomotor centre, direct myocardial depression, decrease in 
peripheral resistance and changes in heart rate are described for all 
intravenous anaesthetics and are mostly dose related. An exception is 
ketamine which causes tachycardia and peripheral vasoconstriction due to the 
liberation of catecholamines. This can cause a marked hypertension. Some 
authors state that ketamine has definitive advantages in the management of 
cardiac and critically ill patients (Zigmond et al. 1980). However because of 
the rise in cardiac oxygen consumption several authors advise against ketamine 
in patients with coronary disease (Dundee and Wyant 1974, White 1983). 
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Etomidate produces no significant changes in arterial pressure, heart rate 
and cardiac output (Gooding and Corssen 1977). It is recommended for 
induction of patients undergoing cardiac surgery (Prys-Roberts 1984). 
Heart rate and blood pressure are under the physiological control of the 
central nervous system. During emotion, e.g. induction of unpremedicated or 
unprepared patients, blood pressure rises, tachycardia developes and 
peripheral veins are constricted. After induction of anaesthesia the 
cardiovascular effects of anaesthetics are influenced by this pre-existing state 
(Prys-Roberts 1984). During the first one or two minutes after the transition 
from the conscious state to the state of anaesthesia following the use of an 
intravenous anaesthetic agent a decrease in blood pressure in relation to 
preoperative values takes place, accompanied by an increase of heart rate 
(with the exception of etomidate and ketamine). The increase of heart rate can 
be a result of the carotid sinus baroreflexes. A number of studies of the 
baroreflex control of heart rate have shown that the tachycardia must be a 
direct effect of the drug, which either suppresses parasympathetic activity or 
enhances sympathetic activity. There is evidence that the tachycardia is more 
the result of a decrease in vagal activity than of an increased sympathetic 
activity (Jones and Prys-Roberts 1983, Russell et al. 1981, Derbyshire 
et al. 1983). The decrease of both adrenaline and noradrenaline in plasma in 
response to induction of anaesthesia would tend to confirm the lack of 
sympathetic activity (Prys-Roberts 1984). 
Other factors of clinical importance in control of blood pressure are the 
pre-existing circulating blood volume and the cardiovascular status of the 
patients. 
2.2.4.3 Respiratory depression 
The CCb response curve is a sensitive indicator of respiratory depression. A 
normal response to carbon dioxide is desirable during anaesthesia with an 
intravenous agent when the patient is expected to breathe spontaneously. This 
is also true when a drug is used for sedation in combination with regional 
anaesthesia. Of the anaesthetics mentioned in tabel 2.1 only gamma-hydroxy 
butyric acid fulfils this requirement. Although respiratory rate falls whith this 
anaesthetic, arterial CO2 remains constant as a result of an increase in tidal 
volume. 
Dose dependent apnoea is frequently seen both in occurence and duration 
during induction with several anaesthetic agents. If anaesthesia is continued 
with a technique involving artificial ventilation the occurence of respiratory 
depression at induction is of no consequence. An exception to this statement is 
when anaesthesia is given for a Caesarean procedure. Placental transfer of the 
drug might result in respiratory depression in the newborn. 
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2.2.4.4 Vascular irritation 
Venous irritation and thrombophlebitis are common complications of the use 
of intravenous anaesthetic drugs (Kawar and Dundee 1982). Many reports with 
different intravenous anaesthetics have been published of such sequelae. 
Variations in methodology, lack of control groups and lack of information 
about the site of administration, the size of the vein and the nature of 
premedication, invalidate the comparison of several studies. Estimation of the 
total frequency of venous sequelae requires an observation period extended to 
7-10 days (Hegarty and Dundee 1977). Kawar and Dundee (1982) taking into 
consideration the pitfalls described above, studied venous sequelae following 
administration of a group of intravenous anaesthetic agents. Some of their 
results are summarized in table 2.6. 
TABLE 2.6 
Overall frequency of venous sequelae and pain on injection of 
some intravenous anaesthetic agents (Kawar and Dundee 1982) 
agent 
0.9% saline 
2.5% thiopentone 
1.0% methohexitone 
0.5% diazepam: 
in propylene-glycol 
in soyabean oil 
0.5% midazolam 
venous sequelae 
% 
2 
4 
10 
40 
2 
8 
pain on injection 
% 
0 
9 
12 
37 
0 
1 
Several attempts have been made to reduce the incidence of venous 
sequelae. In the case of diazepam, pain on injection and thrombophlebitis 
were markedly reduced by the use of a fat emulsion as the vehicle 
(Von Dardel et al. 1976, 1983). This was also observed for etomidate dissolved 
in Intralipid 20% (Gran et al. 1983). Local anaesthetics sometimes are added 
to anaesthetic agents to reduce pain (Brown and Moss 1982). A preinduction 
dose of narcotic analgesic is another possible way to reduce pain on injection 
(Van Dijk 1978). 
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2.2.5 Side effects during recovery from anaesthesia 
A fast uneventful and clear-headed recovery is ideal. Rate of recovery is 
mainly influenced by the pharmacokinetics of the drug itself and its 
metabolites (if they have hynotic properties). 
One of the most distressing side effects following anaesthesia, especially 
from the patients view, is the occurence of nausea and vomiting. Palazzo and 
Strunin (1984a, 1984b) reviewed emetic problems associated with anaesthesia. 
They concluded that age, sex, obesity, operative site and duration of 
anaesthesia play a predominant role. The diffusion of nitrous oxide into the 
stomach is another important factor. The overall incidence of nausea and 
vomiting in the absence of antiemetics is nowadays around 30% (Palazzo and 
Strunin 1984). Of the short acting intravenous anaesthetics etomidate gives the 
highest rate of vomiting and nausea of about 50% (Van Oss et al. 1980). 
Ketamine has a high incidence of postoperative psychic emergence 
reactions. Several premedicants and adjuvant agents have been evaluated in 
attempts to prevent these reactions. Benzodiazepines are still the most 
effective, but their sedative effect is long lasting and remains after recovery 
from ketamine anaesthesia. 
Of the barbiturates methohexitone gives the fastest recovery. It is widely 
used for out patient surgery, but is not ideal for continuous infusion techniques 
because of the cumulative property. 
2.2.6 Interactions 
2.2.6.1 Interaction with other anaesthetic agents 
Intravenous anaesthetics are often used in combination with inhalation 
anaesthetics. Analgesics and neuroleptics are added to provide stable 
anaesthesia. This results not only in potentiation or summation of the main 
effects of these drugs, but also of their side effects. The advantage of 
combining drugs is that lower doses of each drug can be used. 
Dundee (1979, 1980) stated that analgesic properties are no longer 
required of an intravenous anaesthetic as highly selective and very powerful 
analgesics are available. Antanalgesic properties which exist with thiopentone 
and methohexitone, should be avoided. For short painful procedures, like 
dilatation of the cervix followed by curettage, analgesic properties in an 
anaesthetic are desirable to avoid the respiratory depression of narcotics. 
The question can be raised whether slight potentiation of a muscle 
relaxant is acceptable. With the new short acting non depolarising agents and 
while using modern muscle relaxation monitors, slight potentiation can be seen 
as an advantage. 
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2.2.6.2 Interaction with endocrine systems 
Ledingham and Watt (1983) reported increased mortality among patients in 
the intensive care unit who were sedated with continuous infusions of 
etomidate. Following their initial observations the inhibitory side effects of 
etomidate on adrenal steroidogenesis was confirmed by others (Allolio 
et al. 1983, Lambert et al. 1983, Frazer et al. 1984, Kenyon et al. 1984). It has 
become clear that etomidate inhibits llß-hydroxylase in the biosynthetic 
pathway of Cortisol (Wagner et al. 1984, Kenyon et al. 1985, Robertson 
et al. 1985). 
The effect of barbiturates, as well as etomidate on adrenal steroidogenesis 
was examined after Ledingham's observations. Both drugs decrease Cortisol 
levels but the increase after ACTH challenge is only blocked by etomidate. In 
vitro experiments showed that thiopentone reduced the ACTH response only 
at extremely high concentrations (Robertson et al. 1985). 
It is still debated in this respect whether during elective surgery, a normal 
induction dose of etomidate followed by a short continuous infusion should be 
avoided (Metha et al. 1985, Wanscher et al. 1985). 
2.2.7 Porphyria 
Prevention of life-threatening crises of acute porphyria in genetically 
susceptible patients depends on identification of those patients and of the 
avoidance of porphyrinogenic drugs. Screening of drugs for porphyrinogenicity 
is possible. Objective evidence can be obtained by observing the effects of the 
drug on 5-aminolaevulinate synthase (ALAs) activity and on the production of 
certain porphyrin intermediates in liver homogenates of experimental animal 
models (Parikh and Moore 1978). Of the anaesthetic agents the barbiturates 
are known as porphyrinogenic drugs. They are contraindicated in susceptible 
individuals. The benzodiazepines, Althesin and ketamine are considered to be 
safe (Parikh and Moore 1978, Silvay et al. 1979, Harrison et al. 1985). 
Etomidate is classified as potentially porphyrinogenic (Harrison et al. 1985). 
No case reports are available of acute porphyria after etomidate anaesthesia. 
Therefore it can not be absolutely contraindicated in susceptible individuals, 
but should only be used in those patients if there are no convenient 
alternatives available. 
2.2.8 Malignant hyperthermia 
Anaesthesia-induced malignant hyperthermia (MH) is a potentially fatal 
pharmacogenetic disorder associated with the use of certain anaesthetic agents 
in a susceptible population. The identification of MH susceptibility is possible 
by in vitro examination of skeletal muscle biopsies (Britt 1982, Verbürg 1984, 
Fletscher et al. 1984). These in vitro examinations can provide significant 
information with regard to the safety of drugs used in anaesthesia. Muscles of 
proven susceptible patients must be used as controls (Fletscher et al. 1984). Of 
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the newer anaesthetic agents, midazolam was screened in this way and might 
be safe in MH susceptible patients (Fletscher et al 1984). 
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CHAPTER 3 
TOXICITY, ELIMINATION AND ADVERSE EFFECTS 
OF SOYA BEAN OIL EMULSION. 
A BRIEF REVIEW 
3.1 INTRODUCTION 
Soya bean oil 10% with egg phospholipids 0.5% as emulsifier and glycerol 
2.25% is the composition of the solvent for propofol. The composition of this 
emulsion is similar to Intralipid, a lipid solution used for parenteral nutrition. 
Pronounced differences in tolerance and toxicity between the various fat 
emulsions exist and it is therefore incorrect to speak of fat emulsions in 
general terms (Shenkin and Wretlind 1978). Intralipid contains soya bean oil 
10%, purified egg phospholipids 1.2% as emulsifier and glycerol 2.5% to 
obtain isotonicity with the blood. The size of the micelles is 0.5 micrometer or 
less in diameter and is of the same order as that of chylomicrons. In this 
chapter we will discuss briefly the toxicity, elimination and adverse reactions of 
Intralipid. 
3.2 TOXICITY 
Intralipid is the most widely used fat emulsion for parenteral alimentation. 
Other fat emulsions containing cottonseed oil have been shown to have severe 
toxic effects and are no longer available. Jacobson and Wretlind (1970) 
administered various fat emulsions to dogs in amounts equivalent to 9 gram of 
fat kg - 1 day - 1 for 4 weeks. All the dogs on Intralipid survived and gained 
weight. All animals given other fat emulsions, containing cottonseed oil or 
soya bean oil with soyabean phospholipids as emulsifier, died. Anaemia, 
leucocytosis, bleeding in the digestive tract as well as hypertriglyceridaemia 
vomiting and diarrhoea were observed. This study confirmed the severe toxic 
effects of cottonseed oil, soyabean phospholipid emulsions found in an earlier 
study (Hakansson 1968). In man parenteral nutrition with Intralipid over long 
periods of time (up to seven years) was well tolerated. Shenkin and 
Wretlind (1978) have reviewed 31 reports during the years 1961-1975 
concerning the use of Intralipid for periods longer than four weeks. 
3.3 ELIMINATION OF FAT PARTICLES FROM THE BLOOD STREAM 
Hallberg (1965) has shown that in man kinetic principles for elimination from 
the bloodstream of chylomicrons and of the micelles of the fat emulsion 
Intralipid are comparable. 
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At a high concentration of lipids in the bloodstream, the elimination 
process is maximally stressed and proceeds at a constant rate (zero-order 
kinetic) down to a so-called critical concentration. Below this concentration the 
rate of elimination is dependent on the concentration; i.e. a fractional removal 
rate (кг) . It was found that the maximum elimination capacity (k^ from the 
bloodstream is influenced by the nutritional status. Fasting for 39 hours 
increased the ki by 50% as compared to the k) after 15 hours of fasting. The 
elimination rate below the critical concentration is independent of nutritional 
state. The major part of Intralipid is removed from the blood in the splanchnic 
region, the skeletal muscles and adipose tissue (Kayser and Rössner 1975). 
After surgical trauma patients show both an increased ki and кл. 
Increased circulation and possibly increased perfusion through the eliminating 
organs are responsable for the increase of the fractional removal rate 
(Hallberg 1965). Recently Lindholm and Rössner (1982) confirmed these 
results. They also demonstrated that even in critically ill patients - in spite of 
the fact that these patients had multiple organ failure which could affect the 
perfusion of the eliminating tissues - the elimination rate is similar to that in 
the control group. Although Hallberg (1965) used a bolus dose of Intralipid 
and Lindholm a continous infusion, their results of k] and kj are comparable. 
Another factor which influences elimination is the administration of 
heparin. Heparin releases lipoprotein lipase resulting in an increased free fatty 
acid concentration and increased elimination rate (кг) (Elkeles 1974). 
The optimal elimination rate of infused fat from the bloodstream can not 
be known. From a physiological point of view, however, the elimination rate 
of chylomicrons may be regarded as optimal. An infusion rate of 25 gr h r - 1 in 
a 70 kg adult does not exceed the elimination limits (Lindholm and 
Rössner 1982). For neonates the recomended limits are between 
0.15 gr fat kg - 1 h r 1 (Gustafson et al. 1974) and 0.17 gr fat kg - 1 hr - 1 
(Wretlind 1972). 
3.4 ADVERSE REACTIONS 
Fat emulsions containing cottonseed oil are taken up by the reticuloendothelial 
system resulting in a reduction of antibody formation. With Intralipid no 
reduction in the formation of antibodies has been observed, nor cumulation of 
the fat particles in the Kuppfer cells (Shenkin and Wretlind 1978). Intralipid 
has been reported to decrease platelet adhesiveness (Kapp et al. 1971) by 
15% during infusion of 500 ml Intralipid 20% Adhesiveness returned to 
normal 4 hours after termination of infusion. The platelet count did not 
change. In their review Shenkin and Wretlind (1978) concluded that Intralipid 
does not have any major infuence on the coagulation system. 
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Conflicting data exist concerning changes in alveolar oxygen transfer, 
arterial oxygen pressure and saturation due to Intralipid infusion. This may be 
due to inadequacy of the methods used for measuring small changes in 
pulmonary function and also to the use of heparin in some studies. Sundström 
et al. (1973) reported a 15% decrease in CO diffusion capacity. Forty five 
minutes after the end of infusion values had returned to normal. They stated 
that these results have no clinical significance in healthy subjects. Greene 
et al. (1976) reported a decrease in pulmonary diffusion for CO after 
administration of Intralipid lasting at least 4 hours. However heparin, 2500 U 
added to 500 ml Intralipid, prevented the decrease. Järnberg et al. (1981) did 
not observe changes in pulmonary diffusion for CO, or changes in blood gases 
and arterial oxygen saturation during Intralipid 20% infusion either in 
volunteers or in intensive care unit patients. Others (Venus et al. 1984) 
compared Intralipid infusions in patients with intact alveolar capillary 
membranes (non-ARDS group) and in patients with disrupted alveolar 
capillary membranes (ARDS group). Decreased oxygenation, increased 
intrapulmonary shunting and increased mean pulmonary arterial pressures 
were reported for the ARDS group. These changes returned rapidly to their 
baseline values after discontinuation of the Intralipid infusion. The non-ARDS 
group demonstrated no changes. 
Post mortem examination of the lungs of neonates who died after 
Intralipid 20% infusion, demonstrated large fat particles in the lung capillaries 
(Levene et al. 1980). In this study the fat particles contained high 
concentrations of linoleic acid, a marker for Intralpid. Leveve et al. (1980) 
suggested that the immature neonate is poorly equipped to handle the fat 
emulsion. 
Hypersensitivity reactions have been observed only in a small percentage 
of patients given Intralipid and are reviewed by Shenking and Wretlind (1978). 
After administration of cottonseed oil emulsions fat particles are taken up by 
cells of the reticuloendothelial system (RES) by phagocytosis, reducing the 
formation of antibodies (Lemperle et al. 1970). After Intralipid infusion no 
reduction in the formation of antibodies is demonstrated (Lemperle 
et al. 1970). 
The administration of Intralipid is contraindicated in patients with severe 
disturbance of fat metabolism, such as pathological hyperlipaemia and lipoid 
nephrosis (Freund et al. 1975). 
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3.5 CONCLUSION 
In conclusion soya bean oil with egg phospholipids as emulsiner has shown to 
be very well tolerated both by animals and by man The fat particles have the 
same properties as chylomicrons and are utilised in the same way as the fat 
from the ordinary enteral diet 
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CHAPTER 4 
INVESTIGATIONS OF PROPOFOL IN ANIMALS 
4.1 HYPNOTIC ACTIVITY OF HINDERED PHENOLS 
The discovery of the anaesthetic activity of 2,6-diethylphenol in mice has 
resulted in an evaluation of a series of alkyl substituted phenols. About 50 
different compounds were investigated (James and Glen 1980). 
Figure 4.1 Alkyl phenol. 
Mono substituted phenols (R1 or R2 substituted see fig. 4.1) only showed 
moderate activity with poor therapeutic ratios. The same results were obtained 
with para substituted phenols (R2 and R4 substituted) and meta substituted 
phenols (R1 and R4, or R1, R2 and R5 substituted). The di-ortho substituted 
phenols (R1 and R5 substituted) demonstrated the most interesting results. 
These compounds were investigated also in rabbits. 
It was concluded that the optimum requirement for overall anaesthetic 
activity was fulfilled by 2,6-di-sec-alkyl substitution, where the total number of 
С atoms in the alkyl groups is between 6 and 8. Less steric hindrance of the 
phenolic -OH group reduced potency. Reduction of potency was also seen if 
substitution took place at the 2nd and 4th С atom of the phenol ring. 
Therapeutic ratios were good and induction times were rapid when the number 
of С atoms in the chains remained below 7. Longer side chains with 8 or more 
С atoms resulted in slower kinetics, prolonged recovery and smaller 
therapeutic ratios. 
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Figure 4.2 2,6-Düsopropyl phenol. 
2,6-Diisopropyl phenol (fig 4.2) is a compound superior in its overall 
profile to other analogues evaluated and was therefore selected for further 
development. 
4.2 SUMMARY OF ANIMAL PHARMACOLOGY 
4.2.1 Physico-chemical and pharmaceutical properties 
Propofol is chemically unrelated to any of the currently used barbiturate, 
imidazole or steroid anaesthetic agents. The molecular weight is 178. At room 
temperature (20oC) it is a colourless to pale straw-coloured liquid which is only 
slightly soluble in water. It has a pKa of 11. The melting point is at 18eC. The 
boiling point is reached at 2560C. For initial pharmacological studies, propofol 
was dissolved in an aqueous Cremophor solution. These studies were 
performed in the Biology Department of ICI Pharmaceutical Division at 
Alderly Park and reported by Glen (1980). After the disadvantages of the 
vehicle Cremophor became apparent, efforts were made to devise an 
alternative formulation. This was achieved with a free-flowing oil-in-water 
emulsion containing 10% soyabean oil and 0.5% egg phosphatide. Glycerol 
2.25% was added to the solution to make it isotonic with blood. Propofol in 
this emulsion formulation has a concentration of 10 mg ml - 1 . In this 
formulation it has a neutral pH. It can be stored at room temperature and is 
stable in this formulation over a period of at least one year. 
4.2.2 Pharmacodynamics 
4.2.2.1 Hypnotic potency 
In mice the hypnotic potency lies between that of thiopentone and 
methohexitone (table 4.1). The median hypnotic dose (HDso), estimated as 
that dose required to abolish righting reflexes for a minimum period of 30 sec 
in 50% of the animals (Glen 1980), was higher for the emulsion formulation 
compared to the Cremophor formulation, demonstrating a slight loss of 
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potency for the former (Glen and Hunter 1984). With a dose of 1.25 χ ИО50 
injected over a period of 10 sec induction is rapid and comparable with 
thiopentone and methohexitone. 
TABLE 4.1 
ACTIVITY AND LETHALITY OF PROPOFOL, THIOPENTONE AND 
METHOHEXITONE IN MICE (GLEN 1980, GLEN AND HUNTER 1984) 
Agent 
propofol (in Cremophor) 
propofol (in emulsion) 
thiopentone 
methohexitone 
HDso 
mg kg ' 
11.9 
12.9 
21.7 
7.9 
LD,() 
mg kg ' 
40.5 
57.9 
84.7 
37.7 
Therapeutic Index 
3.4 
4.5 
3.9 
4.8 
4.2.2.2 Duration of action 
Sleeping time with a dose of 2 χ Н05
П
 in mice was about 5 min and similar to 
that obtained with thiopentone, but slightly longer than that observed with 
methohexitone. The time required to regain coordination in mice, as measured 
by the interval between recovery to walking and their ability to maintain their 
balance for 20 sec on a rod, was similar for methohexitone and propofol 
(3 min). After thiopentone mice needed about 40 min before they recovered 
completely. In contrast to thiopentone and propofol some exiratory effects, 
such as muscle tremor and twitching were noticed during recovery from 
methohexitone (Glen 1980). 
4.2.3 Pharmacokinetics 
Only a few reports are available about animal pharmacokinetics (Rhodes 
et al. 1977, Adam é ta l . 1980, Adam éta l . 1981). Adam éta l . (1981) have 
described a method for estimation of propofol in blood by high performance 
liquid chromatography. They used Gibbs reagent to couple propofol to 
increase the sensitivity of the assay. Their earlier method, using fluorescence 
assay procedure, had a detection limit of 300 μg m l - 1 (Adam et al. 1980). 
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4.2.3.1 Distribution 
In table 4 2 the most important pharmacokinetic parameters of some species 
are given as reported by Adams et al (1980) The data were treated according 
to a two-comparment model In these animals the central compartment is 
greater than the blood volume and varied between 33% body weight in rabbits 
to 90% body weight in cats This means that the central compartment contains 
also well perfused organs such as the brain This has been confirmed by 
autoradiography About 30 sec after intravenous administration propofol was 
accumulated in the central nervous system, liver and brown fat (Rhodes and 
Longshaw 1977) As can be expected from a lipophilic drug the total apparent 
volume of distribution is large between 133% body weight in cats to 275% in 
Pigs 
TABLE 4.2 
PHARMACOKINETIC PARAMETERS OF PROPOFOL 
IN SOME LABORATORY ANIMALS (ADAM ET AL. 1980). 
Species 
Rat 
Pig 
Rabbit 
Cat 
V 
% body weight 
43 
82 
33 
90 
Vx 
% body weight 
гЭД 
275 
15Ï 
133 
T l / 4 I 
mm 
1 1 
3 0 
19 
5 8 
τ,/>β 
min 
19 
40 
16 
55 
4.2.3.2 Metabolites 
In the species mentioned in table 4 2 the metabolites of major importance are 
the sulphate and glucuromdate of propofol itself and of 2,6-diisopropyl 1,4-
quinol (Glen, personal communication) 
4.2.3.3 Clearance 
Metabolic clearance from the body is rapid with an elimination half life (T^p) 
of 16-51 mm In some species, e g the rabbit, awakening occurs during the 
first distribution phase (Τι,
α
) Studies with continuous infusions of propofol 
were performed in pigs Their blood concentrations of propofol at awakening 
were similar to those at awakening after single bolus administration 
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Propofol has a sufficiently high vapour pressure at room temperature to 
be removed from the tissue section used for autoradiography. By examining 
low temperature sections and freeze dried sections at room temperature 
Rhodes and Longshow (1977) have demonstrated the presence of metabolic 
products of propofol in the liver 30 sec after intravenous injection. They 
concluded that the short anaesthetic action of propofol is a result of a rapid 
metabolism and not the result of distribution. 
4.2.3.4 Cumulation 
To compare the cumulative effects of propofol with thiopentone a dose 
sufficient to produce 5 min sleep, was given to mice. Thirty seconds after 
return of the righting reflex the same dose was administered. Recovery after 
the 10th dose of propofol was 15 min, indicating that there was slight 
cumulation. For thiopentone recovery after the 4th dose was more than 3 
hours (Glen 1980, Glen and Hunter 1984). 
Effects of over-dosing were studied in cats, because of their inability to 
conjugate phenols. These experiments demonstrated that large doses of 
propofol produce respiratory and cardiovascular depression. The lethal dose 
was 20 mg kg - 1 when ventilation was not supported. With controlled 
ventilation a dose of 30 mg kg - 1 was survived (Glen 1980). 
4.2.4 Hypersensitivity 
As described in chapter 2 histamine release can be caused by the drug itself or 
by the solubilising agents. The propensity of the Cremophor and emulsion 
formulation of propofol to produce histamine release was examined in a cross­
over experiment in dogs. In the animals given the emulsion formulation 
histamine concentration remained at base line value, whereas with the 
Cremophor formulation histamine level increased markedly (Glen and 
Hunter 1984). 
In anaesthetised pigs propofol had no effect on the resting bronchomotor 
tone. Injection of histamine 250 μgг kg - 1 i.v. produced a typical 
bronchoconstrictor effect (Glen 1985). 
4.2.5 Side effects 
4.2.5.1 Haemodynamic effects 
Haemodynamic studies were performed in Large White and Landrace pigs. 
The decrease in mean arterial blood pressure was similar for propofol 
(2.5 mg kg" ') and thiopentone (10 mg kg - 1 ) . Increase in heart rate with 
thiopentone was more pronounced (Glen 1980). Peripheral resistance 
decreased after propofol. This reduction in peripheral resistance was confirmed 
by other experiments with isolated perfused hind limb in cats. Under these 
circumstances reduction in peripheral resistance was dose related (Glen 1980). 
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For the haemodynamic responses no difference was found between the 
Cremophor formulation and the emulsion formulation (Glen and Hunter 
1984). 
Arterial blood pressure, cardiac output or total peripheral resistance did 
not change during propofol administration after pretreatment with propranolol 
or atenolol, although the size of the doses was not reported. This indicates that 
propofol anaesthesia is not accompanied by any significant sympathomimetic 
activity (Glen 1985). 
4.2.5.2 Respiratory effects 
In rabbits the respiratory effects of propofol were compared with those of 
thiopentone (Bellman and Pleuvry 1981). Sub-anaesthetic doses of both drugs 
produced no increase in artcrialized venous Рссь- Anaesthetic doses of both 
drugs resulted in an increase of arterialized venous Pco2· The time-course of 
this effect showed that thiopentone caused a significant increase of Pco2 for up 
to 20 min whilst for propofol Pco, values returned to normal in 10 min. For 
both agents the depression of respiratory rate was dose related, but the slope 
of the dose-response relationship was steeper for thiopentone than for 
propofol. Similar changes were observed in tidal volume. 
4.2.5.3 Perivenous and intra-arterial administration 
In the mid-tail region of mice tissue necrosis did not follow perivascular 
injection of propofol. Intra arterial administration in the rabbit central ear 
artery failed to produce any damage. Thiopentone produced macroscopic 
tissue necrosis (Glen 1980). 
4.2.5.4 Blood coagulation 
In rats the emulsion vehicle itself appeared to have a direct inhibitory effect on 
ADH induced platelet aggregation. With propofol emulsion the degree of 
aggregation was not significantly different from the results obtained with saline 
or thiopentone (Glen 1985). 
4.2.6 Interactions with anaesthetic adjuvants 
4.2.6.1 Premedication 
In mice sleeping time after an intravenous dose of propofol 25 mg kg - 1 was 
significantly increased following premedication with subcutaneous 
administration of chlorpromazine, diazepam, papaveretum or amylobarbitone. 
After premedication with opiates respiratory depression was more pronounced 
(Glen 1980). 
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4.2.6.2 Volatile anaesthetic agents 
Interaction studies with inhalation agents were performed in cats. After an 
induction dose of propofol anaesthesia was maintained with inhalation 
anaesthetics. The responses of the cats during maintenance reflected the 
pharmacological properties of the inhalation agents employed (Glen 1980). 
4.2.6.3 Neuromuscular blocking agents 
Potentiation of the action of suxamethonium, vecuronium and pancuronium by 
propofol in Cremophor has been demonstrated using a rat phrenic nerve 
hemidiaphragm preparation (Fragen et al. 1983). In this study Cremophor 
alone caused potentiation of action of suxamethonium and antagonised the 
effect of vecuronium and pancuronium. Furthermore complete recovery was 
not obtained by washing the preparation. It was postulated that propofol had 
an effect on the muscle itself and that the mechanism might involve an 
intracellular action. 
Another study (Wali 1983) suggested that propofol might increase 
intracellular calcium ion concentration. At present no literature is available 
concerning propofol in the emulsion formulation and its interaction with 
muscle relaxants in animals or in vitro preparations. 
Glen (1980) paid attention to the interaction between neuromuscular 
blocking drugs and the anaesthetic activity of propofol. No prolonged recovery 
could be demonstrated, nor were unexpected interactions observed. 
4.2.7 Interaction with endocrine systems 
The effect of propofol on ACTH stimulated Cortisol synthesis has been 
examined in bovine adrenocortical cells (Kenyon et al. 1985), guinea pig 
adrenal cells (Lambert et al. 1985, Robertson et al. 1985) and in vivo in rats 
(Glen 1985). The in vitro studies showed inhibition of 50% of the ACTH-
stimulated output with propofol concentrations of 1.1-1.7xl0_4mol litre -1 . 
Compared with thiopentone similar concentrations resulted in the same effect. 
However with etomidate 50% reduction was achieved with much lower 
concentrations l-4.6xl0_7mol litre -1. In rats anaesthetized with propofol a 
marked increase in corticosterone concentration followed the administration of 
ACTH. This increase could not be evoked in rats under etomidate anaesthesia. 
The effect of LH-stimulated testosterone output from Leydig cell preparations 
decreased by 50% with propofol 1.8xl0-4mol litre -1., whereas etomidate had 
no effect (Robertson et al. 1985). This observation suggests that propofol 
interferes with the initial stages of the biosynthesis of Cortisol, while etomidate 
acts at the level of llß-hydroxylase. 
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4.2.8 Teratogenic effect 
The investigations performed in the Biology Department of ICI 
Pharmaceutical Division to study the teratogenicity of propofol in rats and 
rabbits and its effect on fertility in male and female rats indicated that 
propofol, at least in these animals, is free from such side effects (Glen, 
personal communication) The results of these studies are not published yet. 
4.2.9 Porphyrinogenicity 
Parikh and Moore (unpublished data) examined the porphynnogenicity of 
propofol They could not demonstrate an increase of 5-aminolaevulinate 
synthase activity or changes in porphyrin synthesis 
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CHAPTER 5 
EFFECTS OF PREMEDICATION ON DIPRIVAN INDUCTION 
R J FRAGEN, Ρ M DE GROOD, E N ROBERTSON, L Η D J BOOIJ 
AND J F CRUL* 
INTRODUCTION 
Dipnvan, ICI 35868, a phenolic compound with the chemical structure 2,6-di-
isopropyl phenol, has been used to induce anaesthesia ι ν (Kay and Roily 
1977a and b, Kay and Roily 1980, Roily et al 1980, Rutter et al 1980) 
Dipnvan is dissolved in 16% cremophor EL and provided as a 1% solution A 
dose of 2 mg kg - 1 is recommended for induction in unpremedicated patients 
(Briggs et al 1981) The short duration of action is apparently caused by 
redistribution and rapid metabolism and the drug can be given by repeated 
injection or continuous infusion without cumulation (Adam et al 1980) 
Induction time may be dependent on dose and speed of injection (Kay and 
Stephenson 1980), a rapid injection time being advantageous Because studies 
with the current formulation have been performed mainly on unpremedicated 
patients, we examined the effects of premedication on speed of induction and 
frequency of side-effects 
METHODS 
Forty-five healthy adults were studied after giving verbal consent at the time of 
the preoperative visit They underwent elective surgery, did not abuse drugs or 
alcohol, had not recently been exposed to cremophor, had no history of atopy 
or allergy, and were not pregnant or nursing women They were randomly 
assigned to one of three groups to receive no premedication (group A), 
diazepam 10 mg orally (group B) or diazepam 10 mg orally plus 
dropendol 2 5-5 0 mg and pintramide 7 5-15 mg ι m (group C) 60-90 mm 
before induction of anaesthesia 
An ι ν infusion was inserted to a vein of the hand or forearm and arterial 
pressure, heart rate and respiratory rate were measured and recorded 
Induction of anaesthesia was accomplished with dipnvan 2 mg kg - 1 injected 
ι ν over 20 s Patients began counting at the onset of injection and induction 
time was defined as the time which elapsed from the start of injection until 
cessation of counting The time from the start of injection until eyelash reflex 
* As published in British Journal of Anaesthesia 54 913 
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disappeared was also measured. At the end of each minute for the next 3 min, 
arterial pressure, heart rate and respiratory rate were measured. Mean arterial 
pressure (MAP) was calculated by the formula: 
(diastolic pressure + pulse pressure/3). If apnoea occurred, its duration was 
recorded. Thereafter, conventional anaesthetics and myoneural blockers were 
administered. Any side-effects were recorded. If no spontaneous complaint on 
injection occurred, patients were asked if they had pain, and, if so, where. 
Comparisons of all measurements were analysed by a one-way analysis of 
variance except frequency of apnoea and pain on injection which were 
analysed by the Chi-square test (Runyon and Haber 1977). Differences were 
considered significant when P<0.05. 
RESULTS 
There were 10 females and five males in each group. A dose of diprivan 
2 mg kg" l produced unconsiousness in all patients. 
TABLE 5.1 
DEMOGRAPHIC DATA AND EFFECTS OF PREMEDICATION. 
Age (yr) 
Weight (kg) 
Stop counting (s) 
Loss of eyelash reflex (s) 
Apnoea (frequency, %) 
Apnoea (duration, s) 
Pain on injection (%) 
None 
32.3 (2.7) 
71.5 (2.9) 
39.7 (2.4) 
53.7 (3.0) 
80 
55.0 (5.6) 
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TYPE OF PREMEDICATION 
Diazepam 10 mg 
34.1 (2.4) 
72.2 (4.0) 
33.0(1.8) 
47.7 (2.2) 
80 
61.3 (7.7) 
60 
Diazepam 10 mg 
Droperidol 2.5-5.0 mg 
piritramide 7.5-15 mg 
34.5 (4.4) 
63.7 (2.0) 
35.0 (2.1) 
39.3 (2.9)* 
100 
64.7 (11.0) 
20 
* P<0.05 compared with no premedication. All other comparisons are not 
statistically significant. Except for the frequency of apnoea and pain on 
injection, all values shown are mean with SEM between perentheses. 
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Table 5 1 shows the ages, weights, induction times, frequency and duration of 
apnoea and frequency of pain on injection The only significant difference 
between the groups occurred m the time from the start of injection until loss 
of the eyelash reflex, with a shorter time for patients in group С compared 
with those who had no premedication There was a trend to a longer duration 
of apnoea as the amount of premedication increased There was also a lesser 
frequency of pain on injection (20%) in the group receiving a narcotic for 
premedication, and all patients in this group who experienced pain had the 
infusion to the back of the hand The back of the hand was the infusion site 
for two of seven who had pain on injection and no premedication, and seven 
of nine who had pain and received only diazepam The overall frequency of 
pain on injection was 42%, but in the groups not receiving a narcotic it was 
53% Spontaneous complaints of pain were offered by four patients who 
received no premedication, seven who received only diazepam and only one 
who received a narcotic The other complaints of pain were elicited by 
questioning the patient after the injection was completed 
Eight of the group who had no premedication and six of the group who 
had only diazepam (47% of both groups) began to awaken before the end of 
the 3-min period of observation Awakening did not occur in group С 
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Figure 5.1 Mean ± SEM for heart rale and mean arterial pressure (MAP) 
at control (0) and 1, 2, and 3 mm after injection of dipnvan Group A 
received no premedication, group В diazepam 10 mg orally, and group С 
diazepam ¡0 mg orally plus dropendol 2 5-5 0 mg and pintramide 7 5-
15 0 mg ι m f P<0 05 versus the same time in groups A and В 
* Р<0 05 versus control All other comparisons within the group or 
between groups are not significant (P>0 05) 
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Significant changes in mean arterial pressure (MAP) occurred within 
groups. MAP decreased from control at each of the three subsequent 
observations in the group with no premedication and at 2 and 3 min after 
injection in group C. The only significant differences between groups 
(FIG. 5.1) were for MAP recorded at 2 and 3 min, which was less in group С 
than in the group which received no premedication. There were no significant 
changes in heart rate from control in any group. Heart rates recorded at 1 min 
were significantly less than control in group C. 
DISCUSSION 
Premedication had no influence on the speed of induction when defined as 
time to cessation of counting. The mean times of 33.0-39.7 s are comparable to 
those reported by Major and others (1981), Roily, Versichelen and Zubair 
(1980) and Briggs, Dundee and Clarke (1981), and slightly faster than those 
reported by Rutter and colleagues (1980) and Rodgers and others (1980). Time 
to the loss of eyelash reflex was influenced by the amount of premedication 
and was significantly less when the oral and i.m. premedication was given than 
when patients were unpremedicated. The loss of eyelash reflex may not be a 
good end-point with diprivan as a mask can be applied to the face and other 
anaesthetics introduced when the patient stops counting. 
Premedication with droperidol and a narcotic in addition to diazepam 
caused the sleep produced by diprivan 2 mg kg "' to be of sufficient duration to 
last for the 3-min period of observation. Another advantage of this 
premedication was the reduced frequency of pain on injection. It appears that 
pain on injection can be reduced in both its frequency and severity by previous 
administration of a narcotic and by injecting to the forearm rather than the 
hand. 
Production of apnoea appears to be a feature of diprivan, since it 
occurred in 87% of the patients and lasted for the same amount of time 
regardless of the premedication used. A few patients were still apnoeic when 
they showed evidence of awakening from the injection. 
Diazepam, droperidol and piritramide produced a slower control heart 
rate than the other premedications. Diprivan itself caused no change in heart 
rate from control in our study, which differs from an increase in heart rate 
reported by Major and colleagues (1981). 
Most other investigators have reported, after diprivan, a decrease in 
arterial pressure of short duration which returned rapidly toward control. We 
also noted small decreases in mean arterial pressure which we considered to be 
clinically insignificant and which returned toward control by the end of the 3-
min observation period. 
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Although hypersensitivity reactions have been observed after injections of 
other drugs dissolved in cremophor, we observed no local or systemic reactions 
following injection of dipnvan 
We conclude from this study that dipnvan 2 mg kg - 1 administered ι ν 
over 20 s produces rapid loss of consiousness regardless of the premedication 
used This confirms the dose and speed of injection are the most important 
factors in determining time of induction Premedication with a narcotic and 
tranquillizer had the advantage of making the sleep produced by dipnvan more 
profound and reduced the frequency of pain on injection which is the most 
disturbing side-effect reported with dipnvan We consider this amount of 
premedication to be safe because we found no increase in effects on circulation 
or respiration or other side-effects which were clinically significant 
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CHAPTER 6 
PROPOFOL EMULSION FOR INDUCTION 
AND MAINTENANCE OF ANAESTHESIA 
A combined technique of general and regional anaesthesia 
P.M.R.M. DE GROOD, L.G.J. COENEN, J. VAN EGMOND, 
L.H.D J . BOOIJ and J.F. CRUL* 
INTRODUCTION 
Propofol (2,6-diisopropyl phenol), previously dissolved in cremophor EL, is a 
rapidly acting i.v. anaesthetic agent. Recently propofol has become available 
as a 1% w/v aqueous emulsion containing 10% w/v soya bean oil, 0.5% w/v 
egg phosphatide and 2.25% w/v glycerol. Several studies have described the 
properties of propofol in anaesthesia as an induction agent (Kay and 
Roily 1977, Fragen et al. 1982) as well as an agent for maintenance by 
continuous infusion techniques (Fragen et al. 1983, O'Callaghan et al. 1982). 
Dissolved in Cremophor EL propofol 2 mg kg - 1 gives a smooth induction 
within 45 sec. Rapid metabolism and minimal cumulation make this drug 
suitable for continuous infusion. Rapid recovery with a minimum of side 
effects is one of the major advantages. On the other hand, there is a high 
incidence of pain during injection. Another disadvantage is the circumstantial 
evidence for an association between cremophor containing agents and 
anaphylactoid reactions (Briggs et al. 1982). 
Animal studies have shown that in rats and mice the present formulation 
has a similar anaesthetic profile compared with the cremophor formulation 
(Glen and Hunter 1984). A combination of regional blockade and general 
anaesthesia with a continuous infusion of propofol made it possible to study 
the anaesthetic potency without interference from narcotic analgesics or other 
anaesthetic adjuvents. 
* Will be published in Acta Anaesthesiologica Scandinavica (1987) 
volume 31. 
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PATIENTS AND METHODS 
Thirty healthy (ASA class 1 or 2) unpremedicated patients, scheduled for 
elective surgery, consented to participate in this study, which was approved by 
the Hospital Ethics Committee. All patients had normal hepatic, renal, 
haemopoietic and endocrine function. They had no history of allergy to the 
drugs used in this study nor evidence of atopy. Grossly obese (more than 20% 
overweight in relation to their height) and pregnant patients were excluded 
from participation. 
Three combinations of doses for induction and maintenance of anaesthesia 
were used, as presented in table 6.1. Patients were randomly assigned to each 
group of 10 patients by a computer generated random series. 
TABLE 6.1 
DOSE REGIMENS OF PROPOFOL FOR INDUCTION AND MAINTENANCE 
IN THREE GROUPS OF 10 PATIENTS 
INDUCTION MAINTENANCE 
mg kg -1 mg kg^hr"1 
group 1 2.0 9 
group 2 2.5 12 
group 3 2.5 9 
In all patients a continuous i.v. drip infusion with saline 0.9% was started. 
The electrocardiogram was continuously monitored together with a finger 
plethysmogram. Arterial pressure was taken at 3 min intervals, using an 
automatic non-invasic blood pressure monitor (Dinamap). End-expiratory 
carbon dioxide pressure (PECO ) was monitored continuously using a calibrated 
capnograph. The baseline values of arterial pressure, heart rate, and 
ventilation rate were measured before induction and at intervals throughout 
the procedure. 
Regional blockade was achieved using: spinal anaesthesia with 4 ml 
buvivacaine 0.5%; epidural anaesthesia with 16-20 ml bupivacaine 0.5% with 
adrenaline or brachial plexus block with 30-40 ml prilocaine 1.5% with 
adrenaline. After successful induction of regional anaesthesia and stabilisation 
of the hemodynamic variables, the induction dose of propofol was 
administered over a period of 20-23 sec, directly followed by gallamine 10 mg 
and suxamethonium 1.5 mg kg"1 to facilitate endotracheal intubation. 
Anaesthesia was maintained with a continuous infusion of propofol using a 
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calibrated infusion pump commenced at induction. At the end of surgery the 
infusion was stopped. Additional bolus doses of propofol 30 mg were given on 
signs of light anaesthesia such as chewing on the tube, coughing or 
movements, or a sharp rise of arterial pressure not related to surgical stimuli. 
After suxamethonium had lost its clinical effects, spontaneous ventilation 
was allowed to return if surgical circumstances permitted this, and as long as 
P E r n remained below 6 kPa. When needed, patients were ventilated artificially 
with P E r o at 5 kPa. All patients received 40% oxygen in air. 
All side effects were recorded from induction of anaesthesia up to 24 h 
postoperatively. Abnormal or unexpected values of arterial pressure, heart 
rate or ventilation rate were noted as side effects. Bradycardia was defined as 
heart rate lower than 55 beats min - 1 . Hypotension was defined as a decrease 
of 25% or more of mean arterial pressure as related to preoperative values. 
The intensity of pain on injection was recorded as being mild, moderate or 
severe depending on the response of the patient to questioning: mild when a 
small amount of sensation was noted, moderate if discomfort was indicated 
and severe if discomfort was indicated spontaneously. Postoperatively the 
control of depth and smoothness of anaesthesia was evaluated by the lack or 
need for additional bolus doses. Onset of induction was defined in two ways: 
as the interval between start of administration of propofol and cessation of 
counting and secondly as the interval between start of administration of 
propofol and disappearance of eyelash reflex. Also two recovery times were 
defined: first as the interval from cessation of infusion until eyes were opened 
on command and secondly until simple questions were answered correctly. 
The mean rate of utilization of propofol was expressed in two ways. 
Rate 1 (mg kg^ 'hr - 1 ) was defined as the total dose of propofol given, 
including induction doses, divided by the time between induction and first sign 
of recovery. Rate 2 (mg kg - 1 hr~ l ) was defined as the total maintenance dose 
of propofol divided by the time between the end of the induction period (the 
moment when the endotracheal tube was inserted) and the first sign of 
recovery. For all patients the total induction dose of propofol per kg was 
calculated, including the extra doses if any were needed. 
Statistical calculations were carried out using the SPSS routine package 
(SPSS Inc., Chicago, Illinois). Analysis of variance (ANOVA) was used as a 
statistical test to analyse differences between groups. The Pearson correlation 
coefficient was used to investigate correlation between various parameters. 
Comparisons of incidences were performed by x2-test or Fisher's Exact Test 
(in a 2 χ 2 table). In statistical tests ρ < 0.05 was considered significant. 
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RESULTS 
The 10 patients in each group were comparable for age, weight, height and sex 
distribution and duration of anaesthesia (table 6.2). Distribution of types of 
regional blockade and the types of surgical procedures are presented in 
table 6.3. In group 2 two patients underwent a laparotomy; one for tube 
reconstruction and one for removal of the gallbladder. Both patients had 
epidural anaesthesia. 
TABLE 6.2 
DEMOGRAPHIC DATA MEAN AND (SD) 
Group 1 Group 2 Group 3 
η = 10 η = 10 η = 10 
Age (yrs) 39.8 (14.6) 41.8 (9.3) 35.6 (14.0) 
Weight (kg) 76.7 (9.6) 69.2 (13.6) 72.4 (11.8) 
Duration of anaesth. (hours) 0.9 (0.2) 1.1 (0.6) 0.8 (0.3) 
Sex (male/female) 5/5 5/5 6/4 
There is no significant difference between groups for either variable. 
Induction 
With both induction doses all patients lost consciousness. There were no 
differences between groups in induction times, whether measured from the 
start of injection until stopping of counting or until disappearance of eyelash 
reflex (table 6.4). 
However, during intubation a number of patients demonstrated a sharp 
rise of arterial pressure and heart rate accompanied by movements or coughs. 
These patients received an extra bolus dose of propofol. In group 1 this 
occurred more frequently than in the other groups. The total mean induction 
dose of propofol for the entire population was 2.55 mg kg - 1 . There were no 
differences between groups for the total induction dose (table 6.4). 
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TABLE 6.3 
DISTRIBUTION BY GROUPS OF REGIONAL ANAESTHESIA 
AND TYPES OF OPERATION. 
Groupl Group2 Group3 
n=10 n = 10 n=10 
TYPE OF REGIONAL ANAESTHESIA: 
Epidural 
Spinal 
Brachial block 
TYPE OF OPERATION: 
Hernia repair 
Laparotomy 
Orthopaedic surgery lower leg 
Orthopaedic surgery arm 
Urologica! surgery 
Vancous veins 
5 
3 
2 
1 
0 
5 
2 
0 
2 
2 
7 
1 
0 
2 
4 
1 
1 
2 
3 
7 
0 
3 
0 
5 
0 
1 
1 
Given are numbers of patients. 
TABLE 6.4 
Induction Times and Total Induction Dose of Propofol 
Number of Patients which were too light for Intubation and 
Incidence of Apnoea. 
Stop counting(sec) 
Vanish eye lash 
reflex (sec) 
total induction 
dose (mgkg - 1) 
Too light for 
intubation (n) 
apnoea(n) 
Groupl 
n=10 
53 (18) 
92 (46) 
2.4 (0.4) 
5* 
4* 
Group2 
n=10 
52 (23) 
73 (30) 
2.5 (0 1) 
1 
9 
Group3 
n=10 
48 (28) 
80 (60) 
2.7 (0.6) 
1 
9 
Group2+3 
n=20 
51 (24) 
77 (45) 
2.6 (0.5) 
2 
18 
Mean and (SD); * ρ < 0.05 vs group 2+3 (Fisher Exact Test) 
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The incidence of apnoea increased with the increasing induction dose 
(table 6.4). Because patients were under the influence of muscle relaxants 
immediately after induction, duration of apnoea was not measured. 
Thirty seven percent of all patients complained of pain on injection. Pain 
occurred more frequently (69%) when propofol was administered to the veins 
on the dorsum of the hand, than when it was injected to the larger veins of the 
fore arm (24%). Only one patient complained of severe pain. No other side 
effects such as excitatory phenomena or hiccups were seen during induction. 
Maintenance 
After recovery of neuromuscular block spontaneous ventilation was restored in 
all patients if surgical circumstances permitted, including those showing apnoea 
after induction. During maintenance no respiratory depression was observed. 
Respiratory rate as well as PEco remained within physiological limits. Two 
patients needed artificial ventilation because laparotomy was undertaken. 
Another two patients were ventilated because surgery had to be performed in 
the prone position. They all tolerated the ventilator without further muscle 
relaxation. 
In only one patient with spinal anaesthesia (group 1) did a fall of mean 
arterial pressure below 65 mmHg occur. This was successfully treated with 
ephedrine 10 mg i.v., and 500 ml extra fluid loading. No cardiac dysrhythmias 
occurred. 
During the whole procedure swallowing or chewing and bucking on the 
endotracheal tube was observed in 4 patients in group 1 and in one patient in 
each of group 2 and 3. Four patients in group 1, six patients in group 2 and 
five in group 3 had these symptoms, which disappeared after a single bolus of 
propofol 30 mg. Most of these extra bolus doses were given in the first 15 min 
of anaesthesia (fig 6.1). One patient (group 3) vomited after intubation. In 
only 9 patients was the continuous infusion of propofol alone sufficient for 
proper depth of anaesthesia. No patient woke up during maintenance and 
none had any awareness. The total dose of propofol (rate 1: 10.7-
12.9 mg kg_1hr_1) did not show differences between groups (table 6.5). If 
induction doses and the extra doses for intubation were excluded (rate 2) 
group 2 had the highest total maintenance dose of 10.3 mg kg^h r - 1 , 
statistically different from other groups (table 6.5). 
Recovery 
Recovery times varied widely and no significant differences between groups 
could be demonstrated (table 6.5). All patients in group 1 woke up within 
30 minutes. Two patients in groups 2 and 3 each had recovery times longer 
than 30 minutes. The longest recovery time, measured from stopping infusion 
till opening of eyes on command, was 59 minutes (group 2). Two minutes later 
this patient was capable of giving correct answers to simple questions. This 
short delay between the two differently defined recovery times was observed in 
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all patients. Moreover, after patients were able to answer simple questions 
correctly, there was no tendency to fall asleep again. Recovery was uneventful. 
Only short periods of mild euphoria occurred directly after awakening. All 
patients declared themselves satisfied with the anaesthesia technique and 
would choose the same technique, if possible, if they needed further 
operations. 
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FIG. (6.1) Histogram of the number of extra bolus doses propofol by group administered 
during the first 25 min of anaesthesia. 
DISCUSSION 
The combined technique of regional anaesthesia with a continuous infusion of 
propofol has the disadvantage of superimposing the cardiovascular 
disturbances. If hypotension occurs it may be an effect of propofol, of 
sympathetic blockade or of a combination of both. However, no major 
drawback was met during this study. 
Comparing propofol in the cremophor EL formulation with the new 
emulsion formulation, animal studies have shown a slight loss of potency in the 
emulsion form when it was given for induction of anaesthesia (Glen and 
Hunter 1984). From clinical studies the generally recommended induction dose 
of propofol in cremophor is 2 mg kg-1 over a period of 20 sec (Fragen 
et al. 1983, Rutter et al. 1980). In this study of the emulsion formulation 
(group 1) this appears to be too low a dose to allow intubation in a fair 
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number of patients. This supports the observations of the first clinical 
experience of propofol emulsion where a dose of 2.5 mg kg - 1 was sufficient to 
induce anaesthesia in 95% of unpremedicated patients (Cummings et al. 1984). 
TABLE 6.5 
RECOVERY TIMES AFTER CESSATION OF PROPOFOL INFUSION AND 
THE TOTAL DOSE AND MAINTENACE DOSE OF PROPOFOL 
Eyes open on 
command (min) 
Recall date of 
birth (min) 
total dose 
rate 1 (mgkg - 1 hr" 
maintenance dose 
rate 2 (mgkg - 1 hr" 
-
1) 
-
1) 
Groupl 
n= 
11.8 
13.6 
11.0 
8.6 
= 10 
(10.2) 
(10.6) 
(2.9) 
(2.3) 
Group2 
n= 
20.7 
22.6 
12.9 
10.3 
= 10 
(18.9) 
(19.2) 
(3.8) 
(2.3) 
Group3 
n= 
13.6 
19.1 
10.7 
7.5 
= 10 
(11.6) 
(18.9) 
(2.1) 
(1.4) 
Mean and (SD); * ρ < 0.05 ANOVA 
Nevertheless, in the present study there was no difference in onset of induction 
between the 2 mg kg - 1 and 2.5 mg kg - 1 induction doses. 
Pain during injection still occurred with the emulsion formulation, 
however, the incidence was lower than reported with the cremophor solution 
(Fragen et al. 1983). It would be expected, that with regional anaesthesia in 
the lower part of the body, the veins in the hand are more vasoconstricted. 
This may be an explanation for the higher incidence of pain here presented 
than found in another study with the emulsion formulation (Cummings 
et al. 1984). However Hynynen et al. (1985) reported an incidence of 67% 
severe pain during induction with propofol using the same criteria as in our 
study. 
A short period of apnoea due to induction with propofol has been 
reported for both formulations (Fragen et al. 1982, Fragen et al. 1983, 
O'Callghan et al. 1982, Rutter et al. 1980, Cummings et al. 1984, Major 
et al. 1981). In this study spontaneous ventilation during maintenance did not 
result in an increase of P E c o . With the cremophor formulation a slow increase 
of P E c o has been reported (Major et al. 1981, Prys-Roberts et al. 1983). 
However, in those studies the patients were premedicated with either pethidine 
or morphine i.m.. 
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The recovery times found in this study are comparable to those found in 
studies with the cremophor solution (Wright et al. 1984). For the nursing staff 
in the recovery room, it was very difficult to distinguish between patients with 
regional anaesthesia alone and patients with the combined technique of 
propofol and regional anaesthesia: more evidence for complete recovery from 
propofol anaesthesia. 
Several infusion rates (between 8-12 mg kg^'hr-1) needed to maintain 
general anaesthesia with propofol in cremophor have been reported (Fragen 
et al. 1983, Wright et al. 1984, Major et al. 1982). In those studies propofol 
infusion was combined with either fentanyl or nitrous oxide. One study 
reported a combination of general anaesthesia and regional block in well 
premedicated patients (O'Callaghan et al. 1982). In the latter study an infusion 
rate of 4.26 mg kg-1hr_1 was enough to allow toleration of a Hudson mask. 
Similar studies with propofol emulsion reported a mean administration rate of 
7.8 mg kg^'hr-1 with repeated bolus doses in unpremedicated patients 
(Mackenzie and Grant 1985) and a mean maintenance dose of 6.1 mg kg_1hr_1 
with a continuous infusion in premedicated patients (Jessop et al. 1985) 
It is obvious that acceptance of the endotracheal tube requires a deep 
level of anaesthesia. None of the combinations of induction and maintenance 
doses used in this study were sufficient to maintain anaesthesia at a level 
allowing toleration of an endotracheal tube in an accepetable percentage of 
patients. Bucking accompanied by hypersalivation, occurring in 60% of the 
patients during the maintenance period, supports these observations. 
Especially in group 1 extra bolus doses were also required during the induction 
period. This reflects the differences between groups for the maintenance dose 
of propofol (rate 2) in contrast with the total dose of propofol (rate 1). Since 
most of the extra bolus doses are given in the first 15 min of anaesthesia, it 
would be expected that higher infusion rates than used in this study are 
required during the initial part of the maintenance period; this needs to be 
studied separately. 
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CHAPTER 7 
PROPOFOL ('DIPRIVAN') EMULSION 
FOR TOTAL INTRAVENOUS ANAESTHESIA 
P.M.R.M. DE GROOD, A.H.C. RUYS, J.VAN EGMOND, L.H.D.J. BOOIJ 
and J.F. CRUL* 
INTRODUCTION 
Total intravenous anaesthesia (TIVA) has been used since the introduction of 
the first intravenous anaesthetics, thiopentone and hexobarbitone. Early 
experience was not encouraging, as the pharmacokinetics, toxicity and the side 
effects of the agents used were not well understood. Results were such that 
this type of anaesthesia was described as "an ideal form of euthanasia" 
(Halford 1943). More recently TIVA has gained in popularity as shorter 
acting, less toxic intravenous hypnotics and analgesics agents have become 
available (Dundee 1978). A second reason why TIVA is advocated nowadays 
is the avoidance of the possible harmful effects of waste anaesthetic gases on 
anaesthesiologists and operating theatre personnel. 
Propofol (2,6-diisopropylphenol), one of the more recent intravenous 
anaesthetic drugs, possesses good properties for induction and maintenance of 
hypnosis during TIVA (Major et al. 1982, Fragen et al. 1983). In the early 
clinical studies propofol, solubilized in Cremophor EL 16%, was shown to be a 
rapidly acting hypnotic with a short duration of action (Kay and Roily 1977). 
Rapid metabolism and little evidence of accumulation made propofol a 
promising drug for TIVA as well as for techniques which combine regional and 
general anaesthesia. However, its solvent Cremophor EL 16% was responsible 
for hypersensitivity reactions in susceptible individuals (Briggs et al. 1982, Dye 
and Watkins 1980) and a high incidence of pain during injection was seen with 
this early formulation. Propofol in Cremophor was therefore withdrawn from 
clinical trials. 
Recently, propofol has become available as a 1% w/v aqueous emulsion 
containing 10% w/v soya bean oil. Animal studies have shown that in mice and 
rats, this new formulation has anaesthetic properties similar to those of the 
earlier Cremophor formulation (Glen and Hunter 1984). The first studies with 
the propofol emulsion in man have shown a slight loss of potency during 
induction (Cummings et al. 1984). 
* As published in Postgraduate Medical Journal 
(1985) 61 (suppl 3), 65-69. 
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This paper reports our first experiences with the propofol emulsion for 
TIVA in 30 patients during routine procedures By following the same study 
design as Fragen et al (1983) we have been able to compare the hypnotic 
properties of this new formulation with the previously available Cremophor 
solution 
METHODS 
For TIVA we used the combination of propofol for hypnosis, fentanyl for 
analgesia and vecuronium for muscle relaxation when needed 
The protocol of the study was approved by the Hospital Ethics 
Committee Thirty healthy (ASA grade I or II) patients of either sex, 
between 18-65 years old, scheduled for elective surgery of less than 60 mm 
duration, gave their written consent to participate in this study of TIVA All 
patients had normal hepatic, renal, haemopoietic and endocrine function They 
had no history of allergy to the drugs used m the study, nor evidence of atopy 
Pregnant and grossly obese (more than 20% overweight in relation to height) 
patients were excluded from participation 
On arrival in the operating room, patients received a continuous 
intravenous infusion of Ringer's solution The electrocardiogram was 
continuously monitored together with a finger plethysmogram Arterial 
pressure was measured every 3 minutes using an automatic non-invasive blood 
pressure monitor (Dinamap®) End expiratory P C O i was monitored 
continuously using a calibrated capnograph The baseline values of arterial 
pressure, heart rate and respiration rate were measured before induction and 
at intervals throughout the procedure 
Patients received a single dose of fentanyl 1 875 μg kg - 1 90 sec before 
induction of anaesthesia which was achieved with a single dose of propofol 
2 mg kg - 1 given over 20-25 sec After the patients had lost consciousness, 
vecuronium 0 08-0 1 mg kg - 1 was given to facilitate endotracheal intubation A 
supplementary bolus dose of propofol 30 mg was given at this stage if 
anaesthesia was considered unsatisfactory for intubation 
Anaesthesia was maintained immediately after induction by infusions of 
propofol and fentanyl using two calibrated infusion pumps For the first 
30 minutes the infusion rate of propofol was 9 mg kg - 1 h r - 1 and that of 
fentanyl was 7 5 μg kg - 1 h r - 1 Thereafter both infusion rates were decreased by 
50% 
Additional bolus doses of propofol 30 mg were given on signs of 
lightening anaesthesia such as chewing on the tube, coughing or movement not 
related to surgical stimuli Additional bolus doses of fentanyl 0 05 mg were 
given in the event of painful reaction to surgical stimuli, judged by movement 
or the cardiovascular response Patients were ventilated to normocapnia with 
40% oxygen and expiratory Pco was maintained between 4 5 and 5 5 vol% 
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The speed of induction was defined in two ways: as the interval between 
the start of administration of propofol and the cessation of counting; and also 
as the interval between the start of administration of propofol and the loss of 
the patient's eyelash reflex. Two recovery times were defined: as the interval 
from cessation of the infusion to opening eyes on command and to answering 
simple questions correctly. All side effects were recorded from induction up to 
24 hr postoperative. Abnormal or unexpected values of arterial pressure, heart 
rate or respiration rate were noted as side effects. Bradycardia was defined as 
heart rate lower than 55 beats min - 1 Hypotension was defined as decrease of 
25% of mean arterial pressure as related to preoperative values. The intensity 
of pain on injection was recorded as being mild, moderate or severe depending 
on the response of the patient; mild after a small amount of sensation, 
moderate if discomfort was indicated after questioning and severe if discomfort 
was indicated spontaneously or the arm used for injection withdrawn. 
At the end of surgery, recovery from the neuromuscular blockade was 
determined by a muscle relaxation monitor (Myotest®) and, if indicated, 
edrophonium with atropine was given to antagonize muscle relaxation before 
stopping the infusion pumps and the ventilator. During recovery, apnoeic 
patients in whom end expiratory P c o , was above 7.0 vol% received 0.04 mg 
naloxone i.v. at 1 min intervals until spontaneous respiration was restored. 
After the procedure the anaesthetist assessed the control of anaesthesia 
by considering the need for additional bolus doses of either fentanyl or 
propofol and also the occurrence of side effects. The quality of recovery from 
anaesthesia was assessed within 3 hours after the procedure and the need for 
nalaxone, duration to opening of eyes on command and the occurrence of side 
effects were considered. 
The mean rate of utilization of propofol was expressed in four ways. 
Rate 1 was defined as the total dose of propofol divided by the duration of the 
infusion of propofol. Rate 2 was defined as the total dose of propofol, minus 
the induction dose, divided by the duration of the infusion of propofol. Rate 3 
was defined as the total dose of propofol divided by the interval between 
induction and the first indication of recovery (eyes open). Rate 4 was defined 
as the total dose of propofol, minus the induction dose, divided by the interval 
between induction and the first sign of recovery. Trieger tests (Newman 
et al. 1969) were performed 1 and 3 hr after the infusions had been 
discontinued and were compared to baseline values taken prior to surgery. 
Because the infusion rates of propofol and fentanyl were decreased by 
50%, 30 min after induction, three groups of patients were formed 
retrospectively with regard to the duration of anaesthesia. The duration of 
anaesthesia in group 1 (23 patients) was less than 30 min; the duration of 
anaesthesia in group 2 (5 patients) was between 31 min and 60 min and the 
duration of anaesthesia in group 3 (2 patients) was greater than 1 hour. 
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Patients were grouped in this way in order to explore the possibilty of 
accumulation of propofol 
Analysis of variance and Student's t test were used for testing differences 
between group means The Pearson correlation coefficient was used to discuss 
correlation between data Ρ < 0 05 was considered to be significant 
RESULTS 
Nineteen women and eleven men were included m this study Sixteen women 
had a laparoscopy or dilatation and curettage The remaining patients 
underwent a variety of general procedures including orthopaedic and urological 
surgery Two procedures were of longer duration than expected (65 mm and 
180 mm) The age, weight and duration of anaesthesia of the patients are 
presented in Table 7 1 
TABLE 7.1 
DETAILS OF 30 PATIENTS AND THE INDUCTION TIMES AND RECOVERY TIMES 
mean 
SD 
range 
Age 
(У) 
31 5 
7 7 
19 48 
We1ght 
(kg) 
62 9 
9 0 
46 5-78 5 
Duration of 
anaesthesia 
(h) 
0 52 
0 52 
0 15-3 
Stop count 
(s) 
39 4 
11 5 
20-68 
Vanish eve-
lash reflex 
(s) 
56 9 
26 5 
20 142 
Eyes open 
(mm) 
10 5 
9 3 
2 7-53 
Oriented 
(mm) 
11 5 
9 6 
2 9-54 
Induction 
Anaesthesia was successfully induced after a single dose of propofol 
2 0 mg kg- 1 in all but one patient who required a further supplement of 
propofol 50 mg This patient ceased counting after 38 sec, but the eyelash 
reflex was still present after 100 sec The mean time from the start of injection 
to cessation of counting was 39 4 sec and that to the loss of the eyelash reflex 
was 56 9 sec (Table 7 1) Apnoea during induction occurred in all patients 
although the duration was not recorded as vecuronium was given immediately 
after anaesthesia was induced 
Intubation was difficult in 3 patients as the result of insufficient 
anaesthesia These patients coughed and manifested a rise in arterial pressure 
and heart rate Pain on injection was seen m 6 patients, 2 patients complained 
of severe pain, one patient had moderate pain and the remaining 3 patients 
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described mild pain during injection. No other side effects were recorded 
during induction. 
Maintenance and recovery 
Anaesthesia was judged satisfactory in 12 patients. No supplementary bolus 
doses were required. Six of these patients required nalaxone to antagonize the 
respiratory depression related to fentanyl. Periods of unsatisfactory anaesthesia 
were observed in 18 patients, nine of whom also showed reactions to painful 
stimuli and required an extra dose of fentanyl. Only one of these nine patients 
received nalaxone during recovery. 
During the maintenance period anaesthesia was considered to be good in 
11 patients, adequate in 16 patients. In 3 patients anaesthesia was 
unsatisfactory throughout the procedure and judged as poor. 
Changes in heart rate and arterial pressure varied with the quality of 
anaesthesia. Hypotension (more than 25% decrease of mean arterial pressure 
related to preoperative values) was not observed. Only one patient had 
bradycardia (48 beats min - 1) which was easily treated with atropine. No 
cardiac dysrhythmia occurred. 
TABLE 7.2 
UTILIZATION OF PROPOFOL (mg kg^hr"1) IN 30 PATIENTS 
Mean 
SD 
Range 
Rate 1 
15.6 
4.5 
8.45-24.4 
Rate 2 
10.0 
2.4 
6.6-16.9 
Rate3 
11.6 
3.8 
4.1-20.3 
Rate 4 
7.5 
2.2 
13.6-23 
RATE 1: total dose propofol per kg body weight per hour duration of 
anaesthesia. RATE 2: total dose propofol during maintenance per kg body 
weight per hour duration of anaesthesia. RATE 3: total dose propofol per kg 
body weight per hour the patient was asleep (from induction until eyes open). 
RATE 4: total dose propofol during maintenance per kg body weight per hour 
the patient was asleep (from induction until eyes open). 
The mean rate of utilization of propofol, rates 1 to 4, were 
15.6, 10.0, 11.6 and 7.5 mg kg - 1 hr - 1 , respectively (Table 7.2). The mean time 
interval between discontinuation of the propofol and fentanyl infusions and 
patients opening there eyes was 10.5 min (Table 7.1). The mean interval 
between dicontinuation of the infusions and patients being orientated and 
65 
being capable of giving adequate answers to simple questions was 11.5 min. 
One patient had extremely prolonged recovery times of 53 and 54 min, 
respectively (Table 7.1), which we were unable to explain. The short delay 
between being able to open eyes on command and to being orientated was 
seen in all patients. Three hours postoperatively there was no significant 
difference in the performance of the Trieger tests compared with those 
preoperatively (Table 7.3). One hour postoperatively, one patient failed in the 
Trieger test (score 25% of the base line value). 
TABLE 7.3 
TRIEGER TEST IN 30 PATIENTS 
Mean 
SEM 
Range 
Praeoperative 
97.8 
0.8 
80-100 
1 hr 
postoperative 
93.6 
2.7 
25-100 
3 hrs 
postoperative 
97.7 
1.1 
75-100 
100% no dots are missed; at 0% all dots are missed 
The most notable side effects occurring during early recovery were short 
periods of euphoria which occurred in 8 patients and periods of depression 
which occurred in 7 patients. Cough, resulting from an irritated airway due to 
endotracheal intubation, occurred in 2 patients. Four patients vomited, one 
complained of headache and one patient, who underwent a laparoscopy, had 
hiccups. Three patients vomited a few hours after their laparoscopy (Table 7.4) 
Three hours postoperatively the side effects had disappeared. The anaesthetist 
recorded the quality of recovery as good in 19 patients, adequate in 4 patients 
and poor in the remaining 7 patients. 
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TABLE 7.4 
POSTOPERATIVE COMPLICATIONS 
Euphoria 
Depression 
Cough 
Headache 
Hiccups 
Nausea/vomiting 
First 3 hours 
8 
7 
2 
1 
1 
4 
3-24 hours 
0 
0 
0 
0 
0 
3 
TABLE 7.5 
CLASSIFICATION ACCORDING TO DURATION OF ANAESTHESIA 
Duration of 
anaesthesia (min) 
number of patients 
Body weight (kg) 
Age (years) 
Open eyes (min) 
Oriented (min) 
Rate 1* (mg k g ^ ' h r - 1 ) 
Rate 2* (mg k g ^ h r " 1 ) 
Rate 3* (mg k g - ' h r - 1 ) 
Rate 4 (mg kg^ 'hr" 1 ) 
fentanyl* ^ g k g ^ h r - 1 ) 
0 
61 
33 
9.9 
10.9 
17.4 
10.8 
12.8 
8.0 
145 
-30 
23 
(9) 
(7) 
(10.3) 
(10.5) 
(3.3) 
(2.1) 
(3.6) 
(2.3) 
(3) 
31 
68 
26 
12.5 
14.2 
10.8 
7.9 
8.5 
6.2 
96 
-60 
5 
(8) 
(6) 
(7.2) 
(7.0) 
(8.0) 
(0.4) 
(0.9) 
(0.9) 
(0.7) 
>60 
70 
24 
12.4 
12.8 
7.3 
6.0 
6.5 
5.4 
72 
2 
(0) 
(0) 
(2.3) 
(2.4) 
(1.6) 
(0.8) 
(1.1) 
(0.4) 
(0.2) 
* Ρ < 0.01 ANOVA. For Rate 1 - 4 see Table 7.2. Fentanyl: 
total dose fentanyl per kg per hour duration of anaesthesia. 
Results are given in mean and SD between parentheses. 
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The results of the groups classified by duration of anaesthesia are shown 
in Table 7 5 There was no statistically difference in recovery between the 
groups In contrast there was a significant difference between the groups with 
respect to the utilization rates of propofol (rate 1, rate 2 and rate 3), as well as 
the utilization rates of fentanyl 
DISCUSSION 
Both animal studies (Glen and Hunter 1984) and clinical studies in man 
(Cummings et al 1984) have shown a slight loss of potency in propofol in the 
emulsion formulation when given for induction as compared with the 
Cremophor formulation 
Induction with propofol 2 mg kg - 1 preceded by fentanyl 0 1875 μg kg - 1 
resulted in the same induction times as reported after an induction dose of 
propofol 2 5 mg kg - 1 alone (Cummings et al 1984) Pain on injection with the 
present formulation was much lower than with the cremophor formulation 
(Fragen et al 1982) However, fentanyl may have influenced these results 
The sixteen patients presented for laparoscopy or dilatation and curettage 
in this study were fully comparable with the patients reported earlier by 
Fragen et al (1983) Mean recovery times were similar in both studies 
although there was greater inter-individual variation in this study resulting in a 
greater standard deviation (Table 7 6) 
TABLE 7.6 
RECOVERY TIMES WITH PROPOFOL IN AN EMULSION FORMULATION 
COMPARED WITH PROPOFOL IN CREMOPHOR EL. 
Number of patients 
Age (y) 
Weight (kg) 
Anaesthesia time (mm) 
Open eyes (mm) 
Oriented (mm) 
Group gynaecology* 
emulsion formulation 
33 
60 
18 
9 1 
10 
16 
( 6 1) 
( 9 7) 
( 5 4) 
(118) 
(119) 
Fragen 
Cremophi 
36 8 
64 2 
21 1 
9 5 
11 9 
et al. (1983) 
эг formulation 
15 
(12 1) 
(10 8) 
( 5 5) 
( 3 1) 
( 3 6) 
* women with laparoscopy and D and С 
Results are given in mean and SD parentheses 
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The overall assessment of the control of anaesthesia could be considered 
as good providing that the need for supplementary doses of either propofol or 
fentanyl was accepted. 
For longer procedures there was evidence of accumulation as shown by 
the recovery times after longer procedures being no different to those after 
shorter procedures in spite of significant lower utilization rates. This confirmed 
the observations with propofol by Major et al. (1982), who, referring to the 
Cremophor formulation, recommended an initial infusion rate of 12 mg kg -1 
which was decreased towards the end of surgery. 
The warning of Wright et al. (1984) that with Cremophor formulation of 
propofol infusion rates of 7.8 mg kg-1 produced unacceptable decreases in 
arterial pressures was not confirmed by our observations with the emulsion 
formulation. 
Unpleasant side effects seen during recovery were nausea and vomiting, 
these occurred only in female patients having had laparoscopics. Euphoria and 
depression were of short duration and accepted by the patients as harmless. 
The wide variability in induction times and recovery times indicated that 
the dose requirements of propofol varied considerably between patients. This 
could be attributed to the emulsion formulation since studies with the 
Cremophor formulation indicated less variability (Major et al. 1982, Fragen 
et al. 1983). However, variations in dose requirements were demonstrated in 
pharmacokinetic studies with propofol in Cremophor in man (Adams 
et al. 1982). 
In conclusion, propofol in the emulsion formulation is a suitable agent for 
TI VA. The main advantage is the rapid recovery and the absence of "hang-
over" sedation. A disadvantage is the variability in control of anaesthesia 
during the maintenance period, caused by inter-individual variability in dose 
requirements. In our opinion this disadvantage will disappear when more 
experience with propofol is gained. 
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CHAPTER 8 
LACK OF EFFECTS OF EMULSIFIED PROPOFOL ('DIPRIVAN') 
ON VECURONIUM PHARMACODYNAMICS. 
Preliminary results in man. 
P.M.R.M. DE GROOD, J. VAN EGMOND, M. VAN DE WETERING, 
H.B. VAN ВЕЕМ, L.H.D.J. BOOIJ AND J.F.CRUL* 
INTRODUCTION 
Potentiation of neuromuscular blocking drugs with propofol in Cremophor EL 
has been demonstrated in animal studies (Fragen et al. 1983) as well as in man 
(Robertson et al. 1983). These authors distinguished between the influence of 
propofol itself and its solvent Cremophor EL on nondepolarizing and 
depolarizing drugs. The possible mechanism was stated to be a direct effect on 
muscle possibly at an intracellular level, resulting in potentiation of 
nondepolarizing muscle relaxants such as vecuronium. On the other hand 
Cremophor appeared to inhibit Cholinesterase activity, resulting in potentiation 
of the effect of suxamethonium and inhibition of the effect of the 
nondepolarizing blockers (Fragen et al 1983). 
In man, during steady state neuromuscular blockade induced with an 
infusion of vecuronium, propofol (2 mg kg-1) in Cremophor caused a decrease 
in twitch height of 21.8% (Robertson et al 1983). 
With the recent availability of propofol in an emulsion formulation we 
have studied the influence of the new formulation, given as an intravenous 
(i.v.) bolus or an infusion, on the pharmacodynamics of vecuronium. 
METHODS 
Studies were performed in 42 healthy (ASA I or ASA II) patients aged 
between 18 and 65 years. Patients gave their informed consent before 
participating in the study. The protocol was approved by the Hospital Ethics 
Committee. Only patients with normal hepatic, renal, haemopoietic and 
endocrine function without a history of allergy to the drugs used in this study 
and without an atopy were allowed to participate. 
* As published in Postgraduate Medical Journal 
(1985) 61 (suppl 3):28-30. 
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The patients were randomly allocated to two groups. "Propofol 
anaesthesia" was given in one group; "thiopentone anaesthesia" was given in 
the second group. Induction was with fentanyl 4 μg kg - 1 and with either 
propofol 2 mg kg - 1 over 20 sec i.v. or thiopentone 5 mg kg - 1 . Anaesthesia 
was maintained with either propofol 9 mg k g ^ h r - 1 i.v. for the first 30 min and 
4.5 mg k g ^ h r - 1 thereafter, or with incremental doses of thiopentone 50 mg 
given at regular intervals. In both groups fentanyl 0.05 mg was given 
intravenously as required, the need for a supplementary dose being indicated 
by signs such as changes in arterial pressure, heart rate and amplitude of finger 
plethysmogram in response to painful stimulation. In all patients, intubation 
of the trachea was performed shortly after induction (without muscle relaxants) 
after spraying the pharynx, larynx and trachea with 4% lignocaine (up to 
4 ml). Mechanical ventilation of the lungs with 67% nitrous oxide in oxygen 
was used to maintain the end-expired carbon dioxide concentration between 
4.5 and 5 vol%. 
The ulnar nerve was stimulated supramaximally through surface 
electrodes near the wrist at a rate of 0.1 Hz and a pulse duration of 0.2 ms. 
The isometric twitch tension of the thumb was measured with a force-
displacement transducer, and recorded on a polygraph. Three different 
investigations were undertaken: 
Determination of cumulative dose-response curves of vecuronium. 
When the twitch height had been stable for 10 min, small cumulative doses of 
vecuronium (initial dose 0.015 mg kg - 1 , then smaller doses of 0.005 mg kg - 1 ) 
were given intravenously to 11 patients under propofol anaesthesia and to 
9 patients with thiopentone anaesthesia. Incremental doses were given when 
three consecutive twitches of equal height were observed following the 
previous dose. From the results, a dose-response curve was constructed for 
each patient using the model in which the blockade is described as a "normal 
probability integral" (NPI) function (integrated Gaussian). For each patient, 
ED50 (dose expected to give 50% block), σ (standard width of the underlying 
Gaussian) and ED90 (EDso + 1.28 x σ) were calculated (Robertson 
et al 1983). The mean ED50 , EDÇQ and σ of each anaesthesia group were 
compared. 
Determination of pharmacodynamic variables after i.v. bolus injection of 
vecuronium. 
Bolus injections of vecuronium 0.043 mg kg - 1 were given intravenously to 
9 patients in each group. The onset time (from end of injection to maximum 
effect), duration 25 (time from end of injection to 25% twitch recovery), 
duration 90 (time from end of injection to 90% twitch recovery), recovery 
index (time from 25% to 75% recovery) and degree of blockade were 
determined for each patient. 
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Determination of influence of propofol on neuromuscular function in the 
presence of steady-state neuromuscular blockade. 
For five patients with thiopentone anaesthesia and five patients with propofol 
anaesthesia, a continuous infusion of vecuronium at a rate of 2-3 mg hr" ' was 
started after an initial bolus of 0.02 mg kg - 1 . A constant twitch depression of 
30-60% was obtained by this method. After a stable blockade for at least 
15 min, a bolus injection of propofol 2 mg kg - 1 over 20 sec for the 
thiopentone group and 4 mg thiopentone for the propofol anaesthesia group 
was given i.v.. And the effect on the twitch height was recorded while the 
infusion of the neuromuscular blocking drug was continued at constant rate. 
After the second patient had participated in this part of the study, we 
deceided to lower the bolus dose of propofol and thiopentone with 50%. The 
reason for this change was a decrease in systolic blood pressure below 
80 mmHg in the second patient (with propofol bolus). 
All results were analysed using Student's t-test for paired or unpaired 
observations when appropriate. P<0.05 was considered to be significant. 
RESULTS 
There were no differences between the two groups in either the cumulative 
dose response curves or the pharmacodynamics of vecuronium 
(Table 8.1 and 8.2). Propofol 1 mg kg - 1 i.v. given over 20 sec during a 
steady-state infusion of vecuronium did not show any change in the degree of 
neuromuscular blockade. Thiopentone 2 mg kg - 1 did not have any effect 
either. 
TABLE 8.1 
ED50, ЕОод AND о CALCULATED FROM DOSE RESPONSE CURVES 
OF BOTH ANAESTHESIA GROUPS. 
Anaesthesia π ED ^  ED 9ц σ 
μ£ kg - 1 μ£ kg - 1 μ« kg 
Propofol 11 25.6 (2.0) 39.3 (3.3) 10.7 (1.1) 
Thiopentone 9 24.0 (1.7) 37.1 (1.9) 10.2 (0.8) 
Values are means with SEM in parentheses, η = number of patients 
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TABLE 8.2 
COMPARISON OF PHARMACODYNAMICS OF VECURONIUM 43 μΟ KG - 1 
DURING THE TWO DIFFERENT ANAESTHESIA TECHNIQUES. 
Anaesthesia 
Propofol 
Thiopentone 
η 
9 
9 
Onset 
time 
(min) 
3.7 (0.4) 
4.3 (0.5) 
Duration 
25 
(min) 
14.3 (1.1) 
16.4 (1.5) 
Duration 
90 
(min) 
29.0 (2.4) 
30.0 (2.5) 
Recovery 
index 
(mm) 
10.2 (0.94) 
9.0 (0.7) 
Maximum 
block 
(%) 
97 (1.6) 
97.3(1.8) 
Values are means with SEM in parentheses. 
During induction of anaesthesia with propofol the vocal cords in all 
patients were wide open and endotracheal intubation was unhindered. After 
induction with thiopentone, the vocal cords half open or closed during 
intubation and coughing was common in these patients. 
DISCUSSION 
The EDjo (25.6), ЕОад (39.3) and σ (10.7 μg kg - 1 ) found in this study are a 
little higher than the values found by Robertson et al. (1983) 
(20.8, 32.4, and 9.1 μg kg - 1 respectively). 
The pharmacodynamics of vecuronium during anaesthesia with propofol 
in the emulsion formulation show a faster onset and longer duration 25 and 90 
and also a longer recovery rate when compared with anaesthesia with propofol 
in Cremophor (Robertson et al. 1983). However, these differences are in the 
range of 1.5 min for the mean values and, therefore, of no clinical relevance. 
Since there is no difference between our groups, and since a bolus of propofol 
has no influence on the steady-state neuromuscular blockade with a 
vecuronium infusion we conclude that there is no potentiation of the 
neuromuscular blockade of vecuronium with propofol in the emulsion 
formulation when compared to thiopentone anaesthesia. This is also to be 
expected with other muscle relaxants. Higher doses of thiopentone than those 
used in this study should provide better intubation conditions, but would also 
cause unacceptable cardiovascular depression. Therefore in studies with 
muscle relaxants, where intubation without muscle relaxants is required, the 
use of propofol for induction is indicated. 
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CHAPTER 9 
COMPARISON OF ETOMIDATE AND PROPOFOL FOR 
ANAESTHESIA IN MICROLARYNGEAL SURGERY 
P.M.R.M. DE GROOD, S. MITSUKURI, J. VAN EGMOND, 
J.M.J. RUTTEN and J.F. CRUL.* 
INTRODUCTION 
Anaesthesia for microlaryngeal procedures requires a special approach. On the 
one hand the surgeon wants an unhindered view on the vocal cords and the 
upper part of the trachea, while on the other the anaesthetist has to provide 
adequate ventilation. Moreover, microlaryngeal surgery necessitates a deep 
level of anaesthesia to prevent vocal cord movements and other reactions to 
surgical stimuli. Recovery from anaesthesia must be rapid to prevent possible 
aspiration of blood or debris (Agosti 1977). 
Jet ventilation is accepted as the best ventilation technique for 
microlaryngeal surgery. Total intravenous anaesthesia in combination with jet 
ventilation is recommended as the technique of choice for vocal cord surgery 
and other procedures in the upper airways (Tobias et al. 1977, Ewalenko 
et al.1981, Gebts and Camu 1981, Sia et al. 1982). The combination of 
inhalation anaesthesia and jet ventilation is difficult. The lack of equipment for 
accurate administration of mhalation anaesthetics as well as the heavy 
pollution with waste anaesthetic gases and vapours (directly into the face of 
the surgeon) are problems still to be solved. 
Several drugs can be used for total intravenous anaesthesia. The 
combination of etomidate, fentanyl and suxamethonium has been 
recommended for microlaryneal surgery (Ewalenko et al.1981, Gebts and 
Camu 1981, Sia et al. 1982) and has been used in our hospital for several 
years. After the introduction of alfentanil, fentanyl was replaced in our 
technique by this new short acting narcotic. Recently propofol (2,6-
diisopropylphenol in an emulsion of soya bean oil) became available as a 
hypnotic agent. It has been demonstrated to have good properties for 
induction as well as for maintenance of anaesthesia (Cummings et al. 1984, 
De Grood et al. 1985, Grounds et al. 1985, Redfern et al. 1985, Rolly 
et al.1985, Robinson et al. 1985, Kay et al. 1986). 
* Will be published in Anaesthesia (1987). 
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The aim of this study is to investigate whether propofol has advantages 
over etomidate for microlaryngeal procedures. 
PATIENTS AND METHODS 
Thirty patients ASA class 1-3, aged between 20 and 79 years, scheduled for 
microlaryngeal procedures were studied. They had no history of allergy to the 
drugs to be used or evidence of atopy. No patient with a history of serious 
hepatic, renal, haematological or metabolic disease was included. All patients 
gave their informed consent before participating in the study, which was 
approved by the Hospital Ethics Committee. The patients were premedicated 
with atropine 0.5 mg intramuscularly approximately 30 mininutes before 
induction. Prednisolone 25 mg intramuscularly was added to the 
premedication to reduce postoperative laryngeal oedema. 
On arrival in the operating theatre, an indwelling cannula was inserted in 
a large vein on the dorsum of the hand or forearm and was connected to an 
infusion of Ringer's solution. The electrocardiogram and finger plethysmogram 
were continuously monitored. Arterial pressure was measured using an 
automatic non-invasive blood pressure monitor (Dinamap®). The baseline 
values of arterial pressure and heart rate were measured before induction and 
subsequent measurements were made 2 minutes after induction and at 
5 minutes intervals thereafter. 
The patients were randomly allocated to two groups of 15 patients each. 
In group 1 propofol 2 mg kg - 1 was used for induction. For maintenance a 
continuous infusion of the same agent was given: 12 mg k g ^ h r - 1 for the initial 
10 minutes, followed by 9 mg kg _ 1 hr _ 1 for another 10 minutes and thereafter 
6 mg kg^'hr - 1 . In group 2 anaesthesia was induced by etomidate 0.3 mg kg - 1 
followed by continuous infusion of 1.8 mg k g ^ h r - 1 for the first 10 minutes 
1.5 mg kg^'hr - 1 for the next 10 minutes and 1.0 mg kg~1hr~I thereafter. Both 
drugs were administered by a calibrated syringe pump. Propofol was given in 
undiluted form (10 mg ml - 1 ) and etomidate was used in a concentration of 
2 mg т Г 1 (4 ml of 125 mg etomidate base per ml of ethyl alcohol diluted to 
250 ml with normal saline). 
In both groups a bolus dose of alfentanil 0.5-1 mg was administered 
60 sec prior to induction. Further bolus doses of alfentanil 0.5-1 mg were given 
on signs of painful reactions to surgical stimuli. Topical anaesthesia of the 
larynx and vocal cords was performed with lignocaine 4% spray with a 
maximum volume of 3 ml. Suxamethonium was given to facilitate tracheal 
intubation and incremental bolus doses of 25 mg were given when needed. Jet 
ventilation was performed with 100% oxygen via a CH14 nasotracheal catheter 
using an Accutronic® high frequency jet ventilator. 
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Onset of anaesthesia was defined in two ways: firstly, as the interval 
between start of administration of the hypnotic agent and cessation of counting 
and secondly as the interval between start of administration of the hypnotic 
agent and disappearance of eyelash reflex. Two recovery times were also 
defined: the interval from cessation of infusion until opening eyes on command 
and that until correct response to simple questions. Recovery of anaesthesia 
was assessed by the Steward score (Steward 1975) 5, 15 and 30 minutes after 
the first response to opening eyes on command. 
All side effects were recorded from induction of anaesthesia up to 
24 hours postoperatively. The intensity of pain on injection was recorded as 
being mild, moderate or severe, depending on the response of the patient to 
questioning : mild when minor sensations were noted, moderate if discomfort 
was admitted on request and severe if discomfort was indicated spontaneously. 
Depth and smoothness of anaesthesia were evaluated postoperatively with 
regard to the lack of, or need for, additional bolus doses of alfentanil and 
suxamethonium. 
The statistical calculations were carried out using the SPSS routine 
package (SPSS Inc., Chicago, Illinois). Analysis of variance was used as 
statistical test to analyse differences between groups. Comparisons of 
incidences were performed by χ2 test or Fischer's Exact Test (in a 2 x 2 table). 
The Student Τ test was used for paired observations. In statistical tests 
ρ < 0.05 was considered significant. 
RESULTS 
Both groups were comparable for age, height, weight and duration of surgery 
and anaesthesia (table 9.1). 
Induction was accomplished in all patients with the induction bolus dose. 
Apnoea was observed in all patients after administration of the induction dose. 
Duration of apnoea was not measured because a muscle relaxant was 
administered immediately after induction. Mild pain on injection was seen in 
one patient in the propofol group and in two patients given etomidate. Five 
patients in the etomidate group showed myoclonus during induction and one 
patient in this group had hiccoughs. In the propofol group induction was 
smooth with no side effects. Approximately 40 seconds after the start of 
induction patients stopped counting, followed 10 seconds later by 
disappearance of the eye lash reflex. There was no significant difference 
between the two groups in eithei* induction time (table 9.2). 
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TABLE 9.1 
DEMOGRAPHIC DATA 
Age (years) 
Weight (kg) 
Length (cm) 
Duration of surgery (mm) 
Duration of Anaesthesia (mm) 
Propofol 
n= 
55 5 
77 1 
171 5 
12 5 
16 6 
= 15 
(13 2) 
(9 9) 
(10 5) 
(15 3) 
(15 0) 
Etomidate 
n= 
54 9 
72 6 
173 0 
16 6 
213 
= 15 
(12 7) 
(14 8) 
(8 8) 
(10 4) 
(10 6) 
ANOVA 
Ρ 
N S 
N S 
N S 
N S . 
N S 
Given are means with SD between parentheses N S means not significant 
Analysis of variance (ANOVA) is used to demonstrate difference between 
groups 
TABLE 9.2 
INDUCTION TIMES AND RECOVERY TIMES 
Stop counting (sec) 
Negative eyelash reflex (sec) 
Eyes open on command (mm) 
Reply on questioning (mm) 
Propofol 
n=15 
39 1 ( 8 ) 
52 4 (11) 
6 9 ( 2 5) 
7 3 ( 4 2) 
Etomidate 
n=15 
36 9 (115) 
49 1 (12 8) 
6 4 (2 6) 
12 4 (9 4) 
ANOVA 
Ρ 
N S 
N S 
N S 
N S * 
Given are means with SD between parentheses Analysis of variance 
(ANOVA) is used to show difference between groups N S means not 
significant * ρ = 0 06 
Muscle relaxants were given during the maintenance period, as indicated 
by return of vocal cord movements. Six patients in the propofol group and 
only one patient in the etomidate group needed no further muscle ralaxation 
during the procedure. The total dose of suxamethonium in the propofol group 
was lower than in the etomidate group (table 9 3) Those who received 
propofol needed less alfentaml than the etomidate group but the difference 
was not significant (table 9 3) 
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The total incidence of side effects during maintenance (table 9 4) was 
greater in the group receiving etomidate One patient in the propofol group 
had bradycardia (below 50 beats m m - 1 ) after a subsequent dose of 
suxamethonium This was easily treated with atropine 0 5 mg Jet ventilation 
was performed in all cases without any problems 
TABLE 9.3 
TOTAL DOSE OF SUXAMETHONIUM AND ALFENTANIL DURING ANAESTHESIA 
Propofol Etomidate ANOVA 
n=15 n=15 ρ 
Suxamethonium (mg kg- 1) 18 (0 9) 2 6 (0 6) 0 005 
Alfentaml ^g kg - 1) 16 (8) 20 (8) N S 
Given are means with SD between parentheses N S means not 
significant Analysis of variance (ANOVA) is used to demonstrate 
difference between groups 
TABLE 9.4 
SIDE EFFECTS DURING MAINTENANCE FOR BOTH TYPES OF ANAESTHESIA 
Cough 
Myoclomus 
Hypertension 
Bradycardia 
Hiccup 
Propofol 
n=15 
2 
0 
0 
1 
0 
Etomidate 
n=15 
8 
4 
3 
0 
1 
F ET 
Ρ 
0 02 
0 05 
N S 
N S 
N S 
Fischer Exact Test (FET) is used to demonstrate difference between 
groups N S means not significant 
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The overall assessment of anaesthesia during maintenance was considered 
good in 12 patients in the propofol group and 5 patients in the etomidate 
group. In seven patients in the etomidate group and three patients in the 
propofol group the level of anaesthesia varied but was controlled easily. 
Coughing and movements indicated that anaesthesia was controlled 
inadequately in three patients in the etomidate group (table 9.5). No patient 
complained of awareness. 
TABLE 9.5 
SIDE EFFECTS DURING RECOVERY 
Cough 
Shivering 
Vomiting 
Nausea 
Headache 
Depression 
Restlessness 
Bad dreams 
Propofol 
n=15 
EARLY 
6 
2 
0 
0 
0 
0 
0 
1 
Etomidate 
n=15 
EARLY 
10 
8 
1 
3 
1 
2 
2 
0 
FET 
Ρ 
N.S. 
0.02 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
Propofol 
n=15 
LATE 
2 
0 
0 
0 
0 
0 
0 
0 
Etomidate 
n=15 
LATE 
6 
0 
1 
2 
1 
1 
0 
0 
FET 
Ρ 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
Early recovery is defined as the first 3 hours postoperatively and late 
recovery from 3 upto 24 hours. Ficher Exact Test is used to demontrate 
difference between groups. N.S. means not significant. 
Recovery from anaesthesia was rapid for both groups as indicated by the 
time from stopping the infusions until opening eyes on command. The patients 
in the etomidate group had a tendency to take more time before they could 
respond correctly to simple questions (table 9.2). During the first 10 min. after 
the moment they opened their eyes on command, recovery of the patients 
given propofol was more complete as compared with the other group, as 
indicated by the Steward score (table 9.6). After etomidate anaesthesia 
patients tended to drift back to sleep if undisturbed. One patient in the 
etomidate group was still asleep but reusable 15 min after opening his eyes on 
command. 
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The incidence of side effects during early and late recovery was higher 
following etomidate One patient who received propofol complained of having 
bad dreams during anaesthesia (table 9 7) The high incidence of cough 
postoperatively was considered to be due to irritation of the upper airways by 
microlaryngeal surgery 
TABLE 9.6 
STEWARD RECOVERY SCORE (maximum score = 6) 
Time after opening 
eyes on command 
3 mm 
5 mm 
15 min 
Propofol 
n= 
5 5 
5 9 
6 0 
= 15 
(4-6) 
(5-6) 
(6 6) 
Etomidate 
n= 
4 5 
5 1 
5 9 
= 15 
(3-6) 
(3-6) 
(4-6) 
ANOVA 
Ρ 
0 005 
0 005 
N S 
Given are mean scores with the range between parentheses Analysis 
of variance (ANOVA) is used to demonstrate difference between 
groups N S means not significant 
TABLE 9.7 
ASSESSMENT OF CONTROL AND STABILITY OF ANAESTHESIA 
Good 
Adequate 
Poor 
Propofol 
n=15 
12 
3 
0 
Etomidate 
n=15 
5 
7 
3 
The χ2 test ρ = 0 02 
There was a discrepancy between the groups as concerns changes in blood 
pressure After an initial decrease during induction with etomidate, blood 
pressure increased above preoperative levels The same pattern was seen with 
heart rate In the propofol group, blood pressure decreased after induction and 
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remained aproximately 10% below preoperative levels during the maintenance 
period. The heart rate was above preoperative levels, but never significantly 
different. The change in heart rate was similar to that observed in the 
etomidate group (fig 9.1). 
257.1 
¿Э '·! l i l i l í 
О 15 30 
mm 
Figure 9.1 Changes in mean arterial pressure and heart rate in relation to preoperative 
values. Standard error of the mean is indicated by vertical bars. Solid line for the 
propofol group and dotted line for the etomidate group. * ρ < 0.05 between groups. + 
ρ < 0.05 in relation to preoperative values 
DISCUSSION 
Stable anaesthesia remaining at a deep level and rapid, uneventful recovery 
are the most important aims in microlaryngeal surgery (Tobias et al. 1977, 
Ewalenko et al. 1981, Sia et al. 1982). Propofol and etomidate are short acting 
intravenous agents whose half-lives are of the same order (Cockshott 1985, 
Fragen et al. 1983). For both drugs recovery after infusion is rapid. Therefore 
they both seem useful for microlaryngeal procedures. In this study the 
propofol group demonstrated better surgical conditions, more stable 
anaesthesia and, despite the same recovery time in both groups under 
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investigation, better Steward recovery scores than the etomidate group. The 
question as to whether the dose regimens for both drugs in this study are fully 
comparable is difficult to answer. For propofol we used induction dose and 
infusion rates based on our experience in previous studies (De Grood 
et al. 1985a). For etomidate we used the induction dose and infusion rates as 
recommended by Fragen et al. (1983). Higher doses of etomidate may result in 
better surgical conditions, but will also result in prolonged recovery (Sia 
et al. 1982, Fragen et al. 1983). It has been observed that during induction, 
propofol provides a better suppression of laryngeal reflexes than thiopentone 
(De Grood et al. 1985b) 
The generally accepted induction dose of propofol is 2.5 mg kg - 1 , 
resulting in induction times from 30 to 40 sec. (Cummings et al. 1984, 
De Grood et al. 1985, Grounds et al. 1985, Redfern et al. 1985, Rolly 
et al. 1985, Kay et al. 1985). A smaller induction dose of 2 mg kg - 1 induced 
anaesthesia in only 80% of unpremedicated patients (Cummings et al. 1984). 
Robinson et al. (1985) found a negative correlation between age and induction 
dose requirements. In this study we used an induction dose of 2 mg kg - 1 
preceded by a small dose of alfentanil resulting in successful induction of 
anaesthesia in all patients. Two factors have contributed to this result: the 
rapid onset of action of alfentanil and the relative high age of our patients. For 
both groups the low incidence of pain on injection was problably due to 
deliberate placement of the intravenous cannula in a large vein and the prior 
injection of a rapidly acting narcotic. This confirms the observation of Kay 
et al. (1986). The changes in blood pressure in the propofol group were 
comparable with those reported by others (Grounds et al. 1985, Redfern 
et al. 1985, Kay et al. 1986). The increase of blood pressure during etomidate 
anaesthesia may have been the result of too low an infusion rate of etomidate 
to guarantee an adequate level of anaesthesia for these procedures. 
It is well known that intermittent bolus doses of suxamethonium for 
muscle relaxation may lead to severe bradycardia. Therefore atropine was 
added to the premedication. The reason that this technique has been chosen 
for muscle relaxation is the unpredictable duration of the procedure. 
The prolonged adrenal suppression after etomidate administration has 
been demonstrated in both in vitro and in vivo studies (Kenyon et al. 1985, 
Metha et al. 1985, Wanscher et al. 1985). In contrast propofol has not been 
shown to interfere with steroid metabolism (Kenyon et al. 1985). Therefore it 
is to be expected that the clinical use of propofol should not be accompanied 
by the same sort of problems as seen with etomidate. 
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In conclusion propofol is preferable to etomidate as a hypnotic agent for 
total intravenous anaesthesia during microlaryngeal surgery with jet 
ventilation More stable anaesthesia and better recovery are the main reasons 
Adrenal suppression after etomidate administration may be another reason 
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CHAPTER 10 
ANAESTHESIA FOR LAPAROSCOPIES: 
A COMPARISON OF FIVE TECHNIQUES INCLUDING 
PROPOFOL, ETOMIDATE, THIOPENTONE AND ISOFLURANE. 
P.M.R.M. DE GROOD, J.B.M. HARBERS, J. VAN EGMOND 
and J.F. CRUL* 
INTRODUCTION 
Recently propofol (2,6 di-isopropylphenol, Diprivan®) has been introduced 
into clinical practice in some countries in Europe. Over the last two years 
several studies have demonstrated the properties of propofol as an induction 
agent (Cummings et al. 1984, Fahy et al. 1985, Roily and Versichelen 1985) 
and as an agent for total intravenous anaesthesia techniques (Kay 1986, 
De Grood et al. 1985, De Grood et al. 1987) Smooth induction in one arm-
brain circulation time and a rapid, uneventful recovery are the most 
remarkable properties. Pain on injection (Hynynen et al. 1985, McCulloch and 
Lees 1985, Stark et al. 1985) decrease in arterial blood pressure (Grounds 
et al. 1985, Prys-Roberts 1982) and a high incidence of apnoea are considered 
to be disadvantages. 
Comparisons of propofol with etomidate, methohexitone and thiopentone 
have been published for several surgical procedures (Fahy et al. 1985, Roily 
and Versichelen 1985, De Grood et al. 1987, Stark et al. 1985, Grounds 
et al. 1985, Wells 1985, Mackenzie and Grant 1985) to evaluate the advantages 
of propofol over other intravenous anaesthetic agents. Propofol has also been 
studied in combination with inhalation anaesthetics (Mackenzie and 
Grant 1985, Valanne and Kortilla 1985) The different types of procedures and 
different methodology makes comparison only possible in general terms. 
Therefore this study has been performed to evaluate five anaesthesia 
techniques for a standard laparoscopy procedure. Propofol and etomidate were 
used for a total intravenous anaesthesia (TIVA) technique. Those two agents 
as well as thiopentone were used as induction agents for an inhalation 
technique with isoflurane. Evaluation and comparison of the induction 
proporties, stability of anaesthesia, speed of recovery and postoperative 
complications were the main aims of this study. 
* As will be published in Anaesthesia (1987). 
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PATIENT? AND METHODS 
After verbal consent 76 unpremedicated female patients (ASA class 1-3) 
scheduled for laparoscopy were included in this study, which was approved by 
the Hospital Ethics Committee. The patients had no history of allergy to the 
drugs used in this study, or evidence of atopy. No patient with a serious 
history of hepatic, renal, haematological or metabolic disease was included. 
On arrival in the operating room patients received an indwelling cannula 
in a large vein on the dorsum of the hand or lowerarm, wich was connected to 
a drip infusion of Ringers solution. The electrocardiogram and finger 
plethysmogram were continuously monitored. Arterial pressure was measured 
using an automatic non-invasive blood pressure monitor (Dinamap®). The 
baseline values of arterial pressure and heart rate were measured before 
induction and subsequent measurements were made 2 min after induction and 
at 5 min intervals throughout the procedure. 
The patients were randomly allocated into five groups. In group 1 
propofol 2.5 mg kg - 1 was used for induction. For maintenance a continuous 
infusion of the same agent was given: 12 mg kg _ 1 hr _ 1 for the initial 15 min 
followed by 9 mg kg~1hr"1 for another 25 min and thereafter 6 mg kg_ 1hr~1. 
In group 2 etomidate 0.3 mg kg - 1 was given for induction followed by a 
continuous infusion of 1.8 mg kg^'hr - 1 for the first 15 min, 1.5 mg kg" 'hr - 1 
for the next 25 min and 1.0 mg k g ^ h r - 1 thereafter. Propofol was given in 
undiluted form (10 mg т Г 1 ) and etomidate was used as 2 mg т Г 1 solution 
(4 ml of 125 mg etomidate base per ml of ethyl alcohol, diluted to 250 ml with 
normal saline). Both drugs were administrated using a calibrated syringe pump 
for the whole of the procedure. 
In group 3, group 4 and group 5 anaesthesia was induced by respectively 
propofol 2.5 mg kg - 1 , etomidate 0.3 mg kg - 1 and thiopentone 5 mg kg"1. 
Anaesthesia was maintained with a nitrous oxide oxygen mixture (2:1) and 
isoflurane. Initially 2% isoflurane was administered. After the first five 
minutes isoflurane was decreased to 1% until the end of the procedure. A 
calibrated vaporizer (Cypranc mk III) was placed in the fresh gas flow for 
administration of the inhalation anaesthetic agent. 
For all groups a bolus dose of fentanyl 0.1 mg was administered 60 sec 
prior to induction. Further bolus doses of fentanyl 0.05-0.1 mg were given on 
signs of painful reactions to surgical stimuli. An extra bolus dose of the 
induction agent was given on signs of lightening of anaesthesia such as 
perspiration, lacrimation and cardiovascular changes or movements not relating 
to painful stimuli. For propofol a dose of 0.5 mg kg. - 1 was used for this 
purpose, for etomidate 0.06 mg kg."1 and for thiopentone 0.3 mg kg."1. 
Suxamethonium Img kg"1 was given to facilitate endotracheal intubation and 
90 
incremental bolus doses of 25 mg when needed. All patients were mechanically 
ventilated with an open system (Engström 300); for the TI VA groups with a 
mixture of oxygen and air and for the others with nitrous oxide and oxygen. 
Onset of induction was defined in two ways: as the interval between start 
of administration of the hypnotic agent and cessation of counting and secondly 
as the interval between start of administration of the hypnotic agent and 
disappearance of eyelash reflex. Also two recovery times were defined: first as 
the interval from stopping administration of the hypnotic agent until opening 
eyes on command and secondly until answering simple questions correctly. 
Recovery of anaesthesia was assessed by the Steward score (Steward 1973) 
five, fifteen and thirty minutes after the patients responded to opening eyes on 
command. Preoperatively, one hour and three hours postoperativily patients 
had to perform a pencil-paper test (Dixon and Thornton 1973). The scores 
were calculated as the percentage of the preoperative values. The next 
postoperative day the patients were interviewed. Side effects, perioperative 
awareness and venous sequelae were evaluated. 
All side effects were recorded from induction of anaesthesia up to 24 hr 
postoperatively. The intensity of pain on injection was scored as being mild, 
moderate or severe depending on the response of the patient to questioning : 
mild when a slightly painful sensation was noted, moderate if discomfort was 
indicated on request and severe if discomfort was indicated spontaneously. 
Depth and smoothness of anaesthesia were evaluated postoperatively with 
regard to the need for additional bolus doses of the induction agent, fentanyl 
or suxamethonium. 
The statistical calculations were carried out using the SPSS routine 
package (SPSS Inc., Chicago, Illinois). Analysis of variance as well as one way 
analysis of variance with Tukey-HSD procedure were used as statistical tests to 
analyse difference between groups. Comparisons of incidences were performed 
by χ2 test or Fischer's Exact Test (in a 2 x 2 table). In statistical tests Ρ < 0.05 
was considered significant. 
RESULTS 
All groups were comparable for age, height, weight and duration of surgery 
and anaesthesia (Table 10.1). 
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TABLE 10.1 
DEMOGRAPHIC DATA 
Group 
1 
2 
3 
4 
5 
η 
16 
15 
15 
15 
15 
ANOVA 
Age 
(yean) 
30 4 
310 
32 3 
33 5 
30 5 
(4 3) 
(3 8) 
(8 3) 
(7 2) 
(3 6) 
N S 
Weight 
(kg) 
63 7 (10 0) 
63 3 (12 9) 
66 0 (113) 
65 6 (10 6) 
59 2 ( 7 8) 
N S 
Height 
(cm) 
167 8 
165 4 
166 3 
165 1 
164 1 
(6 2) 
(7 1) 
(7 7) 
(6 4) 
(8 1) 
N S 
Anaesth.time 
(mm) 
35 2 
29 8 
33 9 
29 7 
25 3 
( 9 3) 
(10 9) 
(19 3) 
( 8 4) 
( 7 8) 
N S 
Surgery lime 
(mm) 
25 6 ( 9 3) 
18 6 ( 9 7) 
23 5 (19 3) 
19 1 ( 7 2) 
15 3 ( 7 1) 
N S 
Given are means with standard deviation between parentheses Analysis of variance 
(ANOVA) is used to demonstrate differences between groups, N S means not significant 
TABLE 10.2 
INDUCTION TIMES AND INCIDENCE OF APNOEA 
Induction agent η Stop counting Loss of eyelash Apnoea 
Propofol 31 39 5 (36-44) * 49 9 (48-55) 25 ( 81%) 
Etomidate 30 32 4 (28-37) * 57 3 (45-70) + 19 ( 63%) 
Thiopentone 15 31 5 (27-36) 37.1 (33-41) t 15 (100%) 
Induction times are given in seconds with 95% confidence limits between 
parentheses One way analysis of vanance is used to demonstrate differences 
between groups * and t denotes pairs of groups significantly different at 
the 0 05 level (Tukey-HSD procedure). Incidence of apnoea is given as 
number of patients with percentage between parentheses 
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INDUCTION 
Induction was successful in all patients. Comparing the three induction agents 
cessation of counting was a few seconds later for the patients to whom 
propofol was administered. Disappearance of eyelash reflex however was much 
later and less predicatable for the patients to whom etomidate was 
administered. The most rapid induction was obtained for those patients where 
thiopentone was administered (Table 10.2.). However four patients in this 
group had reactions on intubation indicating that the level of anaesthesia was 
too low. After administration of the induction dose, apnoea in excess of 20 sec 
was observed in all patients induced with thiopentone. During induction with 
etomidate 37% of the patients continued spontaneous respiration. In 81% of 
the patients with propofol induction apnoea was observed (Table 10.2). The 
duration of apnoea was not measured because muscle relaxation was 
administered immediately thereafter. Several side effects were noticed during 
induction (Table 10.3). In the thiopentone group cough was observed before 
intubation. One patient induced with propofol had bronchospasm during 
intubation. She was known to be a heavy smoker. 
TABLE 10.3 
INCIDENCE OF SIDE EFFECTS DURING INDUCTION 
Myoclonia 
Hiccup 
Cough 
Bronchospasm 
Total group 
Propofol 
-
-
1 
1 
31 
Etomidate 
12 
3 
2 
-
30 
Thiopentone 
_ 
-
3 
-
15 
Given arc number of patients. 
Discomfort on injection was seen in only one patient in the thiopentone 
group although for all patients in this group the site of injection was on the 
dorsum of the hand. Complaints of pain along the veins was noticed in about 
35% of the patients receiving etomidate or propofol.The site of injection for 
the patients in these groups was more carefully selected. The indwelling 
cannula was only placed on the dorsum of the hand when there was a large 
vein available. Only four patients complained of severe pain: two during 
propofol administration and two during etomidate administration (Table 10.4). 
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TABLE 10.4 
INCIDENCE OF DISCOMFORT ON INJECTION 
Induction agent 
Propofol 
Etomidate 
Thiopentone 
η 
31 
30 
15 
No pain 
21 (68) 
19 (63) 
14 (93) 
Mild 
5(16) 
4(13) 
0 
Moderate 
3 ( 9 ) 
5(17) 
1 ( 7 ) 
Se>ere 
2 ( 7 ) 
2 ( 7 ) 
0 
Given are number of patients with percentages between parentheses 
Criteria are described in the text 
TABLE 10.5 
TOTAL DOSE OF FENTANYL AND SUXAMETHONIUM 
Group 
1 
2 
3 
4 
5 
Fentanyl 
μ§Γ kg - 1 
3 9 (3 4 -
4 4 (3 8 -
2 5 (2 2 -
2 6 (2 1 -
3 0 (2 5 • 
4 5)*+4 
5 l)§**t 
2 9)*§ 
3 0)+** 
3 5)lt 
Suxamethonium 
mg kg" 1 
1 7 ( 1 5 - 19) 
1 9 ( 1 6 - 2 2 ) * φ 
1 5 (1 4 - 1 7)* 
1 5 (1 4 - 1 6)t 
1 6 ( 1 5 - 1 8 ) 
Given are mean total doses with the 95% limits of confidence between 
parentheses One way analysis of variance is used to demonstrate 
differences between groups *, t, 4, §, ** and t denotes pairs of groups 
significantly different at the 0 05 level (Tuke>-HSD procedure) Group 1 
TIVA with propofol, group 2 TIVA with etomidate, group 3 propofol 
and isoflurane, group 4 etomidate and isoflurane and group 5 
thiopentone and isoflurane 
MAINTENANCE 
During the maintenance period the anaesthetic conditions were suitable for 
surgery for all patients Both TIVA groups needed more fentanyl than the 
groups with inhalation anaesthesia This was also valid comparing the groups 
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with the same induction agent but different techniques (respectively group 1 
with group 3 and group 2 with group 4) 
There was also a difference in control of depth of anaesthesia between the 
groups with TIVA and with isoflurane In group 1 fourteen patients needed 
nineteen extra bolus doses of the induction agent and in group 2 eleven 
patients needed thirty-nine extra doses, indicating that in the last group the 
prescribed dose regimens for infusion were insufficient to control depth of 
anaesthesia Of the total of 45 patients with isoflurane only six patients needed 
an extra bolus of the induction agent Especially in group 2 supplemental doses 
(with a total of 13) of suxamethonium were needed to control unvoluntary 
movements and coughs besides the extra measures taken as described above 
(Table 10 5) The overall assessment of the quality of maintenance was poor m 
six patients group 2 and one patient in group 3 (Table 10 6) The patient in 
group 3 was the patient with bronchospasm, mentioned before 
TABLE 10.6 
QUALITY OF MAINTENANCE 
Group 
1 
2 
3 
4 
5 
η 
16 
15 
15 
14 
15 
Good 
11 
6 
13 
13 
14 
(69) 
(40) 
(88) 
(87) 
(93) 
Adequate 
5 
3 
1 
2 
1 
(31) 
(20) 
( 6 ) 
(13) 
( 7 ) 
Poor 
0 
6 (40) 
1 ( 6 ) 
0 
0 
Given are number of patients with percentages between parentheses 
Group 1 TIVA with propofol, Group 2 TIVA with etomidate, 
Group 3 propofol and isoflurane, Group 4 etomidate and isoflurane, 
Group 5 thiopentone and isoflurane 
RECOVERY 
With regard to opening eyes on command thiopentone with isoflurane 
anaesthesia resulted in the longest recovery time On the other end of the 
scale TIVA with propofol had the most rapid recovery TIVA with etomidate 
resulted not only in the longest time for complete recovery of consiousness as 
indicated by reply on simple questions, but recovery was also less predictable 
as indicated by the 95%-limits of confidence (Table 10 7) 
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TABLE 10.7 
RECOVERY TIMES AND THE RESULTS IN PENCIL-PAPER TEST 
Group 
1 
2 
3 
4 
5 
η 
16 
15 
15 
15 
15 
Eyes open 
minutes 
7.9 
13 8 
9 7 
12 9 
15 8 
95% limit 
( 6-10) * 
( 9-19) 
( 6-13) 
( 9-16) 
(12-20) * 
Answering questions 
minutes 
8 6 
19 3 
113 
15 5 
18 0 
95% limit 
( 6 - l l ) t § 
(12-25) §** 
( 7-15) ** 
(11-20) 
(14-22) t 
Pencil-
1 hour 
6 5 ( 7 ) 
5 3 ( 6 ) 
7 7 ( 7 ) 
60 (10) 
4 3 ( 8 ) 
paper test 
3 hours 
8 1 ( 6 ) 
8 6 ( 4 ) 
8 2 ( 6 ) 
100 (12) 
7 7 ( 8 ) 
Recovery times are given as minutes since end of anaesthesia and 95% limits of 
confidence between parentheses One way analysis of variance is used to 
demonstrate differences between groups. *, X, § and ** denotes pairs of groups 
significantly different at the 0.05 level (Tukey-HSD procedure) For pencil-
paper test are given percentages of preoperative scores after one and three 
hours postoperative, with SEM between parentheses Group 1. TI VA with 
propofol, Group 2 TIVA with etomidate, Group 3· propofol and isoflurane, 
Group 4 etomidate and isoflurane, Group 5 thiopentone and isoflurane 
For both recovery times there was no difference between group 1 and 
group 3. Clinical assessment of recovery as indicated by the Steward scores 
correlated well with the two recovery times. Five minutes after opening eyes 
on command 2 patients of group 2 and group 4 each had recovery scores 
below 5, while all other patients scored 5 or more. Ten minutes later 4 patients 
of group 2 and group 4 each, had recovery scores below 6. After 30 minutes 
all patients had the maximum recovery score of six The results of the pencil-
paper test are presented in Table 10.7. There was a high inter-individual 
variation in the performance of the postoperative tests as related to the 
preoperative values Several patients were unable to perform this test after 
one hour of recovery because of impaired psychomotor function or severe side 
effects such as nausea or vomiting. After one hour of recovery the mean 
values for each group did not reach the preoperative values Three hours after 
the end of anaesthesia the mean values differed from 77% to 100% . 
Postoperatively the most important side effects were nausea, vomiting, 
headache and mental depression. Restlessness and coughing were also 
observed (fig. 10.1). Approximately 60% of the patients in group 2, and 
group 5 complained about nausea and vomiting. Patients who received 
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propofol had a remarkably lower incidence of these side effects. Propofol with 
isoflurane (group 3) resulted in more nausea and vomiting as compared with 
the TIVA with propofol (group 1), but the difference was not significant. For 
the other side effects there was a difference between the patients with 
inhalation anaesthesia and TIVA, in that TIVA had less side effects. Twenty-
four hours postoperatively all patients had comfortably returned to their daily 
routine activity. 
ja HL M JHffl ш 
HEADACHE RESTLESNESS 
1 2 3 4 5 
DEPRESSION 
Figure 10.1: Side effects during the first three postoperative hours. Group 1: TIVA with 
propofol; Group 2: TIVA with etomidate; Group 3: propofol and isoflurane; Group 4: 
etomidate and isoflurane; Group 5: thiopentone and isoflurane. 
CARDIOVASCULAR VARIABLES 
During the first ten minutes after induction most patients showed an increase 
of heart rate as related to their preoperative values (fig 10.2). These values 
returned to the baseline and remained stable during the further progress of the 
procedure. After an initial short lived increase directly after induction, mean 
arterial pressure (MAP) decreased below baseline values in the groups with 
inhalation anaesthesia (fig. 10.3). Ten to fifteen minutes after induction MAP 
returned to the baseline until the end of procedure. In group 3 the decrease of 
MAP was more than 25% as related to the baseline values seven and eight 
minutes after induction of anaesthesia. In the TIVA groups no significant 
changes in MAP were seen during induction nor during maintenance. 
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MAPS 
GROUP 1 
10 30 50 MIN 
Figure 10.2: Mean arterial pressure as percentage change related to preoperative values 
during surgery. Group 1: TIVA with propofol; Group 2: TIVA with etomidate; 
Group 3: propofol and isoflurane; Group 4: etomidate and isoflurane; Group 5: 
thiopentone and isoflurane. 
DISCUSSION 
It has been reported that the relative potency of propofol as compared to 
thiopentone is 1:1.6 (Grounds et al. 1986). In spite of the ratio 1:2 in this 
study 4 patients (out of 15) with thiopentone showed a level of anaesthesia too 
light for intubation, compared to one patient (out of 31) with propofol. 
Others, using the same doses as used in this study, failed to demonstrate 
differences in induction time between propofol and thiopentone with regard to 
cessation of counting (Mackenzie and Grant 1985). Comparing etomidate 
(0.2 mg) and the Cremophor formulation of propofol (1.5 mg) no differences 
were demonstrated in induction time with regard to loss of eyelash reflex 
(Wells 1985). Using the emulsion formulation there was no difference between 
etomidate 0.3 mg and propofol 2.0 mg for both induction times after a 
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preinduction dose of alfentanil (De Grood et al. 1987). Although differences 
were found in this study for both induction times, these are fast for all three 
agents, and the differences are of minor clinical importance. Unless the 
preinduction dose of fentanyl was given the incidence of myoclonus during 
induction with etomidate was still high. 
Figure 10.3: Heart rate as percentage change related to preoperative values during 
surgery. Group 1: TIVA with propofol; Group 2: ТГ А with etomidate; Group 3: 
propofol and isoflurane; Group 4: etomidate and isoflurane; Group 5: thiopentone and 
isoflurane. 
From this study it can be concluded that propofol gives a smooth and 
rapid induction, only pain during injection can be considered as a serious side 
effect. 
The anaesthetic agents used for TIVA have to replace inhalation 
anaesthetics. With the dose regimens for propofol (group 1) stability was 
similar to the inhalation groups, but full replacement of inhalation anaesthetics 
was only possible with the addition of higher doses of fentanyl. Not only 
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isoflurane itself but also the analgesic proporties of nitrous oxide have to be 
replaced with intravenous agents in the TIVA groups. The dose regimens of 
propofol in group 1 were based on our previous work (De Grood et al. 1985, 
De Grood et al. 1987). They were higher than the doses needed to maintain 
anaesthesia in combination with regional anaesthesia (Jessop et al. 1985) or 
needed for a TIVA technique in combination with a continuous infusion of 
alfentanil (Kay 1985). For group 2 (TIVA with etomidate) the dose regimen of 
etomidate resulted in unstable anaesthesia and therefore extra doses of 
fentanyl, as well as extra doses of the induction agent were needed to deepen 
anaesthesia. Most of these extra doses were given in the first part of the 
surgical procedure. For group 1 the prescribed dose regimen alone was also 
not sufficient to control the depth of anaesthesia, but the overall conduct was 
much easier to stabilize than in group 2. The concentration of isoflurane used 
in this study is a little lower than the 1.2% reported by Forrest 1983 for 
clinical requirement, but with the preinduction dose of fentanyl 0.1 mg and a 
supplementary dose of 0.1 mg just before start of surgery, maintenance was 
very stable. 
Decrease in arterial blood pressure was reported for propofol and 
thiopentone (Grounds et al. 1985, Prys-Roberts 1982). Etomidate has been 
described to provide stable cardiovascular parameters (Wells 1985). Changes in 
cardiovascular variables demonstrated during carefully performed studies of 
the effect of single agents do not necessarily reflect the everyday situation. In 
this study the changes in blood pressure and heart rate showed considerable 
variation and seemed to be more related to the surgical stress than to the 
effect of the agent itself. The lack of discrepancy between groups and the 
absence of initial decrease in blood pressure may be related to the 
endotracheal intubation which was performed as soon as possible after 
induction. In the groups with isoflurane anaesthesia there was a mean decrease 
of blood pressure after intubation but before the start of surgery, increasing to 
normal values during the procedure. The higher concentration of isoflurane 
during this presurgical period may have contributed to this effect. 
Recovery of anaesthesia after propofol was short. The recovery times of 
this study are similar to those reported by others (Kay 1986, De Grood 
et al. 1985, De Grood et al. 1987, Valanne and Korttila 1985). As observed 
earlier the time between opening eyes on command and answering questions 
was remarkably short. The slowest recovery was shown after thiopentone-
isoflurane anaesthesia and after TIVA with etomidate. Higher doses of 
etomidate in this last group may lead to more stable anaesthesia but also to 
longer recovery times. For the groups with isoflurane recovery should be 
expected to be independent of the induction agent. No difference could be 
demonstrated for these groups by the very sensitive Tukey-HSD procedure. 
However after propofol-isoflurane (group 3) the mean recovery times were 
much shorter than after thiopentone-isoflurane and a little longer than after 
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TIVA with propofol. Groups 1 and 3 with propofol had both significantly 
shorter recovery times as compared with etomidate (group 2). For the 
evaluation of the progression towards complete recovery we used a pencil-
paper test, which measures both accuracy and ability to concentrate as well as 
return of psychomotor function (Dixon and Thornton 1973). We could not 
demonstrate statistical differences between any of the groups, mainly as a 
result of the great inter-individual differences in test scores. One hour after the 
end of administration of the hypnotic agent the mean scores of the patients in 
the thiopentone group were only 43% of the preoperative scores, while the 
patients in the propofol-isoflurane group reached 77%. This correlated with 
the clinical observation that the patients in group 5 suffered more residual 
effect from the general anaesthesia than the patients in all other groups. Three 
hours postoperatively there was less difference and some patients completed 
this test as well as before operation, but only in group 4 did the patients 
reached a mean of 100%. 
Of the postoperative side effects nausea and vomiting have the highest 
incidence. The aetiology of these side effects is reviewed by Palazzo and 
Strunin (1984). They concluded that nowadays the incidence of emetic 
problems in the absence of antiemetics associated with anaesthesia is still 
around 30 percent. Nitrous oxide, etomidate and fentanyl are agents known to 
cause vomiting. Reviewing 25 clinical studies with propofol Stark et al. (1985) 
reported incidences of vomiting and nausea of 2-2.5% for this new intravenous 
anaesthetic and about 10-12% for their comparator agents thiopentone and 
methohexitone. Laparoscopies are known to be surgical procedures with a high 
incidence of nausea and vomiting. Recently Lowie and Harper (1986) reported 
after laparoscopies an incidence of these side effects of about 50%. Their 
anaesthesia technique was similar to group 5 in this study, with the exception 
that they used enflurane instead of isoflurane. This study confirms that 
propofol anaesthesia is accompanied by a low incidence of nausea and 
vomiting in spite of the larger doses fentanyl in group 1 and nitrous oxide in 
group 3. The differences between the TIVA groups and inhalation groups for 
the other postoperative side effects suggest that they are related to isoflurane 
(Tracey et al. 1982). 
In conclusion the new intravenous agent propofol has several advantages 
over the other anaesthetics used in this study. In particular the rapid 
uneventful recovery makes TIVA with propofol suitable for outpatient 
laparoscopies, but propofol induction followed by isoflurane maintenance 
provides a more stable anaesthesia technique. 
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CHAPTER 11 
HPLC DETERMINATION AND 
PRELIMINARY PHARMACOKINETICS 
OF PROPOFOL AND ITS METABOLITES 
IN PLASMA AND URINE OF MAN 
T.B. VREE, A.M. BAARS, P.M.R.M. DE GROOD* 
INTRODUCTION 
Propofol (2,6-diisopropylphenol) in soya bean egg phospholipid emulsion is the 
newest intravenous anaesthetic agent to become available for clinical use (Kay 
et al.1985, Simons et al. 1985, Kay and Roily 1977, Kay et al. 1986). The 
pharmacokinetics of the compound itself after a single bolus injection can be 
described in a three compartment model with Т^ values of respectively 1.8, 34 
and 180 min (Kay et al. 1985). It has been suggested that the short anaesthetic 
activity of propofol after a single bolus dose is the result of rapid metabolism 
(Simons et al. 1985). Propofol glucuronide (40%) and the 1- and 4-
glucuronide and 4-sulphate conjugates of 2,6-diisopropyl 1,4-quinol are 
described as the major metabolites in man (Simons et al. 1985). After a 
subanaesthetic dose of 1 4C propofol, 88% of the isotope is excreted in the 
urine as metabolites and less than 0.3% is excreted as propofol (Simons 
et al. 1985, Kay and Roily 1977). 
Adams et al. (1981) described an HPLC analysis of propofol in blood 
following coupling with Gibbs' reagent. This technique has a detection limit of 
O ^ g m l "', but fails to measure the metabolites. Kay et al. (1986, 1986) 
analysed propofol by HPLC with fluorescence detection following extraction 
into cyclohexane. The limit of sensitivity of this assay is approximately 
2 ng m l - 1 . Both methods are time consuming and do not include the 
metabolites in their analysis. A new technique for the estimation of propofol 
and its metabolites in plasma and urine of man was developed. 
* As will be published in J. Chromatogr. Biom. Appi. 1987 
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MATERIALS AND METHODS 
Patients 
Four unpremedicated patients undergoing superficial surgery gave their 
informed consent to participate in the study, which was approved by the 
hospital Ethics Committee. 
Blood 
Blood samples of 5 ml were taken from an arterial cannula into blood gas 
syringes at predetermined times immediately before and after the dose of 
propofol. The blood samples were centrifuged and the plasma was stored at 
-20oC pending analysis. 
Urine 
Urine was collected over predetermined time intervals and the volume and pH 
measured. Urine samples were stored at -20CC pending analysis. 
Chromatography 
A Spectra Physics 3500B liquid Chromatograph was used, equipped with a 
variable wavelength spectrophotometer (Spectroflow 757, Kratos, USA). The 
detector was connected to a 10 mV recorder (BD7, Kipp and Zonen, 
The Netherlands); the chart speed was 1 cm min - 1 . A stainless steel column 
(25 cm in length and 4.6 mm ID) was packed with Spherisorb 5 ODS 
(Chrompack, Middelburg, The Netherlands). A guard column, tap-filled with 
pellicular reversed phase material was placed between the sampling valve and 
the analytical column. 
Detection of propofol, its 1,4-quinone and 1,4-quinol derivativs was 
effected at 270 nm. The mobile phase was a mixture of water-acetonitrile-
methanol, 400-500-10 (V/V/V) with a solvent flow of 2 ml min - 1 , at a pressure 
of 230 atm. The injection volume was 100 μΐ. The chromatographic analysis 
was carried out at room temperature. 
Materials 
ß-Glucuronidase (Escherichia coli), ß-glucuronidase / arylsulphatase (Helix 
pomatia) and arylsulphatase (Aerobacter aerogenes) were purchased from 
Sigma Chemical Company (St.Louis, MO, USA). The solvents acetonitrile and 
methanol were of reagent grade (Merck, Darmstadt, W-Germany). Propofol, 
its 1,4-quinone and 1,4-quinol derivate were a gift from Imperial Chemistral 
Industries (UK). 
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Sample preparation 
Plasma 
To 0.2 ml of plasma in an Eppendorf reaction vessel, 0.2 ml of acetonitrile was 
added and mixed thoroughly on a vortex mixer. The mixture was centrifuged 
in a Biofuge A (Heraeus Christ, FDR) at 11,000 g for 5 min. A 100 μΐ volume 
of the clear supernatant was injected into the column. 
Urine 
Urine was diluted 50 times with the mobile phase, the solution was mixed and 
100 μΐ was injected into the column. 
Enzymatic hydrolysis of propofol and metabolites 
Plasma 
To 0.2 ml plasma inn Eppendorf reaction vessel was added 50 μΐ of a β-
glucuronidase (Escherichia coli) solution (1000 U ml - 1 of phosphate buffer, 
pH 6.8). The solution was incubated at 37°C. After 5 hours of incubation, 
0.2 ml of acetonitrile was added, mixed thoroughly, kept at 40C and 
centrifuged just before analysis. A 100 μΐ volume was injected into the column. 
Urine 
To 10 μΐ of urine were added 0.2 ml of a phosphate buffer, pH 6.8 and 25 μΐ 
of a ß-glucuronidase (Escherichia coli, Sigma, USA) solution (1000 U ml-1 
phosphate buffer, pH 6.8). The solution was incubated at 37°C. After 5 hours 
of incubation 0.2 ml of acetonitrile was added, mixed thoroughly, kept at 4°C 
and centrifuged just before analysis. A 100 μΐ volume was injected into the 
column. 
A 10 μΐ volume of urine was also incubated in 0.2 ml of acetate buffer 
(pH 5.0) with 25 μΐ of a ß-glucuronidase/arylsulphatase (Helix pomatia, Sigma, 
USA) solution, containing 10,000 U ml-1 ß-glucuronidase and 403 U ml-1 of 
arylsulphatase and with 100 μΐ of an arylsulphatase (Limpets, Sigma, USA) 
solution in 50% glycerol, 0.01 M Tris solution, pH 7.5. 
Chemical hydrolysis of plasma and urine samples 
To 0.1 ml of plasma in an injection vial (2-3 ml) were added 0.4 ml of 
5 N HCL and 0.5 ml of methanol. The vials were tightly closed with rubber 
and felscap and put in a thermo-bath at 100oC. After 1.5 hours of incubation 
the vials were cooled in cold water and kept at 40C. Just before analysis the 
mixture was transferred into an Eppendorf reaction vessel by means of a 1 ml 
gas-tight syringe. The solution was centrifuged at 11,000 g for 5 min and 100 μΐ 
of the clear supernatant was injected into the column. 
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To 10 μΐ of urine were added 0.1 ml of water, 0.4 ml of 5 N HCL and 
0.5 ml methanol. The solutions were treated in the same way as the plasma 
samples. 
Recovery and precision 
The recovery of propofol added to human plasma in the concentration range 
of 0.1-20 μg ml - 1 was 99.5±0.5%. The recovery of the 1,4-quinone and 1,4-
quinol metabolite in the concentration range of 0.060-6.0 ug ml - 1 was 
100±2%. The recovery for all compounds added to urine in the concentration 
ranges of 10-500 μg ml - 1 was similar to that of the plasma recovery. 
Calibration curves for propofol (r= 0.9996) and its 1,4-quinone metabolite (r= 
0.9990) were linear. 
plasma 
ι qumol 
2 propofol 
3 quinone 
, 0 0 2 A 
23 
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urine 
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~öoi A 0 0 2 A 
± 
L Л after hydrolysis 
0 0 2 A 
vj 
0 1 A 
I I I I I I I I I I I I I I I I 
0 5 10 min 
Figure 11.1 Η PLC profiles of propofol and its dérivâtes 1,4-quinol and 1,4-quinone in 
plasma and urine, before and after hydrolysis. 
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RESULTS 
Chromatography 
Propofol is well separated from its 1,4-quinol and 1,4-quinone derivate as is 
shown in figure 11.1. The absorption maximum of propofol in the mobile 
phase is at 270 nm. At this wavelength the absorbtion maxima of both the 
1,4-quinol and 1,4-quinone derivales are about 8 times higher. 
Virtually all the unconjugated propofol was found in plasma; in urine it 
accounted for less than 0.3% of the administered dose. After 
deglucuronidation no increase in the plasma propofol concentration was found. 
Increase of the propofol concentration in plasma and urine was estimated after 
hydrolysis with 5 N HCL. 
The 1,4-quinol derivate was not detected in human plasma or urine, even 
after hydrolysis with ß-glucuronidase, arylsulphatase or 5 N HCL. The 1,4-
quinone metabolite of propofol appeared after hydrolysis with ß-glucuronidase 
and with 5 N HCL. Arylsulphatase did not hydrolyse either the propofol 
conjugate, or the 1,4-quinone conjugate, even after a week of incubation at 
3TC. Stock solutions of propofol and its 1,4-quinone metabolite were prepared 
in methanol and kept at 4°C in the refrigerator. Once the 1,4-quinone solution 
was diluted with water, it became unstable. Standard solutions in plasma and 
urine containing the 1.4-quinone metabolite were therefore prepared fresh 
every day before analysis and they were not incubated at 370C or l()0oC. After 
incubation the linearity decreased, especially for the 1,4-quinone metabolite. 
Figure 11.2 shows some optima in peak heights of free propofol and the 
1,4-quinone after hydrolysis of plasma and urine samples of different patients 
after incubation for different periods. These optima were found 1.5 hour after 
incubation at 100°C and 5 hours after deglucuronidation at 370C. The 
minimum detectable concentrations of propofol and its 1,4-quinone metabolite 
in plasma after hydrolysis at 100oC were 0.10 and 0.015 μg ml - 1, respectively 
and in urine 1.0 and 0.15 μg ml - 1, respectively. 
Kinetics 
Figure 11.3 shows the plasma concentration-time curves and renal excretion 
rate-time profiles of propofol with its glucuronide and of the 1,4-quinone 
metabolite and its conjugate in a patient after i.v. administration of 250 mg 
propofol. Propofol is extremely rapidly metabolized to its conjugate (sulphate) 
and to the 2,6-diisopropyl-l,4-quinone which in turn is glucuronidated and 
conjugated (sulphated). Table 11.1 and 11.2 summarize some pharmacokinetic 
parameters of propofol and its metabolites obtained from 4 patients. 
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Figure 11.2: The yield (peak height cm) of some hydrolysis processes plotted against 
time 
TABLE 11.1 
ELIMINATION HALF LIFE IN HOURS OF PROPOFOL AND ITS METABOLITES. 
Subject 
Propofol 
Propofol sulphate 
Quinone glucuronidc 
Quinone sulphate 
1 
1 
9 
9 
9 
2 
125 
20 
20 
20 
3 
125 
7 
10 
10 
4 
175 
12 5 
12 5 
12 5 
110 
plasma cone ug/m) 
renal exer rale ug/mn 
250mg propofol Iv 
Figure 11.3: Plasma concentration time curves and renal excretion time profiles of 
propofol (Ρ), its conjugate (Pconj.) and its 1,4-quinone conjugate (Qconj.) and 1,4-
quinone glucuronide (Qgluc.) after i.v. administration of 250 mg propofol to a patient 
undergoing superficial surgery. 
DISCUSSION 
This HPLC method enables the measurement of plasma and urine 
concentrations of propofol and its 1,4-quinone in man and can be used for the 
determination in patients. Reported methods of analysis of propofol did not 
include the analysis of the metabolites (Kay et al. 1985, Kay et al. 1986, 
Simons et al. 1985). The enzymatic and chemical hydrolysis have to be carried 
out in sealed vials, due to the volatility of propofol and the 1,4-quinone. 
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TABLE 11.2 
EXCRETION IN URINE OF METABOLITES 
in percentage of the total administered dose of propofol. 
Subject 
At(h) 
Propofol 
Quinone 
Quinone 
Total 7c 
sulphate 
glucuronide 
sulphate 
1 
16 
33.3 
0.6 
22.5 
56.4 
2 
48 
26.8 
0.8 
50.3 
77.9 
3 
20 
15.6 
2.4 
37.2 
55.2 
4 
22 
18.0 
0.9 
25.9 
44.8 
Propofol, as a phenolic compound, can be partly glucuronidatcd and 
sulphated (Mulder 1981). The rate of enzymatic dcsulphation depends highly 
on the molecular structure of het compound. Desulphation can be achieved by 
treating the sample with 5 N HCl. It can be therefore assumed that when 
deglucuronidation does not occur, propofol is conjugated by sulphation. 
Glucuronidation of propofol seems to be inhibited by the steric hindrance of 
the two isopropyl groups. The metabolite 1,4-quinone can therefore be 
glucuronidatcd at the 4 position and sulphated at the 1 position. The two 
metabolites are found in plasma and urine. Table 11.2 shows that 15-33% of 
the parent drug is conjugated by sulphation, and 20-50% is oxidized to the 
1,4-quinone. The quinone is predominantly conjugated by sulphation, 
glucuronidation accounting for only 1-3%. More elaborate pharmacokinetic 
analysis will be presented elswhere (Chapter 12). 
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CHAPTER 12 
PHARMACOKINETICS OF PROPOFOL AND ITS 
METABOLITES IN PLASMA AND URINE OF MAN. 
P.M.R.M. DE GROOD, T.B. VREE, A.M. BAARS, H.B. VAN ВЕЕМ, 
E.F.S. TERMOND* 
INTRODUCTION 
Propofol (2,6 diisopropylphenol) in soya bean egg phospholipids emulsion is 
the lastest intravenous anaesthetic agent which became available for clinical 
practice. Smooth induction in one arm-brain circulation time and rapid clear 
headed recovery are the main advantages over other agents (De Grood 
et al. 1987a, 1987b). 
The pharmacokinetics of the compound itself after a single bolus injection 
can be described with a three compartment model with Ty2a of 1.8 - 8.3 min.; 
Τι,β of 34 - 64 min and T ^ of 184 - 382 min. The blood clearance is 1.29 -
2.19 1 m i n - 1 (Cockshot 1985). 
It has been suggested that the short acting anaesthetic activity of propofol 
after a single bolus dose is the result of rapid metabolism and not that of 
distribution (Rhodes and Longshaw 1980). Propofol glucuronide (40%) and 
the 1- and 4-glucuronide and 4-sulphate conjugates of 2,6-diisopropyl 1,4-
quinol have been described as the major metabolites in man (Simons 
et al. 1985). After a subanaesthetic dose of 14C-labelled propofol, 88% of the 
isotope is excreted with urine as metabolites and less than 0.3% is excreted as 
propofol (Kay and Roly 1977, Simons et al. 1985). 
Adams et al. (1981) have described an estimation of propofol in blood by 
high performance liquid chromatography (HPLC) following coupling with 
Gibbs' reagent. This technique has a detection limit of 0.2 μg m l - 1 . Kay 
et al. (1985, 1986) mentioned a technique following extraction into 
cyclohexane by HPLC method using fluorescence detection. In whole blood 
the limit of sensitivity of their assay is approximately 2 ng m l - 1 and the 
coefficient of variation over the concentration range measured is 
approximately 8%. 
* Submitted to British Journal of Anaesthesia. 
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Both methods are relatively time consuming. Analysis of the metabolites 
has never been reported. Therefore we developed a new technique for 
estimation of propofol and its metabolites in plasma and urine. With these 
data pharmacokinetic modelling becomes possible. 
PATIENTS AND METHODS 
Patients 
Four unpremedicated patients (ASA 1) (Table 12.1) scheduled for superficial 
surgery gave their informed consent to participate in the study, which was 
approved by the hospital Ethics Committee. Three patients received a bolus 
dose of propofol 2.5 mg kg - 1 and to one patient a continuous infusion of 
propofol 16 mg kg^hr" 1 was given for 30 min. Anaesthesia was maintained 
with midazolam as a continuous infusion 5 mg hr - 1 and vecuronium as a 
continuous infusion to maintain a 50% neuromuscular blockade. Piritramidc 
20 mg i.v. was administered for analgesia. During the whole procedure 
electrocardiogram, finger plethysmogram, intra arterial blood pressure, end-
tidal carbon dioxide concentration and muscle relaxation were continuously 
monitored. 
TABLE 12.1 
PROFILE OF THE PATIENTS 
Subject 
Sex 
Age (years) 
Weight (kg) 
Length (cm) 
1 
female 
16 
54 
162 
2 
male 
57 
69 
173 
3 
male 
22 
100 
172 
4 
female 
36 
64 
166 
Sampling programme 
Samples of 5 ml were taken into blood gas syringes from a 20 G cannula which 
was introduced in the radial artery, immediately before the dose of propofol 
and at the following times after the start of administration of propofol: 1, 2, 4, 
6, 8, 10, 15, 20, 30, 45, 60, 90, 120 min followed by once every hour for as 
long the arterial cannula was in situ. The blood samples were ccntrifuged and 
the plasma was stored at -20°C pending analysis. Urine was collected and the 
volume was measured over the first 30 min after administration of propofol, 
over the second 30 min and further over every hour. Urine samples were 
stored at -20oC pending analysis. 
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Assay of propofol and its metabolites 
Propofol and its metabolites were determined using a high performance liquid 
Chromatograph (Spectra Physics 3500B) equipped with a variable-wavelength 
spectrophotometer (Spectroflow 757, Kratos USA) and connected to a 
recorder (BD7, Kipp en Zonen, The Netherlands). The urine samples, after 
50 fold dilution, and the plasma samples were mixed with acetonitrile 1:1 
before detection. With this method recovery of propofol added to human 
plasma was 99.5% (sd=0.5%) over the concentration range of 0.1-20 μg m l - 1 . 
The recovery of the 2,6-diisopropyl 1,4-quinone and the 2,6-diisopropyl 1,4-
quinol was 100% (sd=2%) over a concentration range of 0.06-6.0 μg m l - 1 . 
Enzymatic deglucuronidation was performed by ß-glucuronidase (Escherichia 
Coli) in a phosphate buffer pH 6.8 at 37CC for 5 hours. Arylsulphatase 
solution, or a ß-glucuronidase/arylsulphatase mixture was used for enzymatic 
dcsulphatation. Chemical hydrolysis of plasma and urine samples was 
performed by a 5 N HCl methanol mixture at 100oC for 1.5 hours in tightly 
closed flasks. Detailed data of the assay will be published elswere (Vree 
et al. 1987) 
Kinetic analysis 
After determination of the plasma levels, the data were weighted using an 
extended least square modelling system ELSMOS (Francis 1984). 
RESULTS 
Figure 12.1 shows the plasma concentration-time curves and renal excretion 
rate-time profiles of propofol and its metabolites. The pharmakokinetic 
variables of the parent drug derived from the plasma concentration curves 
(figure 12.2) are presented in Table 12.2. The elimination half-life of propofol 
in the α-phase varied between 0.6 and 1.4 min; that in the ß-phase between 3 
and 9 min and that in the terminal γ-phase between 1.0 and 2.3 hours. 
After deglucuronidation no increase in propofol concentration was found. 
However, increase of the propofol concentration in human plasma was 
estimated after hydrolysis with 5 N HCl. The half life of this unknown 
conjugate varied between 9 and 20 hours (Table 12.3). A 2,6-diisopropyl 1,4-
quinone metabolite of propofol appeared after hydrolysis with ß-glucuronidase. 
After hydrolysis with 5 N HCl even higher levels of this 1,4 quinone derivate 
could be detected (Table 12.3). Arylsulphatase hydrolysed neither the propofol 
conjugates, nor the 1,4-quinone conjugate, even after a week of incubation at 
370C. In urine similar results were obtained. The 1,4 quinol derivate was not 
found in human plasma or urine, even not after hydrolysis with ß-
glucuronidase, arylsulphatase or 5 N HCl. 
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30h 
Figure 12.1 Plasma concentration-time and renal excretion-rate profiles of propofol (P), 
propofol sulphate (P conj ) , 2,6-diisopropyl 1,4-quinone sulphate (Qconj ) and 2,6-
dusopropyl 1,4-quinone glucuronide (Qgluc ) after an intravenous dose of 2 5 mg kg" 
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TABLE 12.2 
PHARMACOKINETIC VARIABLES OF PROPOFOL 
Subject 
Α (μ
β
 ml"1) 
α (min 1 
В (»g тГ1) 
β ( m i n - 1 
С (Hg т Г 1 ) 
γ (min 1 
Τι^α (min) 
Ti/,β (min) 
Т 4у (min) 
AUG* (mg min" 1 ! ! ! ! " 1 ) 
Vi(€ ) 
V ' i (€) 
V d (€ ) 
CI {€ min"1) 
1 
_ 
-
7.2 
0.17 
0.7 
0.011 
-
4.2 
62.9 
290.4 
-
55.0 
8776 
1.49 
2 
14.6 
0.49 
0.8 
0.08 
0.08 
0.005 
1.4 
8.9 
141.7 
57.7 
9.0 
-
8951 
2.43 
3 
61.23 
1.1 
2.0 
0.8 
0.3 
0.009 
0.7 
9.0 
77.0 
121.1 
3.9 
-
9424 
2.06 
4 
_ 
-
2.9 
0.2 
0.10 
0.008 
-
3.1 
82.3 
34.5 
-
38.8 
11763 
3.48 
Vj : central compartment with a three compartment model. 
V'j: central compartment with a two compartment model. 
TABLE 12.3 
ELIMINATION HALF LIFE IN HOURS OF PROPOFOL AND ITS METABOLITES. 
Subject 
Propofol 
Propofol sulphate 
Quinone glucuronide 
Quinone sulphate 
1 
1 
9 
9 
9 
2 
1.25 
20 
20 
20 
3 
1.25 
7 
10 
10 
4 
1.75 
12.5 
12.5 
12.5 
Less than 0.1% of propofol was excreted unchanged in the urine and 15 -
33% as a conjugate. Of the total dose of propofol 1 - 2% was excreted as the 
2,6-diisopropyl 1,4-quinone glucuronide and between 2 2 - 5 0 % as another 
quinone conjugate. For patient 1 56.4% of the given dose propofol could be 
detected as metabolite in urine over a period of 16 hours. For patient 2 77.9% 
was excreted in the urine over a period of 48 hours. (Table 12.4). 
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TABLE 12.4 
EXCRETION IN URINE OF METABOLITES 
in percentage of the total administered dose of propofol. 
Subject 
At(h) 
Propofol sulphate 
Quinone glucuronide 
Quinone sulphate 
Total 
1 
16 
33.3 
0.6 
22.5 
56.4 
2 
48 
26.8 
0.8 
50.3 
77.9 
3 
20 
15.6 
2.4 
37.2 
55.2 
4 
22 
18.0 
0.9 
25.9 
44.8 
100 plasma cone ug/ml 
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Figure 12.2 Plasma concentration of propofol of three patients after a dose of 
2.5 mg kg~l. 
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Pharmacokinetic modelling. 
The plasma concentration-time curve of propofol can be described with a three 
compartment model (fig 12.3). In figure fig 12.1. the estimated curve for 
propofol is plotted together with the plasma concentration. The plasma 
concentration-time curves of the three metabolites separately can be described 
in a two compartment model with first order formation (fig 12.3.). However, 
fitting was only possible when a 'lag-time' for appearance was introduced for 
each metabolite. For the quinone conjugate the 'lag-time' was 10 min, for 
conjugated propofol 3.6 min and for the 2,6-diisopropyl 1,4-quinone 1.6 min. 
, 0 0 2 0 
0 0 0 7 ' 
0 0 3 3 ^ - ' 
^_0 29_ 
o n ' 
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Figure 12.3 Pharmacokinetic model of propofol. My: propofol sulphate; Мз·" 
diisopropyl l,4-qiiinone sulphate; M3.· 2,6-diisopropyl 1,4-quinone glucuronide. 
2,6-
DISCUSSION 
The only available data on the pharmacokinetics of propofol and its 
metabolites are from Simons et al. 1985. In their study 14C-labelled propofol 
was administered to volunteers. They stated that propofol glucuronide was the 
major component in plasma, 30 min after administration. The assay method 
for this conjugate was not mentioned. In the present study it was not possible 
to demonstrate the glucuronide conjugate of propofol in blood and urine. 
However, hydrolysis with 5 N HCl demonstrated the occurrence of a propofol 
conjugate. Desulphatation of this conjugate with arylsulphatase was not 
possible. The question remains whether this is the glucuronide conjugate, the 
sulphate conjugate or another conjugate. 
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In man phenolic compounds are partly glucuronated and sulphated 
(Mulder 1981). Since we succeeded in demonstrating the presence of 2,6-
diisopropyl 1,4-quinone glucuronide it is unlikely that propofol glucuronide is 
one of the metabolites of propofol. Another argument is that the 1-OH group 
is sterically hindered by the two isopropyl groups. The 1,4-quinone derivale 
has another binding site available for the large glucuronide at the 4-0 position. 
It seems that only the small SO4" group can be coupled to the 1-OH group of 
propofol. The rate of enzymatic desulphatation of phenolic compounds 
depends largely on their molecular structure, and varies between high and zero 
rates. Desulphatation by hydrolysis will always succeed (Mulder 1981). This 
may explain the negative results of desulphatation with arylsulphatase. 
The l,4quinone derivate has two possible binding sites: the l-O group 
and the 4-0 group. The l-O group is hindered in the same way as in the 
parent compound by the two isopropyl groups and sulphatation of this binding 
site is the only possibility left. Absolute proof of the existence of the sulphate 
conjugates of propofol as well as of the quinone derivate can only be obtained, 
when these compounds are synthesized and can be measured by HPLC 
analysis. 
Another possibility for a 'conjugate' could be the coupling of the quinone 
and quinci derivate. This product can be split in an acid medium, and cannot 
be split by enzymatic hydrolysis. However, this possibility can be ruled out, 
due to the absence of the quinol metabolite. 
The pharmacokinetic data of propofol are comparable to those reported 
by others (Simons el al. 1985, Kay et al. 1985. Kay et al.1986). The half-life for 
the sum of the metabolites is similar to the half-life of 14C in plasma after 14C-
labelled propofol administration (Simons et al. 1985). In one patient it was 
possible to collect urine over 48 hours. Of the administered dose of propofol 
78% was recovered as metabolite in the urine, confirming the conclusion of 
earlier studies (Kay and Roily 1977 and Simons et al. 1985) that renal 
excretion is the main pathway of elimination of the metabolites. 
Pharmacokinetic modelling of propofol and its metabolites resulted in a 
nine compartment model. Curve fitting of the total model was not possible due 
to the 'lag-time' in appearance of the metabolites. Simulation, however, gives 
a good correlation with the plasma curves. The model suggests that besides 
elimination of propofol by metabolism there is an additional pathway of 
elimination. This should account for approximately 20% of the dose. This 
may be another unknown metabolite or direct elimination of propofol by the 
digestive tract. Simons et al. (1985) collected less than 2% of the dosed 
radioactivity in faeces in their study with 14C-labelled propofol. Elimination by 
ventilation could be another possibility due to the relatively high volatility of 
propofol. However, due to the extreme dilution in expired air, the 
concentration must be extremely low: i.e < 1 ng ml - 1 . 
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In conclusion this study demonstrates that metabolism is the main route 
of elimination of propofol Propofol sulphate, and the sulphate and 
glucuronide conjugate of 2,6-diisopropyl 1,4-quinone are the metabolites 
found. Renal excretion is the main pathway of elimination of the metabolites. 
For propofol itself renal excretion is negligible 
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CHAPTER 13 
SUMMARY AND CONCLUSIONS 
Propofol emulsion became available in 1983 and has since been administered 
to patients during clinical trials to profile its properties. It is impossible to 
describe all the properties of propofol based on the results of our own studies 
(chapter 1). Amplification in consideration with the results of other research 
groups is necessary. 
In chapter 2 we have described properties of an ideal intravenous 
anaesthetic agent. The question is whether an ideal agent will ever exist. The 
ideal properties, as described in chapter 2, are deduced more from clinical 
practice than from a well defined theoretical model describing how an 
anaesthetic agent interferes with the central nervous system. 
Propofol is a chemical structure which belongs to the group of hindered 
phenols. Its anaesthetic activity is discovered a few years ago (chapter 4). 
Animal studies have demonstrated that propofol has promissing properties 
(chapter 4). This drug is lipophilic and poorly water soluble, which 
necessitates a suitable solvent. A 10% w/v emulsion of soya bean oil and egg 
phospholipids has been chosen, after it became clear that the previous solvent, 
Cremophor EL, has the disadvantage of inducing anaphylactoid reactions. The 
composition of this emulsion is similar to that of Intralipid, which has been 
used world-wide over 20 years for parenteral nutrition. Intralipid has 
demonstrated to be well tolerated by man (chapter 3). Whether it is an 
advantage or not, the clinician should be aware that during continuous infusion 
of propofol he also gives parenteral nutrition to the patient, particularly when 
propofol is used for sedation during intensive care treatment. Experiences with 
long term sedation by continuous infusion of propofol have not yet been 
reported. 
Induction. 
The induction properties of propofol are described in chapter 5, 6, 7, 9 and 10. 
In all these studies induction time was defined in two ways: as the time from 
the start of administration until stoping of counting and until disappearance of 
eyelash reflex. Recently we demonstrated in EEG studies during propofol 
anaesthesia that only at the moment of disappearance of eyelash reflex - in 
contrast to the moment of cessation of counting - significant changes in EEG 
could be observed. This indicates that stopping of counting is a less reliable 
parameter to measure induction time of propofol (Van Beem et al. 1986). 
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In man with an induction dose of 2 - 2 5 mg kg anaesthesia is 
established in about 50 sec Induction is smooth without excitatory side 
effects Table 13 1 summarizes the results of the studies presented in chapter 
5, 6, 7, 9, and 10 Individual variations exist, but the speed of induction and 
the volume required make titration possible according to the individual 
demand and without a risk of overdose With increase of age the dose 
requirements are reduced for induction (Dundee et dl 1986) as well as for 
maintenance of anaesthesia (Hilton et al 1986) For all patients mentioned in 
Table 13 1 the induction dose was administered over a period of 20 sec Slower 
injection results in longer induction time, while faster administration shortens 
induction (Roily et al 1985) Premedication results in a more profound sleep 
by propofol and a faster induction defined as the moment of disappearance of 
eyelash reflexes (chapter 5) 
TABLE 13.1 
INDUCTION OF ANAESTHESIA WITH PROPOFOL 
summarized data from chapter 5-7, 9 and 10 
Propofol 
mg/kg 
2 * 
2 * 
2 * 
2 
2 5 
2 
2 
2 5 
Number of 
patients 
15 
15 
15 
10 
20 
30 
15 
31 
Premedication 
none 
diazepam 10 mg 
diazepam 10 mg 
dropendol 2 5-5 mg 
pmtramide 7 5 15 mg 
none 
none 
fentanyl 1 875 μg/kg 
alfentanil 0 5-1 mg 
fentanyl 0 1 mg 
Stop counting 
sec 
40 
34 
35 
53 
51 
39 
39 
40 
Eyelash 
sec 
54 
48 
39 
92 
77 
57 
52 
50 
* Propofol in Cremophor EL 
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Maintenance 
In the studies decribed in chapter 6, 7, 9 and 10 a continuous infusion of 
propofol was given for maintenance of anaesthesia. These studies 
demonstrated that also after continuous infusion for more than one hour 
patients awake clear headed in a remarkably short time, but large individual 
variations exist. A few patients opened their eyes on command about one hour 
after cessation of infusion. In contrast, these patients could answer simple 
questions correctly two minutes later. This very short delay between opening 
eyes on command and full recovery is a remarkable property of propofol. 
Based on our studies it is difficult to advocate in general terms a dose 
regimen for continuous infusion with propofol. The dose regimen (induction 
with 2.5 mg kg - 1 and infusion with 12 mg kg~1hr~1) to provide general 
anaesthesia with endotracheal intubation combined with regional blockade was 
found to be insufficient. Supplementary bolus doses, titrated on the individual 
demand were necessary to acquire a stable anaesthesia. Without intubation a 
lower infusion rate of 6 mg kg 'hr - 1 , is sufficient to maintain a light level of 
anaesthesia with eyelash and pupiliary reflexes absent (Jessop et al. 1985). 
Propofol infusion techniques combined with analgesics are described in 
chapter 7, 9 and 10. In these studies anaesthesia was more stable and much 
easier to controle in comparison with the stability and contrability of the 
anaesthesia technique described in chapter 6. Based on these results the 
following dose regimen is recommended for total intravenous anaesthesia: for 
the first 20-30 min 12 mg kg " 'hr - 1 , for the next 20-30 min 9 mg kg " 'hr - 1 , 
followed by 6 mg kg " 'hr - 1 . 
Pharmacokinetics 
In chapter 11 we described a new assay for determination of propofol and its 
metaboilites in plasma and urine. Kinetics after a bolus injection of 
2.5 mg kg - 1 in three patients and after an infusion in one patient have been 
described in more detail in chapter 12. This part of our studies indicated that 
the plasma concentration of propofol rapidly decreases by distribution and 
metabolism. The elimination half-life is about one hour. The major 
metabolites are 1-sulphate 2,6-diisopropylphenol and the 4-glucuronide of 2,6-
diisopropyl 1,4-quinone and 1-sulphate or 1,3-sulphate 2,6-diisopropyl 1,4-
quinone. They are mainly excreted by the kidneys. Renal excretion of the 
parent drug itself is negligible. About fourty-eight hours after an induction 
dose, 80% of propofol is eliminated as a metabolite from the body. No data 
are available of metabolism in patients with limited kidney function. Since 
kinetics of metabolites can be determined, further investigation can provide 
answers to the remaining kinetic problems. 
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Hypersensitivity 
With the Cremophor formulation of propofol anaphylactoid reactions have 
been described, but they were related to Cremophor and not to propofol itself. 
None of our patients had any reaction which could be related to release of 
histamine. Doenicke et al. (1985) measured immunoglobulin levels, 
complement C3 levels and plasma histamine levels in human volunteers prior 
and following induction of anaesthesia with propofol. No changes consistent 
with a propensity to produce anaphylactoid reactions could be observed. 
Side effects 
Haemodynamic effects 
After an induction dose of 2.5 mg kg - 1 Grounds et al. (1985) found a decrease 
in mean arterial blood pressure of 30%, wich lasted for about 8 min. Heart 
rate remained unchanged as well as cardiac output. Systemic vascular 
resistance decreased. The absence of a tachycardia with no significant fall in 
cardiac output is beneficial in that there is no increase in myocardial oxygen 
demands. These observations are similar to those reported by others (Coates 
et al. 1985). There is evidence that this is dose dependent (Dundee 
et al. 1986). For patients undergoing coronary artery surgery propofol in 
combination with a suitable analgesic was found to be more capable of 
blocking autonomic sympathetic responses to noxious stimuli than high-dose 
fentanyl anaesthesia (Stephan et al. 1986). 
The changes in blood pressure without a change in heart rate, as seen 
after an induction dose of propofol during steady state anaesthesia, which was 
performed in part 3 of the study on the interaction with muscle realaxants 
(chapter 8), indicate that propofol is modifying the normal baroreflex response 
and/or has a direct effect on the myocardium. In none of the patients in our 
studies has decrease in blood pressure become a clinical problem. The changes 
in blood pressure seems to be more related to surgical stress than to the effect 
of the agent itself. 
Ventilatory effects 
Apnoea after induction with propofol was observed in nearly all of our 
patients. Apnoea is dose realted. Spontaneous respiration is restored within 
three minutes. In this way propofol does not differ from other induction agents 
(chapter 9 and 10, Taylor et al. 1986). During maintenance of anaesthesia 
with a continuous infusion of propofol spontaneous ventilation remains within 
normal physiological limits (chapter 6). 
Pain on injection 
Propofol is not free from pain during injection, which is a disadvantage. With 
premedication, narcotic analgesics preceding the induction and by using larger 
veins for administration the incidence of pain can remarkebly be reduced. The 
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incidence of venous sequelae is low (Mattila and Koski 1985). 
Postoperative side effects 
The rapid and clear headed recovery, observed in all studies presented in this 
thesis, is one of the most remarkable properties of propofol. The incidence of 
postoperative side effects is low (chapter 9 and 10). These properties makes 
propofol the drug of choice for those patients where rapid clear headed 
recovery is indicated. 
Interaction with muscle relaxants 
Propofol does not potentiate or antagonize either nondepolorizing muscle 
relaxants or suxamethonium (chapter 8, Nightingale et al. 1985). 
The above described properties of propofol makes this drug a suitable 
agent for induction of anaesthesia. Given as a continuous infusion it can be 
used for total intravenous anaesthesia and for sedation combined with regional 
blockade. It has good properties for anaesthesia in out patient surgery and 
other procedures which demand a rapid and clear headed recovery. 
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KLINISCHE EVALUATIE VAN PROPOFOL: 
EEN NIEUW INTRAVENEUS ANESTHETICUM 
SAMENVATTING EN CONCLUSIES. 
Propofol emulsie kwam beschikbaar in 1983 en is sindsdien, tijdens klinisch 
onderzoek, bij patiënten toegepast om de eigenschappen van deze stof te 
profileren. Het is onmogelijk een volledig beeld te geven van de 
eigenschappen van propofol aan de hand van de resultaten van onze eigen 
studies (hoofdstuk 1). Het is nodig onze resultaten samen te voegen bij die van 
de andere onderzoeksgroepen. 
In hoofdstuk 2 hebben wij de eigenschappen beschreven van een ideaal 
intraveneus anestheticum. Het is echter de vraag of een ideaal middel ooit zal 
worden ontwikkeld. De ideale eigenschappen, zoals beschreven in hoofdstuk 2, 
zijn eerder voortgekomen uit de anesthesiologische praktijk, dan dat zij zijn 
afgeleid van een welomschreven theoretisch model, dat beschrijft op welke 
wijze een anestheticum het centrale zenuwstelsel beïnvloedt. 
Propofol is een chemische verbinding die behoort tot de groep van 
gehinderde fenolen. De anesthetische werking werd enige jaren geleden 
ontdekt (hoofdstuk 4). Onderzoek met proefdieren heeft aangetoond, dat 
propofol over veel belovende eigenschappen beschikt (hoofdstuk 4). Het bleek 
noodzakelijk een geschikt oplosmiddel te vinden voor propofol, omdat deze 
lipofiele stof slecht oplosbaar is in water. Nadat duidelijk was geworden dat 
het oorspronkelijke oplosmiddel Cremophor EL het nadeel had een 
anafylactoïde reaktie te kunnen veroorzaken, werd een 10% emulsie van soja-
olie met eiwit fosfolipidcn verkozen als oplosmiddel. De samenstelling van 
deze emulsie is gelijk aan Intralipid; een emulsie die meer dan 20 jaar over de 
hele wereld gebruikt wordt voor intraveneuze voeding. Intralipid wordt door 
de mens goed verdragen (hoofdstuk 3). Of men het als een voordeel 
beschouwt of niet, de arts dient zich ervan bewust te zijn dat door toediening 
van een continu infuus met propofol, de patiënt tevens intraveneus gevoed 
wordt. Dit geldt in het bijzonder als propofol wordt toegediend als Sedativum 
tijdens intensieve zorg. Tot nu toe zijn nog geen ervaringen beschreven met 
propofol voor langdurige sedatie. 
Inductie van de anesthesie 
De eigenschappen van propofol tijdens inductie van de anesthesie zijn 
beschreven in hoofdstuk 5,6,7,9 en 10. De inductietijd werd in deze studies op 
twee verschillende wijze gedefinieerd: als de tijd vanaf het begin van 
toediening tot aan het stoppen met tellen en tot aan het verdwijnen van de 
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ooglid-reflex Kortgeleden hebben wij aangetoond met EEG onderzoek tijdens 
propofol-anesthesie dat signifikante veranderingen in het EEG worden 
waargenomen op het moment dat de ooglid-reflex verdwijnt Geen duidelijk 
veranderingen konden worden waargenomen op het moment van het stoppen 
met tellen Dit impliceert dat het stoppen met tellen een minder betrouwbare 
parameter is om de inductie tijd van propofol vast te stellen (Van Beem 
e a 1986) 
TABEL 1 
INDUCTIE VAN DE ANESTHESIE MET PROPOFOL 
Samenvatting van de resultaten uit hoofdstuk 5-7, 9 en 10. 
Propofol 
mg/kg 
2 * 
2 * 
2 * 
2 
2 5 
2 
2 
2 5 
Aantal 
patiënten 
15 
15 
15 
10 
20 
30 
15 
31 
Premedicatie 
geen 
diazepam 10 mg 
diazepam 10 mg 
dropendol 2 5-5 mg 
pintramide 7 5-15 mg 
geen 
geen 
fentanyl 1 875 μg/kg 
alfentaml 0 5-1 mg 
fentanyl 0 1 mg 
Stoppen tellen 
sec 
40 
34 
35 
53 
51 
39 
39 
40 
Ooglid-reflex 
sec 
54 
48 
39 
92 
77 
57 
52 
50 
* Propofol in Cremophor EL 
Door propofol, in een dosering van 2 - 2 5 mg kg , wordt bij de mens 
een anesthesie geïnduceerd in ongeveer 50 sec De inductie verloopt soepel 
zonder tekenen van excitatie Tabel 1 geeft een samenvatting van de resultaten 
van de studies die zijn beschreven in hoofdstuk 5,6,7,9 en 10 Hoewel 
individuele variaties bestaan, is door het volume wat nodig is voor een 
inductiedosis en door de snelheid waarmee de anesthesie geïnduceerd wordt, 
afstemming van de inductiedosis op de individuele behoefte mogelijk, zonder 
dat het gevaar bestaat van overdosering Zowel de inductiedosis, als de dosis 
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nodig om de anesthesie te onderhouden neemt af bij het stijgen van de leeftijd 
(Dundee e.a. 1986, Hilton e.a.1986). Bij alle patiënten, vermeld in Tabel 1, 
werd de inductiedosis toegediend in 20 sec. Snellere toediening leidt tot 
verkorting van de inductietijd; een langere periode van toediening verlengt de 
inductie tijd (Rolly e.a. 1985). Een premedicatie verkort de inductie met 
propofol en verdiept de bewusteloosheid (hoofdstuk 5). 
Onderhouden van de anesthesie 
In de studies, welke zijn beschreven in hoofdstuk 6,7,9 en 10, werd een 
continu infuus met propofol gegeven om de anesthesie te onderhouden. Deze 
onderzoeken toonden aan dat, zelfs na een continu infuus van meer dan een 
uur, de patiënten in een opmerkelijk korte tijd ontwaakten. Opgemerkt dient 
te worden dat een grote inter-individuele variatie betaat voor de tijd die 
verloopt tussen stoppen van het infuus en het ontwaken. Een paar patiënten 
openden hun ogen op verzoek ongeveer een uur nadat het infuus was stop 
gezet. Zeer opmerkelijk was dat twee minuten later, deze patiënten in staat 
bleken eenvoudige vragen te beantwoorden. Dit zeer korte tijdsverschil tussen 
het openen van de ogen en het volledig wakker zijn, is één van de meest 
opmerkelijke eigenschappen van propofol. 
Het is moeilijk om gebaseerd op ons onderzoek in algemene termen een 
infuus schema voor propofol aan te bevelen. Het infuusschema (inductie met 
2.5 mg kg - 1 en een infuus met 12 mg kg^uur - 1 ) bleek onvoldoende om een 
algemene anesthesie met endotracheale intubatie te onderhouden, in 
combinatie met een regionaal blok. Extra bolusdoses, afhankelijk van de 
individuele behoefte, waren nodig om een stabiele anesthesie te verkrijgen. 
Een lagere infusie snelheid (6 mg kg"'uur - 1) bleek voldoende om een 
opervlakkige anesthesie zonder intubatie te onderhouden, waarbij ooglid-reflex 
en pupilreflex afwezig waren (Jessop e.a. 1985). In hoofdstuk 7, 9 en 10 zijn 
onderzoeken beschreven waarbij een propofol infuus werd gecombineerd met 
analgetica. Gelet op de resultaten van deze studies kan het volgende 
infuusschema worden aan bevolen voor totaal intraveneuze anesthesie: voor de 
eerste 20-30 minuten 12 mg kg^uur - 1 , voor de volgende 20-30 minuten 
9 mg kg_1uur_1 , gevolgd door 6 mg kg_1uur_1. 
Pharmacokinetiek 
In hoofdstuk 11 hebben wij een nieuwe methode beschreven om propofol en 
de metabolieten te bepalen in plasma en urine. In hoofstuk 12 wordt meer in 
detail de kinetiek besproken na een bolus injectie van 2.5 mg kg - 1 bij drie 
patiënten en bij één patiënt na een infusie. Dit deel van ons onderzoek 
toonde aan dat door distributie en metabolisme de plasmaconcentratie van 
propofol snel daalt. De eliminatie halfwaardetijd bedraagt ongeveer een uur. 
De belangrijkste metabolieten zijn het 1-sulfaat 2,6-diisopropylphenol, het 4-
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glucuronide 2,6-diisopropyl 1,4-quinone en het 1-sulfaat of 1,3-sulfaat 2,6-
diisopropyl 1,4-quinone. Deze verbindingen worden hoofdzakelijk door de 
nieren uitgescheiden. Renale excretie van de moeder verbinding zelf is 
verwaarloosbaar. Ongeveer 48 uur na toediening van een inductie dosis heeft 
propofol voor 80% het lichaam verlaten als metaboliet. Over het metabolisme 
bij patiënten met een gestoorde nierfunctie zijn geen gegevens beschikbaar. 
Aangezien wij in staat zijn de metablieten te bepalen, kan verder onderzoek 
het antwoord geven op de vragen over de kinetiek die zijn blijven liggen. 
Overgevoeligheid 
Anafylactoïde reacties zijn beschreven van propofol in Cremophor. Niet 
propofol zelf, maar Cremophor werd hiervoor verantwoordelijk geacht. Geen 
van onze patiënten heeft enige reactie vertoond die toegeschreven kon worden 
aan het vrijkomen van histamine. Doenicke e.a. (1985) heeft 
Immunoglobuline-, complement C3- en histaminespiegels in het plasma 
gemeten bij vrijwilligers vóór en na inductie van anesthesie met propofol. 
Geen veranderingen konden worden waargenomen die het ontstaan van een 
anafylactoïde reactie aannemelijk maakt. 
Bijwerkingen 
Haemodynamische veranderingen 
Grounds e.a. (1985) vonden na een inductiedosis van 2.5 mg kg - 1 propofol 
een daling van de gemiddelde arteriële bloeddruk van 30%, welke ongeveer 8 
minuten bleef bestaan. Zowel de hartfrequentie als de cardiac output bleef 
onveranderd. De systemische vaatweerstand daalde. De afwezigheid van een 
tachycardie, gepaard gaande met een signifikante daling in de cardiac output, 
is van belang omdat daardoor geen toename bestaat in de vraag naar zuurstof 
door het myocard. Deze bevindingen zijn gelijk aan die van anderen (Coates 
e.a. 1985). Er zijn aanwijzingen dat deze haemodynamische veranderingen 
dosis afhankelijk zijn (Dundee e.a. 1986). Bij patiënten voor coronair arterie 
chirurgie werd gevonden dat propofol in combinatie met een geschikt 
analgeticum beter de autonome sympatische respons op noxische prikkels 
blokkeerde dan een anesthesie techniek met hoge doses fentanyl (Stephan 
e.a. 1986) 
De verandering in bloeddruk zonder een verandering in hartfrequentie, 
zoals door ons waargenomen nadat een inductiedosis was gegeven tijdens een 
stabiele anesthesie (deel 3 in het onderzoek naar de interactie met 
spierrclaxantia, hoofdstuk 8), geeft aan dat propofol het normale verloop van 
de baroreflex verandert en/of een direct effect op het myocardium heeft. Bij 
geen van de patiënten die wij verder in onze studies betrokken heeft 
bloeddruk daling geleid tot problemen. De veranderingen in bloeddruk 
schenen eerder veroorzaakt te worden door de chirurgische stress dan door 
propofol zelf. 
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Veranderingen van de ventilatie 
Apneu tijdens inductie met propofol werd waargenomen bij bijna al onze 
patiënten. Apneu is dosisafhankelijk. Spontane ademhaling herstelt zich in drie 
minuten. Propofol onderscheidt zich in dit opzicht niet van de andere 
inductiemiddelen (hoofdstuk 9 en 10, Taylor e.a. 1986). Tijdens het handhaven 
van de anesthesie met propofol door middel van een continu infuus, blijft de 
spontane ademhaling binnen de fysiologische grenzen (hoofdstuk 6). 
Pijn bij toediening 
Pijn tijdens toediening van propofol komt voor. Dit is een nadelige 
eigenschap. Indien sedativa of narcotische analgetica worden gegeven 
voorafgaande aan de inductiedosis, en gebruik wordt gemaakt van de grotere 
venen om propofol toe te dienen, kan de incidentie van pijn bij toediening 
aanmerkelijk worden verminderd. Veneuze sequelae komen zelden voor 
(Mattila en Koski 1985) 
Postoperative bijwerkingen 
Postoperatieve bijwerkingen komen haast niet voor (hoofdstuk 9 en 10). Het 
snel en helder ontwaken met een minimum aan postoperatieve bijwerkingen, 
dat werd waargenomen tijdens alle studies beschreven in dit proefschrift, zijn 
eigenschappen, waarmee propofol zich onderscheidt van de andere anesthetica. 
Door deze eigenschappen heeft propofol de voorkeur bij die patiënten waar 
snel en helder ontwaken vereist is. 
Interaktie met spierrelaxantia 
Propofol potentieert noch antagoneert zowel niet-depolarizerende 
spierrelaxantia als succinylcholine (hoofdstuk 8, Nightingale е.a. 1985) 
Door de bovenbeschreven eigenschappen is propofol een geschikt middel 
om een anesthesie te induceren. Het kan gebruikt worden als hypnoticum voor 
een intraveneuze anesthesietechniek. In combinatie met een regionaal blok 
kan het worden toegepast als Sedativum. Propofol bezit goede eigenschappen 
voor anesthesie bij poliklinische ingrepen en dag behandeling en al die 
ingrepen die een snel en helder ontwaken van de patiënt vereisen. 
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voor Anesthesiologie (Hoofd: Prof. Dr. J.F. Crul) van 1977-1980. Na 
inschrijving in het specialistenregister werd een staffunctie aanvaard bij dit 
Instituut. Binnen zijn huidige werkkring heeft de neuro-anesthesiologie zijn 
speciale belangstelling. 
137 



STELLINGEN 
behorende bij het proefschrift 
Clinical Evaluation of Propofol 
A New Intravenous Anaesthetic 
P.M.R.M. DE GROOD 
Nijmegen 20 maart 1987 
1 Propofol is niet het ideale intraveneuze anestheticum. 
(dit proefschrift) 
2 In vergelijking met de beschikbare middelen komt propofol het ideale 
intraveneuze anestheticum het dichts nabij. 
(dit proefschrift) 
3 Cremophor EL dient niet langer gebruikt te worden als oplosmiddel voor 
intraveneus toe te dienen pharmaca. 
(dit proefschrift) 
4 Selectie van patiënten voor geneesmiddelen onderzoek volgens de 
zogenaamde Seelen-methode is in strijd met de medische ethiek en uit het 
oogpunt van patiënten rechten zonder meer verwerpelijk. 
5 Inhalatie anesthesie met een "gesloten adem circuit" vereist registratie van 
zowel de inspiratoire zuurstofconcentratie als de inspiratoire concentratie 
van het gebruikte dampvormige anestheticum. 
6 Een goed preoperatief gesprek sedeert beter dan een premedicatie met 
10 mg valium per os. 
7 Het continue registreren van het spontane electrornyogram van de 
musculus frontalis tijdens suboccipitale vewijdering van een 
neurilemmoom in de cisterna ponto-cerebcllaris beperkt de peroperatieve 
laesies van de nervus facialis. 
8 Het is een omissie van de Koninklijke Nederlandsche Maatschappij ter 
bevordering der Pharmacie, dat zij in het Artsen-FNA 1986 niet bij alle 
parenterale toe te dienen preparaten vermeldt welke oplosmiddelen 
worden gebruikt. 
9 Monitoring tijdens anesthesie: is een groot goed, kost een vermogen aan 
apparatuur en bevestigt nogal eens hetgeen wij al weten. 
10 Indien isobare dan wel hyperbare oplossingen van locaal anesthetica 
volgens een strikt protocol intrathecaal worden toegediend, is de 
uiteindelijk bereikte maximale blokhoogte onvoorspelbaar. 
(Gielen, de Grood et al. Regional Anesthes. 1984 9:62) 
11 Het Nationaal Verkeersveiligheids Fonds dient een grotere 
maatschappelijke bekendheid en ondersteuning te krijgen zodat, onder 
meer, onderzoek naar de invloed van poliklinisch uitgevoerde ingrepen en 
dagbehandeling op de vaardigheid aan het verkeer deel te nemen, mede 
door dit fonds gefinancierd kan worden. 
12 De Koninklijke Nederlandsche Maatschappij tot bevordering der 
Geneeskunst dient een professionele onderhandelaar aan te stellen, die 
leiding geeft aan alle onderhandelingen betrekking hebbend op het 
inkomen van zowel huisartsen, specialisten als artsen werkend in een 
dienstverband. 
13 Dat mijn vrouw geen zandbank der wetenschap is, bewijst dit proefschrift. 
(Rector Boddens, in: Pieter Bas, door G. Bomans) 



